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ABSTRACT

Protein structure is integral to its function. For the past 70 years differential
scanning calorimetry has been used to measure protein structural stability. More
recently it has been used to study macromolecular interactions. Interactions between
proteins and ligands can manifest on differential scanning calorimetry melting curves
or thermograms. Utilizing differential scanning calorimetry thermograms to detect or
diagnose diseases has been a major goal in disease diagnostics. However, correlating
specific ligand-protein interactions, as manifested in a thermogram, with a disease
specific plasma thermogram, has proven elusive.
Modified human serum albumin was utilized to develop a process to capture and
retrieve ligands from plasma. This process was demonstrated for two ligands that
bind human serum albumin and subsequently perturb plasma thermograms. Human
serum albumin was covalently modified by attachment of biotin to lysine residues. An
investigation was performed to determine if modifications of human serum albumin
affected the ability of the protein to bind ligands, in order to design better capture
reagents.
An analytical differential scanning calorimetry method was devised for determining, quantitatively accurate, ligand binding constants to human serum albumin. This
method was used to demonstrate that modifications of human serum albumin, either
structurally by pH changes or covalently with attachment of biotin, significantly reduced the ability of albumin to bind ligands. To further validate our method, an
additional 29 drug/ligands were examined to determine their binding constants to
human serum albumin.
Drug/ligands were chosen to represent a wide variety of compound classes, including examples of stereochemical and functional derivatives. Within that group of
compounds are those that are insoluble or sparingly soluble in aqueous solvent. A
technique was conceived and implemented that allowed for the insoluble compounds
to be analyzed in aqueous media without the use of any organic solvents. In all cases

i

excellent agreement was found between measured binding constants and those reported in literature. From measurements of binding constants it was also possible to
determine semi-quantitative ligand binding stoichiometries. The ability to determine
binding constants and stoichiometries in a single set of experiments is unique among
available techniques.
Discoveries that were made while developing capture reagents yielded novel insights into the link between ligand binding and global structural stability of human
serum albumin. These insights, along with the new techniques that were developed,
have broader applications than merely assaying ligand binding to human serum albumin. We have demonstrated applications of our methods to analyze ligand binding
in complex mixtures of expressed proteins. An extension of this work would be to
apply these methods in investigating viral infections in complex fluids.
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This dissertation is dedicated in the memory of those important people that are no
longer around to see me complete this PhD but always supported me.
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CHAPTER 1: INTRODUCTION AND BACKGROUND

1.1

Motivation
For the last 70 years differential scanning calorimetry (DSC) has been used to

study macromolecular interactions. More recently, DSC has been applied to plasma
proteome analysis with the goal of serving as a disease diagnostic tool. To that end, in
the past decade, over 38 publications have appeared where DSC was used to generate
thermograms to identify or characterize a disease state [1–37].
In all cases, plasma taken from individuals displaying a particular disease state
(cancer, disease, or induced state/stress) generated thermograms that were significantly different from the canonical ”normal” thermogram for individuals in the absence of the disease state [1, 2, 11]. Statistical routines that have been developed
have proven reliable in identifying abnormal thermograms [1, 10, 11, 25]. However,
the underlying flaw of this approach is that, while accurate in identifying a diseased
thermogram, it provides no determination as to the cause of the perturbation. The
net result is a diagnostic that is able to identify diseased samples in a single-blind
study where it is known that plasma contains either ”normal” samples or samples
for a single disease state. But, when given mixed samples containing a variety or
multiple disease states per sample, it is only possible to identify abnormal samples
with no distinction as to the cause of perturbation.
For DSC to have any future as a disease diagnostic platform, a method is needed
that can connect an abnormal plasma thermogram to a particular disease state. An
initial goal of this dissertation was to develop a capture methodology that can be used
to isolate and retrieve analytes from plasma to identify the cause of the perturbed
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thermogram. Human serum albumin (HSA) was modified for this purpose. Plasma is
known to be the primary transport media for both endogenous and exogenous compounds; 40-60% of human plasma by mass is composed of HSA [38–41]. The function
of HSA is to serve as the primary transport protein for carbohydrates, peptides, fatty
acids, metals, and exogenous drugs [42, 43]. Therefore, the expectation was that any
analyte in plasma, that could cause a perturbed thermogram, would most likely bind
to HSA.
In Chapter 3, the effective capture, retrieval, isolation, and identification of analytes from plasma is demonstrated. In this example, exogenous ligands were added to
plasma and retrieved using a novel capture reagent of modified HSA coupled to magnetic beads. Following retrieval, the ligands were removed from the modified HSA
and identified using mass spectrometry and gel electrophoresis. Following identification, ligands were added back to HSA to demonstrate that the captured and isolated
ligand was the cause for the perturbation of the plasma thermogram. This result
showed that it was possible to connect a perturbed thermogram to a specific ligand.
While successful capture and retrieval was demonstrated, the question arose as to
whether the modified HSA maintained the same binding and structural properties of
normal HSA.
In Chapter 4, HSA was differentially modified to analyze effects of modifications
on structural stability and binding ability of the protein. Knowledge of how modifications effect HSA is integral into designing better and/or more specific capture
reagents. Two classes of modifications were applied, surface and structural, to analyze changes in structural stability and ligand binding. Surface modifications were
accomplished by attaching variable amounts of biotin to surface lysines on HSA. Conversely, structural modifications were induced by pH changes; where HSA is known
to adopt different structural isomers based on pH [42, 44–46]. While DSC was an
ideal tool to analyze how modifications effect structural stability, DSC-based techniques to measure ligand binding have proved extremely poor in determining ligand
association/dissociation constants [47–49]. A completely novel methodology was de-
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veloped to accurately measure ligand binding to protein. It was clear that modification of HSA, away from physiological conditions, significantly decreased ligand
binding constants. However, insight gained from this study provided the basis for
optimizing ligand binding capacity of HSA. This can be applied towards engineering
modified HSA as affinity capture reagents for the directed purpose of binding and isolating ligand analytes from plasma; and as HSA-based therapeutic delivery systems
in blood [23, 50–52].
While accurate determination of ligand binding constants to HSA was determined
for the two ligands examined in Chapter 4, it was important to ensure that the observed phenomena was widely applicable. In Chapter 5, 29 ligands were tested. These
included various classes of drugs, fatty acids, and bilirubin. Not only were binding
constants obtained that were in good agreement with literature, but the additional
thermodynamic information offered by DSC allowed for analysis of effects of specific
structural and functional modifications of drug compounds on ligand binding ability to HSA. Further, testing sparingly or insoluble compounds is a challenging issue
effecting all techniques aimed at measuring drug binding. To overcome the lack of solubility, a novel sample preparation methodology that utilized the extraordinary binding capacity of HSA was developed. Insoluble compounds that were tested showed
binding constants in precise agreement with literature. This was accomplished without the use of organic solvents in protein solutions, thereby preserving native protein
structure. The results provided the first evidence of determining accurate binding
constants for ligands to HSA solely utilizing DSC.
In vivo it would be rare for only a single ligand to be bound to HSA. HSA has
a multitude of binding sites that can bind to a wide-variety of endogenous and exogenous ligands. Thus it is possible that binding at one site may change the ability
to subsequently bind at another. In Chapter 6, the effect of how binding a ligand
to a single drug site on HSA could effect binding of a ligand to a different site, i.e.
allosteric interactions, was investigated. It was demonstrated that the order of ligand binding to specific HSA binding sites determined overall ligand binding affinity.
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Where ligands in Sudlow drug site I were shown to negatively impact ligand binding at
Sudlow drug site II. Conversely, drugs binding in drug site II showed little to no effect
on drug site I binding. The insight gained from Chapters 3, 4, and 5 was combined
to determine how surface modifications impact drug binding and structural stability
caused by allosteric interactions. The goal being to gain a precise understanding of
how to engineer targeted proteins with tailored drug binding strength and capacity
for use as capture reagents or drug-delivery vehicles.
This dissertation begins with descriptions of retrieving and identifying ligands in
plasma that bind to and perturb plasma thermograms. Investigations into fundamental protein behaviors were conducted in order to better understand how HSA can
be engineered for specific purposes, i.e. design of capture reagents. In the process
of investigating HSA, new methodologies were developed that greatly expand the
capabilities of DSC.

1.2

Background
Protein structure is integral to its function. This has been demonstrated in studies

where point mutations are used to manipulate protein structure and observe functional outcomes [42, 53]. Because of its physiological importance, the structure and
activities of HSA have been extensively studied for over 60 years [42]. In these studies HSA has served as a model protein for determination of protein crystal structure
and investigating the role individual amino acids contribute to protein structure and
function. Despite the abundance of research that has been done with HSA, there
yet remains a lack of detail regarding how binding events can impact HSA global
structure and function.
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1.2.1

Human Serum Albumin

Structure
The primary structure of HSA has 585 amino acids on a single polypeptide chain
with molecular weight of ∼66.5 kD. There are no tryptophan or methionine residues.
There is an abundance of charged residues such as lysine, arginine, glutamic acid and
aspartic acid [42, 54, 55]. The x-ray crystal structure of HSA has been determined to
less than 2.5 Å resolution and revealed HSA protein monomer has a 3-dimensional
structure that is heart-shaped. The tertiary structure of HSA is composed of three
domains, I, II and III each comprised of sub-domains A and B arranged in 27 αhelices. There are 17 disulfide bridges and one free sulfhydryl on cysteine residue
34 [42]. Tucked within the tertiary structure two major binding sites for ligands have
been located and named after Sudlow [42, 56–58]. These are referred to as site I
(located in subdomain IIA) and site II (in subdomain IIIA). These sites are known to
bind a wide variety of ligands and drugs of different types and origins. The structure
of HSA with Sudlow Sites are shown in Fig 1.1.
HSA can exist in several different tertiary structures. These are the N (normal)
state, and four isomers denoted E (expanded), F (fast), B (basic) and A (aged) that
form depending on solution pH and other conditions. Ribbon structures of the N, F,
and E forms are shown in Fig 1.2.
A number of solution studies have investigated the thermal stability of HSA using spectroscopic techniques such as Circular Dichroism, Infrared, and Fluorescence
spectroscopy [47, 48, 59–65]. There are far fewer reported studies of analysis of HSA
structure and stability using Differential Scanning or Isothermal Titration Calorimetry (ITC) to analyze the thermal stability of HSA, and evaluate thermodynamics of
ligand binding [47, 59, 65–69]. DSC melting curves, thermograms, can be quite sensitive to structural modifications, isomerization and binding interactions through their
effects on overall thermodynamic stability of the protein.
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Figure 1.1.: Ribbon structure of HSA produced in Chimera 1.13.1rc using Protein
Data Bank structure PDB2BXA. Sudlow Sites I and II are labeled.

Although the structural architecture of HSA has been fairly well documented,
thermodynamics of the structures and modifications thereof, have not. Local binding
to specific sites has been extensively studied in experimental and computer studies.
These models provide little insight into the actual consequences of fatty acid (FA)
binding on the thermodynamics of site-specific ligands or their effect on global structure stability. This is important because modifications that affect global stability can
also affect local binding which can in turn affect global stability of HSA. Based on
coordinates from x-ray structures, in silico molecular modeling and docking/binding
simulations have conjectured the existence of allosteric effects associated with fatty
acid binding, which is 10 to 100 times stronger than most known site-specific
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ligands [70–74]. Inferences have also been made from x-ray structures regarding potential effects of structural modifications on local atomic or amino acid interactions
that might be associated with various ligands around the well-defined binding pockets
of HSA.

Figure 1.2.: pH isomers of HSA. N = pH 7.4, F = pH 4.5, E = < pH 3.5. Ribbon diagrams of serum albumin in its N form, and in its proposed F and E forms.
Reprinted from Advances in Protein Chemistry Vol 45, Structure of Serum Albumin,
p175, (1994) with permission from Elsevier.
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Figure 1.3.: Ribbon structure of HSA with labeled ligand binding sites. Domains are
labeled DI-DIII with subdomains denoted by A and B. Endogenous ligands are listed
in green while exogenous ligands are in red. Crystal structures for HSA bound by
ligands were resolved in saturatable amounts of palmitic acid, fatty acid binding sites
are numbered (1-7) [75]. Reprinted from Frontiers in Immunology, Unraveling the
Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based
Therapeutics, 5, 682 (2015) and is used under CC-BY License.
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1.2.2

Ligand Binding to HSA

One of the remarkable functional features of HSA is the distinct capacity of the
structure to accommodate extraordinary levels of ligand binding. In some cases, so
much so as to actually increase ligand solubility in plasma by substantial amounts
(up to seven times have been reported) [76]. In this way HSA is involved in transport
(distribution) of important therapeutics which can impact their pharmacological effects. Likewise, the enormous binding capacity of HSA can significantly affect drug
pharmacokinetics (metabolism, excretion). Intrinsic to its functions a multiplicity of
reactive sites on HSA have been identified that are known to possess varying binding
affinities for a variety of different ligands [42, 56, 57]. Local binding to specific sites
has been extensively studied in experimental and computer studies [70, 77, 78].

1.2.3

Calorimetry

The history of calorimetry can be traced back to the late 1780s when Antoine
Lavoisier and Pierre-Simon Laplace created the first documented calorimeter to measure the heat of reaction (qrxn ) for melting ice [79]. The power of calorimetry is the
unique capability to directly measure thermodynamic parameters (enthalpy, entropy,
and Gibbs free energy). Accurate measurement of thermodynamic parameters is critical for many applications. To meet the different needs for each application, a number
of specialized calorimeters have been developed, including: adiabatic, reaction, bomb,
isothermal titration, and differential scanning.

Differential Scanning Calorimetry
Differential thermal analysis (DTA) originates from Henry Louis Le Chatelier,
in 1887, where phase transitions of clay minerals were measured as a function of
temperature [80]. This technique was improved by Robert Austen, in 1899, when
a thermocouple was added to both reference and standard cells for more precise
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measurements. The addition of a thermocouple enabled measurements of temperature
differences for sample and reference cells with constant heating. Continued advances
in DTA technology eventually led to a new technique developed by O’Niell and Watson
in 1962. Their technique raised the temperature for sample and reference cells at
the same rate and measured the heat flow needed to maintain that temperature
for both cells [81]. The following year, Privalov and Monaselidze created the first
adiabatic scanning calorimeter for biochemical systems named a differential scanning
calorimeter (DSC) [82].
A schematic view of a modern DSC for biochemical systems is shown in Fig 1.4.
In a DSC experiment, there are four values being reported by the instrument: 1) the
pressure of the system, 2) the temperature of the reference cell, 3) the temperature
of the sample cell, and 4) differential power used by the feedback heater to maintain
the temperature of the sample and reference cells.
The instrument in Fig 1.4 is an example of a power compensated DSC, where
temperature differences between sample and reference are compensated for by the
feedback heaters; in order to maintain a constant temperature. The amount of energy
flowing to the feedback heater, measured in microwatts (µW), is the primary response
used by the instrument to generate a melting curve. The energy flux in microwatts
can be converted into excess heat capacity at constant pressure, ∆CP , given the
molecular weight (MW), partial specific volume (PSV), and density of the solution.
The resulting graph of ∆CP versus temperature is the DSC thermogram.
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Figure 1.4.: Simple schematic of a DSC instrument. The instrument contains a sample
(S) and reference (R) cell designed to hold between 0.25-1mL of dilute protein in buffer
solutions, these cells are machined out of platinum, tantalum, or gold due to their
stability and resistance to corrosion [83]. P is the pressure head for the instrument.
All solutions are held under excess pressure to prevent bubbling or phase change of
the solvent. During heating, the main heater steadily raises the temperature of the
S and R cells. The instrument maintains constant temperature between the sample
cells (∆T1 ) and the adiabatic jacket (∆T2 ). Feedback heaters are used to maintain
the temperature for reference and sample cells [84].
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1.2.4

Protein Unfolding Thermodynamics

Thermograms for proteins are a thermodynamic manifestation of protein unfolding. For example, a measured thermogram for HSA is displayed in Fig 1.5. The area
highlighted in red is the fraction of the total protein that has unfolded over the given
temperature range. The unshaded portion of the thermogram represents the fraction
of the protein remaining in a folded state.

Figure 1.5.: Thermogram of HSA, where the fraction of protein in the folded state as
a function of temperature is highlighted in red.

Consider unfolding of a protein occurs in a two-state manner as the simple equilibrium,
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−−
−−
−
− Denatured (unfolded)

(1.1)

KN D is the unfolding constant and ∆GN D is the Gibbs free energy of unfolding.
The native (folded) protein states are maximally stable under physiological conditions
with ∆GN D = 5-20 kcal/mol, depending on the protein [82, 85–87]. For reference, a
single C-C covalent bond has a ∆G of ≈ 85 kcal/mol. The enthalpic, ∆HN D , and
entropic, ∆SN D , components of ∆GN D are given by the Gibbs equation,

∆GN D = ∆HN D − T ∆SN D

(1.2)

Below a certain temperature where ∆HN D exceeds T ∆SN D the native, folded, state
of the protein is favored and intermolecular interactions remain. As temperature
increases, the protein becomes less stable as the entropic contribution, T ∆SN D , favors
a more disordered and unfolded state; and unfolding occurs when T ∆SN D exceeds
∆HN D .
The above model of protein unfolding assumes a two-state unfolding transition.
That is, the protein goes from a folded to an unfolded state with no intermediates
or complex intermediate pathways. While there are proteins that display complex
unfolding and multiple intermediate states [88–90], the two-state approximation has
proven to be sufficient to accurately determine thermodynamic parameters of protein
unfolding of many proteins including HSA [91]. Results of experiments described in
Chapters 4 and 5 are consistent with two-state behavior.
An alternative representation of a thermogram is shown in Fig 1.6, where the fraction of protein unfolded as a function of temperature results in a sigmoidal curve. For
both Figs 1.5 and 1.6, a two-state unfolding transition results in a nearly symmetrical
curve.
As represented by the dashed red line in Fig 1.6, the melting temperature, Tm , is
the point at which 50% of the protein is in the native state and 50% in the unfolded
or melted state. On a thermogram, Tm is the temperature at maximum peak height.
At the Tm , ∆GN D is zero thus ∆HN D and T∆SN D are equal.
13

Figure 1.6.: An alternative representation of a thermogram displaying the fraction of
HSA in Fig 1.5 that has unfolded as a function of temperature.

∆GN D cannot be directly measured by DSC, but ∆HN D can be directly measured
and ∆SN D can be derived from the Tm and ∆H. Using Eqn 1.6 it was possible to
extract ∆GN D at an arbitrary reference temperature, T.
Calorimetric enthalpy of unfolding, ∆Hcal , can be determined from the integrated
area under the thermogram and is the direct measurement of ∆HN D .
T

∆Hcal = ∫ ∆CP ⋅ dT

(1.3)

0

Similarly, ∆Scal , is the calorimetric entropy of unfolding and is derived from ∆Hcal
and Tm , i.e.
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∆Scal =

∆Hcal
Tm

(1.4)

∆CP
⋅ dT
Tm

(1.5)

Therefore,
T

∆Scal = ∫
0

∆Gcal is obtained by combining Eqns 1.6, 1.3, and 1.5,

∆Gcal = ∆Hcal − T ∆Scal

(1.6)

Generally, ∆Gcal is determined at a reference temperature. To maintain physio◦

logical relevance for collected data, 37 C was chosen corresponding to average human
body temperature. Eqn 1.6 assumes that ∆∆CP = 0 as a function of temperature;
therefore ∆Hcal and ∆Scal are not temperature dependent.
Model analyses have been proposed to analyze DSC denaturation curves assuming
multi-state transitions with ∆∆CP ≠ 0 [53]. The procedure generally involves simultaneously adjusting multiple variable parameters of the predicted thermograms to
fit experimentally measured curves and extracting thermodynamic parameters from
iterations of the model fits. This contrasts with the approach described in Chapter
2 and by others where thermodynamic parameters are evaluated strictly from the
curves themselves and assuming ∆∆CP = 0 [92]. Both methods have produced comparable results [53, 92]. Thus, demonstrating that accounting for ∆∆CP ≠ 0 is not a
significant consideration for evaluating observed thermodynamic parameters of many
proteins.

1.2.5

Plasma Thermograms

The human plasma proteome is a complex fluid containing over 9000 individual
proteins and peptide fragments present in quantities ranging from picograms to tens
of milligrams per milliliter [24, 40, 41, 93]. As such the plasma proteome holds great
promise as a convenient specimen for health status monitoring, disease diagnosis,
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and assessing responses to therapeutic regimes [1, 2, 7, 11, 14, 20, 94, 95]. Blood samples can easily be obtained from individuals who have given informed consent, by
minimally invasive and safe procedures. Proteomics has heightened interest in the
human plasma proteome as a source of indicators and biomarkers of human disease.
A number of FDA approved plasma diagnostic assays are routinely used today. These
include serum protein electrophoresis and a variety of immunochemical assays that
can monitor the concentrations of specific proteins in plasma [39, 96].
For the medical practitioner, analysis of plasma proteins can be a powerful clinical
assessment tool for detecting, diagnosing, and monitoring diseases and pathophysiological processes. A disturbance in the interrelationship among these proteins can
indicate the presence of infection, inflammation, malnutrition, autoimmune or other
diseases [5,11,12,17,18,20]. Since plasma protein analyses can provide valuable information early in the course of a disease, patient outcomes can be improved, and costs of
patient care significantly reduced. Proteomics research spurred interest in the plasma
proteome as a source of biomarkers for human disease and illness [12, 94, 97–101].
Higher resolution methods using a combination of mass spectrometry, coupled with
elaborate sample preparation and fractionation protocols in so-called “shotgun” proteomic approaches have made it possible to identify apparent changes in the composition of the less abundant proteins and peptides in plasma that seem, in some cases,
to correlate with particular diseases or illnesses [14, 39, 93, 97, 102–104].
The plasma proteome is summarized in Fig 1.7 where 90% of the mass of plasma
(by weight) is made up of 10 proteins. These are, in order of abundance: albumin,
IgG, fibrinogen, transferrin, IgA, α2-macroglobulin, α1-antitrypsin, complement C3,
IgM and haptoglobin. Another 12 proteins account for another 9% of plasma mass,
the three most abundant of which are the apolipoproteins A1 and B, and α1-acid
glycoprotein. Thus, 22 proteins comprise 99% of the mass of plasma, making it
a challenge to fractionate and quantify the remaining 1%. Existent and emerging
assays examine different aspects of the plasma proteome. The FDA approved serum
protein electrophoresis monitors changes in the most abundant protein population
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Figure 1.7.: Human plasma proteome [41].

[39]. Low molecular weight peptides represent a mixture of small intact proteins
plus degraded fragments of larger proteins. The low molecular weight region of the
plasma proteome has been dubbed the “peptidome” and touted as a “treasure trove
of diagnostic information that has largely been ignored. . . ” [8]. Many components
of the “peptidome“ were found to be complexed with the more abundant plasma
proteins, particularly HSA and immunoglobulins [4]. This led to the “interactome”
concept in which plasma contains a complex network of protein-protein and peptideprotein interactions in which these analytes or potential biomarkers bind to the most
abundant plasma proteins.
Generally, when a ligand recognizes and binds to a native protein, depending on
the nature of binding (electrostatic, polar, hydrophobic, etc.) it can either stabilize
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or destabilize that protein with respect to thermal or chemical denaturation. Consequently, relative to the unliganded protein, when bound the melting temperature
or concentration of denaturant required to unfold the protein is either increased or
decreased. Analogously, if a ligand were to selectively recognize some feature of the
denatured protein, the melting temperature could also be lowered (or raised). In this
regard, DSC thermograms are highly sensitive to ligand binding interactions. Ranges
of melting temperature shifts on thermograms for proteins in the presence of ligands
can be dramatic (easily tens of degrees), depending on the type and strength of binding interactions. This is a key element since both experimental and clinical studies
support the notion that in diseased states, low molecular weight proteins, peptides,
lipids and circulating nucleic acids characteristic of that disease (and therefore indicative of its presence), increase in concentration in plasma [93, 97, 105, 106]. Such
analytes can form complexes with the more abundant proteins in plasma (specifically
HSA and immunoglobulins). In doing so they alter thermodynamic stabilities of
the proteins, recorded on observed plasma thermograms. Such effects produce characteristic patterns on diseased thermograms that differ from the average “normal”
signature [2]. In this way plasma thermograms are sensitive to binding interactions
in ways that electrophoresis and mass spectrometry are not. Changes in plasma thermograms resulting from binding (for example) of small peptides to a larger receptor
are far more dramatic than changes in either mass or charge associated with the same
binding event. Thermogram perturbations arise from significant interactions between
circulating analytes and the most prominent plasma proteins causing alterations of
their thermodynamic stability observed on the plasma thermogram.
Shifts in melting transitions (thermograms) of proteins that accompany ligand
binding are actually a common observation [1, 2, 107]. Effects of binding on the magnitude and exact shape of a thermogram depend precisely on ligand binding affinity,
enthalpy, stoichiometry, and other factors. It is easy to imagine that (proteins, peptides, fatty acids, nucleic acids and other analyte molecules (biomarker candidates)
in plasma could produce a myriad of thermogram shapes, depending on the proteins
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(and protein binding sites they occupy) and their relative affinities and concentrations. Interactions of unique analytes with different plasma proteins can also produce
a unique characteristic thermogram that reflects underlying complexity of the interactions. DSC is sensitive to interactions of analytes with HSA and the other more
abundant plasma proteins, through their effects on protein stability.
Over the past decade, over 38 publications have appeared relating to plasma
thermogram analysis [1–37]. These have reported results clearly demonstrating that
plasma samples from ”normal” (healthy) individuals display thermograms distinct
from those obtained for samples from “diseased” individuals. Distinct thermograms
are also observed for different diseases [3, 5–13, 108]. Plasma thermograms display
statistically unique patterns for a variety of different diseases and ailments, and thus,
can be a powerful diagnostic [2,9,10]. Statistical analysis of plasma thermograms has
demonstrated the utility of thermograms for monitoring patient response to therapy
and confirmation of clinical diagnosis [1, 27]. Even though correlations between perturbed patterns on thermograms and specific diseases (for a number of different cases)
have been determined, there remains a lack of knowledge or simple means of determining just which analytes are specifically associated with disease and responsible for
observed changes on disease-specific patterns on thermograms.
In disease afflicted plasma, specific analytes (potential biomarkers) circulate in
the blood and interact on some level with one, or more, of the major plasma proteins.
Interactions between circulating analytes in plasma and (binding of the other major
plasma proteins) can affect their thermodynamic stabilities and thereby influence the
shape of the plasma thermogram [1–3]. However, manifestations of these interactions
via thermogram analysis give no insight into the identity of the analyte causing the
perturbation.
What is required to unleash the commercial potential of plasma thermograms is a
fast and simple means for isolating the analytes directly responsible for the observed
thermogram shifts that arise from analyte interactions with HSA. This inability has
been the Achilles’ heel of the plasma thermogram technology, impeding commercial-

19

ization. Although DSC thermograms are highly sensitive to binding interactions, they
provide no insight what-so-ever into identity of the specific analytes involved.
To identify the analytes causing thermogram perturbations necessitated the development of a protocol and capture reagent able for retrieving analytes from plasma.
Initially, the focus was on analytes circulating in plasma. Because HSA is the major
component of plasma (by weight) and known to bind a variety of ligands; it serves
as an ideal base for a capture reagent. HSA modified by biotin or maleimide can be
attached to a surface that can be introduced to a plasma sample in order to retrieve
these circulating entities from plasma.
However, this idea of ”fishing” for analytes is applicable beyond plasma to other
tissue compartments. For example, biofluids (cerebrospinal fluid, urine, mucus, sputum, and other biofluids) are rife with analytes that can cause, or indicate, illness
or disease. Targeted capture reagents can be tailor made depending on the specific
biofluid and protein target of a particular analyte.
Capturing and retrieving disease causing analytes from biofluids will enable rapid
and positive identification of diseases. This can prove especially important for rapid
and early diagnosis of viral disease outbreaks where physical capture of a virus will
enable early detection without relying on viral genome information.

1.2.6

Drug Discovery

Discovering a new drug is a lengthy and expensive process that can take an average
of 12 years with costs of over $1B per drug (2018 dollars). Preclinical drug discovery
efforts aim to define new chemical entities (NCE) capable of successfully navigating
the multiyear, billion dollar pharmaceutical development pipeline. Typically, the drug
discovery process is divided into two major parts, preclinical and clinical trials. Fig
1.8 summarizes the major components that make up the preclinical drug discovery
process and the transition to initial clinical trials [109].
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Figure 1.8.: Drug discovery pipeline. The number of candidates and time for each step are shown [109, 110].

(I) Target validation includes determination of targets having disease relevance
and usually takes at least two years to complete. Results of the target validation phase
might include a determination that the presence or action of the target molecule in an
organism causes or influences some effect that initiates, exacerbates, or contributes
to a disease for which a cure or treatment is sought.
(II) Lead generation and optimization involves identification of lead compounds,
i.e., ligands or compounds that bind the target molecule, and alter effects of the
target through either activation, deactivation, catalysis, or inhibition of the function of the target. Lead optimization involves chemical and structural refinement of
lead candidates into drug precursors. This to improve binding affinity to the desired
target, increase selectivity, and address issues of toxicity, solubility, and metabolism.
Biochemical assays are employed to test selected lead compounds for various pharmacokinetic factors related to drug absorption and membrane permeability, distribution,
metabolism, excretion, toxicity, side effects, and required dosages; the so-called drug
discovery “funnel”. Together lead generation and lead optimization typically take at
least five years to complete. Optimally, these steps can result in the elimination of
all but about 250 of the 5,000-20,000 candidate compounds initially screened.
(III) Preclinical testing: This phase involves analysis of approximately 250 of the
lead compounds that have survived screening steps (1) and (2) above. This preclinical
testing takes approximately one to two years and is comprised of a number of interconnected activities revolving around detailed ADME and pharmacokinetic studies.
(IV) Clinical trials and approval: This phase can take at least six years during
which the drug candidates are tested on human subjects for safety and efficacy [109].
Part of the exorbitant expense of drug discovery today is that many optimized leads
often fail in preclinical and clinical testing, due to side effects or other reasons. As
such, the number of drugs that survive clinical trials that are ultimately approved is
very low.
Binding to plasma proteins is an essential component of drug research and development [111]. As a consequence, characterization and assessment of drug affinity
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for plasma proteins, particularly HSA is absolutely essential. Major pharmaceutical companies have become increasingly more focused on controlling physicochemical
properties of post-tox drug candidates concurrent with the compound optimization
process. This approach has been successful in identification of optimal drug candidates. Despite its influence on compound efficacy, plasma protein binding (PPB) has
been underrepresented due to deficiencies in current plasma protein binding analysis
methods [111].
PPB of drugs is highly important to drug development and research. Therefore, assessing a candidate’s PPB is essential for drug discovery efforts [111]. Major
pharmaceutical companies have prioritized analysis of a compound’s PPK properties
earlier than ever before in the drug pipeline as being highly beneficial in identifying
promising drug compounds [37]. Drug PPB has become more critical for early stage
screening because of the influence protein binding has on pharmacokinetics and pharmacodynamics (PK/PD) [111, 112]. Protein binding is also a significant factor for
determining in vivo hepatic elimination of drugs [77, 113, 114]. Recently, the general
importance of PPB has been asserted, overturning 15 years of misinformation and
dogma [111, 115, 116].
The unbound drug concentration is more closely related to the activity of a drug
than total plasma/serum concentration because it is believed that only an unbound
drug can pass through most cell membranes. Methods for determination of protein binding for a drug or potential drug include equilibrium dialysis, ultrafiltration,
absorbance, fluorescence spectroscopy (and others). Early stage PPB analysis can
reduce the number of ultimately ineffective compounds in the post-tox preclinical
process. Thermograms of plasma proteins are altered when drug ligands interact
with them. This is important because it can reveal binding of drugs to other proteins
in plasma, in addition to the desired target. Perturbed thermograms induced by drug
ligand interactions with proteins can indicate binding strength and capacity for that
protein. Currently, concentrations of drug-bound plasma proteins are inferred from
the amount of free drug available in plasma, i.e. not bound up somewhere.
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But determination of free drug provides no insight what-so-ever into which plasma
proteins are actually binding the ligand or how tightly. DSC thermograms provide
both protein specific binding constants and any cross-reaction with multiple proteins.
The pre-clinical drug development process begins with generation of an initial
set of target compounds. Genomics-based target generation approaches are used
to predict which compounds should be given top priority for further development.
Libraries of close derivatives are generated via combinatorial chemistry. There is a
current lack of high throughput methods capable of screening large chemical libraries
for their PPB properties [111]. This deficiency is a critical bottleneck because PPB
screening is incredibly important for identifying undesirable PPB properties of drug
candidates. Early screening can lead to the elimination of less optimal compounds
from further preclinical and clinical studies.
Analytical methods currently employed for assessing PPB are listed in Table 1.1.
Of the techniques listed, equilibrium dialysis, ITC, surface plasmon resonance (SPR),
and fluorescence assays are the primary commercial methods for drug screening. Each
method has individual strengths but also significant weaknesses that have limited
pre-clinical screening capabilities and accuracy. Equilibrium dialysis is the industry
standard for determining free drug concentration but requires a costly investment,
in terms of sample amounts and equipment (Mass Spectrometer), and only provides
an estimate of the free ligand concentration. SPR and ITC can provide insight into
specific binding and comparable thermodynamic information. However, these techniques are not easily scalable for preclinical drug discovery applications, are not user
friendly (require skilled operators), require high sample volume/concentrations, and
are not capable of high-throughput applications.
All of these techniques require aqueous soluble compounds or the use of organic solvents to allow the study of insoluble compounds. The presence of organic compounds
in solutions, even in minute amounts, have been shown to greatly affect protein structure [67–69, 105]. Changes to protein structure can have drastic adverse effects on
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Table 1.1.: Comparison of PPB methods, modified and summarized from Reference
[111].

25

ligand binding activity. This limitation applies to any technique that requires organic
solvents to be present in protein solutions.
In addition, SPR and fluoresence based assays have significant drawbacks related
to the link between protein structure and function. SPR requires that proteins are
immobilized on the testing substrate [117, 118]. Proteins are generally immobilized
through covalent surface modifications [117,118]. Such modifications and the requisite
immobilization can change the intrinsic structure and behavior of proteins [117, 119].
Two more subtle but equally serious complications associated with fluorescencebased assays are, (1) the requirement that fluorescent probes bind the protein, (2)
HSA, like many proteins, has intrinsic fluorescence. This is a considerable constraint
for this method. An extensive body of literature exists that indicates the presence
of allosteric effects in HSA, where effects of ligand binding on protein structure can
strongly influence subsequent binding of additional ligands [76, 120–127]. Since HSA
contains multiple binding sites, specific probes must be used to target each site to
measure binding. The use of probes combined with drug ligands can have significant
effects on protein structure and stability.
Since 2000, the rate of new drugs reaching the market has sharply decreased.
There are a myriad of reasons, most notably is the exploding costs of new drug development [109]. This has led to decreased development of new drugs for many less
prevalent diseases, so-called orphan drugs. In many cases the diseases that these
orphan drugs could treat may be chronic or life-threatening. But development is
ignored or abandoned due to an unlikely economic return on investment [128]. Universities and small biotechnology companies are now responsible for 42% of all new
drugs approved by the FDA; and over 80% of orphan drugs brought to market are
developed in Universities [110].
The net goal of new and improved drug screening technologies is to increase the
number of drug candidates able to successfully complete clinical trials, or reduce the
number of unsuitable compounds proceeding to trials. Early stage ADME and PPB
characterization is the primary means to ensure bottlenecks are not created by
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unsuitable drug candidates. Enhanced screening technologies and removing bottlenecks would ultimately result in lower costs in bringing a drug to market.

1.3

Summary
Characterizing interactions of proteins with ligands is a fundamental biophysical

problem. The main goal of this dissertation work was to interrogate the effects of
ligand binding on global structural stability of HSA. Initially, this goal was motivated
by the desire to determine the cause of perturbed plasma thermograms in diseased
samples.
Our method to capture and retrieve analytes in plasma was accomplished using
modified HSA. Results obtained in Chapter 3 demonstrated the success of using HSA
to both capture and retrieve drugs from plasma samples. In an effort to produce more
effective capture reagents it was necessary to examine how modifications of protein
structures can impact the ability of modified protein to bind ligands.
DSC has been used to determine ligand binding to proteins based on changes of
thermograms as a function of temperature [47, 48, 125]. However, these results were
always qualitative rather than providing quantitative effects of ligand binding. In
Chapter 4 a new method to analyze DSC was demonstrated and used to measure the
impacts of structural and covalent modifications on ability of HSA to bind ligands.
For the two ligands evaluated, obtained binding constants were in excellent agreement
with literature.
To demonstrate the quantitative value of our method, another 26 additional ligands from a number of different drug classes were evaluated in Chapter 5. To solve
the problem of aqueous insoluble drugs, a novel sample preparation method was developed to solubilize drugs without the use of organic solvents. In all cases, excellent
agreement was found between measured binding constants and reported literature
values.
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In total, we have demonstrated that DSC is an extremely powerful but underutilized tool for quantitative evaluation of ligand binding to proteins. However, much of
that power is derived from the novel sample preparation and data analysis methods
developed in this dissertation. DSC and the applications described in this dissertation
have the potential to enable the use of plasma protein analysis and capture to serve
as a clinical disease diagnostic. Similarly, the ability to quantitatively assess ligand
binding to proteins, without labels or modifications, can provide a powerful tool for
pre-clinical drug discovery.
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and A Ferencz. Differential scanning calorimetry of blood plasma in breast
cancer patients. Magyar Onkologia, 56(4):274–279, 2012.
[14] Nam Ah Kim, Jing Hui Jin, Kyung-Hee Kim, Dae Gon Lim, Heesun Cheong,
Yun Hwan Kim, Woong Ju, Seung Cheol Kim, and Seong Hoon Jeong. Investigation of early and advanced stages in ovarian cancer using human plasma by
differential scanning calorimetry and mass spectrometry. Archives of Pharmacal
Research, 39(5):668–676, 2016.
[15] Sashka Krumova, Svetla Todinova, Avgustina Danailova, Violeta Petkova, Keranka Dimitrova, Lidia Gartcheva, and Stefka G Taneva. Calorimetric features
of igm gammopathies. implication for patient’s diagnosis and monitoring. Thermochimica Acta, 615:23–29, 2015.
[16] Anna Michnik, Zofia Drzazga, Ewa Sadowska-Krepa, and Barbara Klapcińska.
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Differential scanning calorimetry (DSC) analysis of human plasma in different
psoriasis stages. Journal of Thermal Analysis and Calorimetry, 111(3):1801–
1804, 2013.
[19] Zsuzsanna Szalai, Tamás F Molnár, and Dénes Lőrinczy. Differential scanning
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[32] Pawel Góralski, Malgorzata Rogalińska, Jerzy Z Bloński, Edyta Pytel, Tadeusz
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scanning calorimetry (DSC) analysis of human plasma in melanoma patients
with or without regional lymph node metastases. Journal of Thermal Analysis
and Calorimetry, 108(1):149–152, 2012.
[96] N Leigh Anderson and Norman G Anderson. A two-dimensional gel database
of human plasma proteins. Electrophoresis, 12(11):883–884, 1991.
[97] Philipp E Geyer, Lesca M Holdt, Daniel Teupser, and Matthias Mann. Revisiting biomarker discovery by plasma proteomics. Molecular Systems Biology,
13(9), 2017.
[98] Lance A Liotta and Emanuel Petricoin. Cancer biomarkers: closer to delivering
on their promise. Cancer Cell, 20(3):279–280, 2011.
[99] Matthias PA Ebert, Murray Korc, Peter Malfertheiner, and Christoph Röcken.
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CHAPTER 2: MATERIALS AND METHODS

2.1

Materials

2.1.1

Protein Samples

Human Plasma and Serum Albumin were purchased from Sigma Aldrich (St.
Louis, MO) and received as lyophilized powder. Plasma was product number: P9523,
lot number: SLBT0202. Human serum albumin (HSA) advertised as fatty acid and
globulin free, ≥ 99% pure was lot numbers: SLBD7204V and SLBT8667. Plasma
and HSA stock solutions were prepared by re-suspending the appropriate amount
of powder in buffer. Samples were prepared by diluting stock solutions to a final
concentration of 27–28 µM (∼2mg/mL).

2.1.2

Solutions of HSA and HSAB

Protein samples were prepared in standard buffer as stock solutions at a concen◦

tration of 1.0 mM, and stored at 4 C for at least 24 hours before use. For DSC
melting experiments protein samples were confirmed spectrophotometrically at 280
−1

−1

nm using the published molar extinction coefficient: 280 = 35,311 M cm

2.1.3

[1–5].

Buffers and Reagents

Standard buffer for all experiments contained 150 mM NaCl, 10 mM potassium
phosphate, 15 mM sodium citrate adjusted with hydrochloric acid to pH = 7.4.
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2.1.4

Preparation of HSA and HSAB pH Samples

Solutions of HSA and HSAB were prepared at pH = 6.0 and 8.0 in precisely
the same manner, but brought up in McIlvaine Buffer. This buffer contained 0.2M
disodium hydrogen phosphate and appropriate amounts of 0.1M citric acid to make
solutions at pH = 6.0 and 8.0 [6].

2.1.5

Ligand Samples

Drug/ligands for this study were procured from commercial suppliers. Naproxen
(NAP), bromocresol green (BCG), ibuprofen (IB), captopril (CAP), thimerosal (TMS),
fluorescein (FSC), caffeine (CAF) Digitoxin (DTX), bilirubin mixed isomers (BIL),
tetracaine (TET), β-Estradiol (BST), and chloroquine (CQ) were purchased from
Sigma Aldrich (St. Louis, MO). Decanoic acid (DCA) was purchased from Acros
Organics (Geel, Belgium). Metformin (MET) was from MP Biomedical (Irvine,
CA); metoprolol (MEP) from Alfa Aesar (Haverhill, MA); buproprion hydrochloride
(BPR) from Tokyo Chemical Industry (Tokyo, Japan); Multihance (MH) and Prohance (PRO) from Bracco (Milan, Italy). Gadavist (GAD) and Magnevist (MAG)
were purchased from Bayer (Leverkusen, Germany); Dotarem (DOT) from Guerbet
(Villepinte, France); Ablavar (AB) from Lantheus Medical Imaging (Billerica, MA);
and ∆9-tetrahydrocanabinol (THC) Cerilliant (Round Rock, TX).
Novel compound DM1157 [7–9] provided by Professor David Peyton (Portland
State University). BP-DOTA(side), BP-DOTA(corner), NBAM-DO3A, and BPAMDO3A were prepared and provided by Professor Mark Woods (Portland State University).

2.1.6

Psilocin Samples

Psilocin samples were procured as 1mg/mL analytical standards prepared in acetonitrile (Lot: FE12271705) verified to be 1mg/mL ± 0.006mg (Cerilliant).
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2.1.7

DNA Samples

The 25 base pair double stranded (25-mer) and the individual strands (25R and
25L) that comprise it were purchased from IDT and received after having been subjected to their standard desalting routine. The 25R DNA sequence is 5’- CGA CAT
GAC CTT GTC GCT AAC ATC C -3’ (Ref. No. 165820905) DNA 25L is the perfect
complement of DNA 25R; and DNA 25-MER, the 25 base pair duplex made from 25R
+ 25L. 25R with a 5’ cy-5 fluorescent label was also purchased from IDT and received
as HPLC purified and desalted. Labeled 25-MER was prepared by incubating 5’ cy-5
labeled 25R with its complement, 25L. To ensure all duplex molecules were labeled,
the two strands were mixed with a slight excess of unlabeled strand in a 1:1.01 molar
◦

ratio. The mixture was heated to 90 C in a heat block, the heater was turned off and
the sample was allowed to slowly cool back to room temperature.

2.1.8

Capture Solvents and Reagents

Standard PBS buffer solutions contained 10 mM potassium phosphate and 150
mM NaCl, pH = 7.4. Total ionic concentrations of buffers were verified by electrical
conductivity measurements. After preparation and prior to use buffer solutions were
◦

stored at 4 C. TBST magnetic bead wash buffer was 20mM Tris-HCl, 150 mM NaCl
and 0.1% Tween20, pH=7.5. Retrieval high-salt wash buffer was 20mM Tris-HCl
and 500mM NaCl, pH=7.5. Isolation low-salt wash buffer was 20 mM Tris-HCl,
pH=7.5. SDS: 5% Sodium Dodecyl Sulphate, 50% glycerol and 12.5 mM Tris-HCl,
pH=8.0. Retrieval wash solutions, 50:0.1:49.9 (v/v%) acetonitrile:acetic acid:H2 O,
50:0.1:49.9 (v/v%) ethanol:acetic acid:H2 O. All solutions and buffers were prepared
with nanopure deionized water. Chemicals and reagents were molecular biology grade
or higher.
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2.1.9

Gel Electrophoresis Staining

Stains-All was purchased from Sigma Aldrich (St. Louis, MO) (product number:
E9379, lot number: BCBS0570V). Staining solution was 60% 20 mM Tris-HCl pH=8,
20% isopropanol, 20% 0.1% Stains-All in formamide.

2.2

Methods

2.2.1

Preparation of Drug Samples

Drug solids were dissolved in nanopure water to create stock solutions. Gadolinium contrast agents were provided in aqueous solution from the manufacturer. THC
was a 1mg/mL analytical standard prepared in methanol. Aqueous insoluble drugs
were prepared as stock solutions in an appropriate solvent, chloroform (digitoxin) and
ethanol (ibuprofen, β-estradiol, and decanoic acid).

2.2.2

Protein/Ligand Solutions

Solutions of HSA samples for drug binding experiments contained the drug present
at different concentrations. Protein concentration was constant in all mixtures. Protein/Ligand solutions were prepared by adding the desired amount of ligand to the
◦

protein solution and incubated at 4 C for 24 hours before testing.

2.2.3

Ligand Solubilization Procedure

Stock solutions of insoluble drug compounds were pipetted into separate 2mL microcentrifuge tubes to yield the correct molar amounts of drug for a 1mL working
(drug/protein) solution. For drugs with a reported literature binding constant, a
minimum of eight distinct ligand samples were prepared spanning the binding concentration regime. For drugs of unknown binding strength, a logarithmic titration of
concentrations was utilized with further refinements depending on results. Microcen43

trifuge tubes containing different amounts of drug samples dissolved in organic solvent
were placed into a vacuum concentrator (Savant SpeedVac SVC100). Following standard vacuum concentrator procedures to evaporate off organic solvent containing the
sample, resulted in known specific amounts of solid drug in each tube. To each tube,
HSA was added at a pre-determined concentration in standard buffer to produce a
one mL working solution for measurements.

2.2.4

Preparation of Biotinylated HSA Samples

HSAB with different amounts of biotin attached to lysine residues (HSAB ) was prepared using the N-Hydroxy Succinate Biotin (N-HS) reagent (product number 21217
from Thermo Fisher Scientific) as previously described [10]. The reagent attaches
biotin to primary amines of lysine residues. Samples of HSA biotinylated to different levels were prepared by incubation with the N-HS reagent at three biotin:HSA
mixtures resulting in HSAB :X with X =1, 5, 10.

2.2.5

Preparation of Capture Moiety

Biotin was attached to fatty acid free HSA using the EZ-Link Sulfo-NHS-Biotin
kit (product number 21217 from Thermo Fisher Scientific) according to the supplier’s instructions. For attachment reactions, a 10 mM stock solution of Biotin was
prepared by dissolving Biotin in water. A solution containing a 1:5 molar ratio of
HSA:Biotin was prepared by adding appropriate amounts of the Biotin stock solution
◦

to an HSA solution at 2 mg/mL, and stored at 4 C for at least 24 hours. When
attachment reactions were complete, free (unattached) Biotin was removed using a
TM

Zeba

spin desalting column (product number: 89892, lot number: RH236113A,

Thermo Scientific). In this procedure, the column was equilibrated three times with
2 mL standard PBS buffer. An aliquot of 1.5 mL of the attachment reaction solution was then added directly to a spin column and retrieved. Sample volumes were
such that several columns were required. Retrieved products from these runs were
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pooled. From the streptavidin coverage density supplied by the manufacturer of the
magnetic beads, binding capacity of the beads was estimated to be approximately
55µg of biotinylated protein per mg of beads.

2.2.6

Preparation of the Capture Reagent
TM

Pierce

streptavidin magnetic beads were purchased from Thermo Scientific

(product number: 88816, lot number: SG249234). Magnetic beads were prepared
according to the supplier’s instructions, by rinsing 50 µL (0.5 mg) of beads with 1
mL TBST wash buffer. After removal of the wash buffer, 300 µL of the capture
◦

moiety was added to the beads and the mixture was incubated at 4 C for at least
24 hours. After incubation, the sample was placed under a magnetic field and excess
capture moiety in the supernatant was removed. Remaining capture reagent was
never allowed to completely dry and was stored in buffer for future use.

2.2.7

Gel Electrophoresis

DNA samples collected at different steps of the capture procedure were analyzed
by electrophoresis on polyacrylamide gels. All electrophoresis experiments were performed using Lonza PAGEr

TM

Gold Precast Gels: Gradient, 10 x 10 cm, 8-16%,

purchased from Thermo-Fisher (BMA59519). Each supernatant fraction collected at
different steps of the capture procedure was suspended in TAE running buffer and
analyzed. In a typical experiment, 25 µL total volume of solution was loaded per
lane (well capacity). Gels were run in TAE buffer (40 mM Tris, 20 mM Acetic Acid,
0.4 mM EDTA) at a constant current of 20 mA for approximately three hours. Gels
for analysis of DNA were stained with Stains-all solution, destained in water, removed, visualized and imaged on a flat-bed scanner. Gels for analysis of hot labeled
cy5’-25MER DNA were visualized using a Typhoon

TM

Trio+ phosphorimager (GE

Healthcare).
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2.2.8

High-Pressure LC and MS

Samples were analyzed for the presence of analyte (ligand) using HPLC-MS instrumentation consisting of an Accela HPLC system (Thermo Fisher Scientific) coupled
to an electrospray ionization source and LTQ-Orbitrap Discovery high resolution mass
spectrometer (ThermoElectron). Retrieved analyte samples were separated using a
50mm BetaBasic 18 HPLC column (internal diameter 1mm; C18 3µm; Thermo Fisher
Scientific). Each LC-MS analysis used 10µL of sample with a run time of 10 minutes.
Ligand samples were kept in the retrieval wash solution and loaded in buffer A (0.1%
(v/v%) formic acid) and eluted using a linear 5 minute gradient (5-95% buffer B
comprised of 0.1% (v/v%) acetic acid, 99.9% (v/v%) acetonitrile) held for 2 minutes
at 95% (v/v%) buffer B, followed by a 3 minute wash of 95% (v/v%) buffer A, 5%
(v/v%) buffer B. All flow rates were held constant at 500 µL/min and the column
◦

temperature was maintained at 35 C. MS data was acquired using the combination
of a low resolution ion trap and high resolution FTMS. Targeted values for detection
of the ligands was set for a scan range of 100.00-750.00 m/z and a resolution of 30,000
at m/z = 400. Samples were ionized in negative mode with a spray voltage of 2.50
kV and normalized collision energy of 35.0 eV.

2.2.9

MS Data Analysis

MS raw data files were analyzed using Xcalibur software version 4.1 (Thermo
Scientific). MS data are displayed in standard form as plots of relative abundance
versus the m/z ratio. Isotope simulation of mass spectra identified target ligands with
an allowed mass deviation of less than 20ppm.

2.2.10

Analytical Ultracentrifugation

All sedimentation velocity experiments were performed in a Beckman Coulter
ProteomeLab XL-A analytical ultracentrifuge (Beckman Coulter, Inc Brea, Ca) at
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◦

20 C, 50,000 rpm, and 260nm in standard cells. A minimum of 100 scans were collected over 8 hours. Data was analyzed by SedFit using continuous c(s) distribution
mode. Buffer density and viscosity were measured using a Paar DM55A density
meter and Paar AMVn microviscometer. Analytical ultracentrifugation (AUC) has
been an established physical technique for over 50 years. [11] It provides high precision determinations of distributions of molecular populations and can detect significant binding events from measured S-values. Recent results from the AUC consortium
demonstrated standardization and high precision of the technique using bovine serum
albumin (BSA) which is very similar to HSA. [12] Our sample preparations of biotinylated HSAB containing different levels of HSA:biotin attachment at ratios of 1:1, 1:5
and 1:10 were characterized by AUC. The procedure provides a highly accurate measurement of HSA dimer/monomer populations and MW of the different biotinylation
levels and reveals significant changes in structure and conformation (if they exist)
with increased biotinylation.

2.2.11

Differential Scanning Calorimetry (DSC) Measurements

DSC melting experiments were performed using a CSC Model 6100 Nano IIDifferential Scanning Calorimeter (TA Instruments, formerly Calorimetric Sciences
◦

Corporation). Temperature scans were made at a heating rate of 1 C/min, essentially as previously described [10, 13]. Care was exercised in loading both buffer
and sample solutions in the DSC. Airtight gasket tipped mico-pipettes were used to
prevent introduction of air bubbles. The average of at least five buffer scans col◦

lected over the temperature range from 0 to 100 C comprised the buffer baseline.
An overpressure of 3.0 atm was applied and prevented degassing of solutions upon
heating. After each run, sample and reference cells were carefully cleaned with 95%
ethanol. DSC melting experiments measure the excess heat capacity, ∆CP , of the
sample as a function of increasing temperature. Plots of ∆CP versus temperature
are commonly termed DSC thermograms. These were measured for HSA and HSAB
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molecules alone and in mixtures with ligands. For most samples more than three
experiments were performed, but at least two thermograms were measured for every
sample examined. DSC data were analyzed using the NanoAnalyze software package,
version 3.7.5, available from T.A. Instruments.

2.2.12

Experimental Protocol

Data collection, reduction and analysis procedures were similar to those previously
reported [10, 13, 14]. There are six essential steps in the process, summarized below.
(1) Excess heat (in µW) of the sample was measured as a function of temperature
and plotted producing a raw µW versus temperature curve.
(2) Excess heat of the buffer background, µW of buffer versus T, was subtracted from
the raw µW versus T curve of the sample (from step 1) producing the buffer-corrected,
µW versus T curve for the sample.
(3) Buffer corrected µW versus T curves for the sample were normalized for protein
concentration (2.0 mg/mL), molecular mass HSA (66.5 kDa), partial specific volume
3

of the protein (0.733 cm /g) [32] and sample cell volume (0.3268 mL), producing the
normalized excess heat capacity, ∆CPN (T), versus T curve.
rd

(4) Baselines of ∆CPN (T) versus T curves were fit with a 3
th

tion. n+1 data points are required to construct an n
i.e. four points were utilized in the 3

rd

order polynomial func-

order polynomial polynomial,

order fit. The first two points were defined by

the lowest and highest temperature points of the linear region prior to onset of the
transition. The second two points were similarly defined by the linear region between
the lowest and highest temperature points after the transition region. The measured
◦

◦

temperature range typically spanned from 40 C – 90 C. Fits with the 3

rd

order poly-

nomial were constrained to simultaneously fit both the upper and lower temperature
regions connected by a smooth curve; thus producing the fitted baseline.
(5) The fitted baseline (from step 4) was subtracted from the normalized ∆CPN (T)
versus T curve (step 3) producing the concentration normalized, buffer and baseline
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corrected ∆CPN -baseline(T) ≡ ∆CP versus T curve, i.e. the DSC melting curve, or
thermogram.
(6) Analysis of the thermogram yields evaluation of key thermodynamic parameters
characteristic of protein stability and denaturation [15–19]. Throughout is was assumed evaluated parameters corresponded to the denaturation transition of HSA and
HSAB bound by ligands in their standard states. Parameters evaluated from thermograms for HSA and HSAB bound by ligands were the calorimetric enthalpy, ∆Hcal ,
◦

◦

entropy, ∆Scal , and free-energy at T=37 C,∆Gcal (37 C)≈(∆Hcal – (310.15) ∆Scal )
0

≡ ∆G37 .
Characteristic features of the thermogram were (1) temperature at the maximum
peak height, Tm ; and (2) calorimetric enthalpy, ∆Hcal , evaluated from the integrated
area of the thermogram (obtained in 5). With a few reasonable assumptions the
calorimetric entropy, ∆Scal , which is closely related to the ratio, ∆Hcal /Tm , can be
0

semi-quantitatively evaluated and used to calculate ∆G37 . Values of these thermodynamic quantities informed on general effects of ligand binding on the denaturation
equilibrium and stability of HSA and HSAB . DSC data analysis further invoked two
simplifying assumptions: (1) the melting transitions of HSA and HSAB , free or bound
by ligands, occurred in a pseudo two-state manner. (2) although the overall change
∆∆CP for HSA between initial and final temperatures ranged from 7-10 kcal/mol⋅K.
Baseline choice effectively zeroed out this difference between the initial and final ∆CP
values on the final thermogram. For the ligands alone ∆∆CP ≈ 0 compared to the
protein.
Reports on ∆∆CP for HSA range from 7-10 kcal/mol⋅K [19,20]. This corresponds
to enthalpies evaluated at Tm to be approximately 10% higher than calculated at
◦

37 C. Since relative differences of ∆Hcal evaluated at Tm , and calculated at a lower
◦

(physiological) temperature (37 C) were the same for all samples examined, negative
impact of the invoked assumptions was taken to be minimal.
Sophisticated, parameterized model predictions of HSA thermal denaturation
curves that consider multi-state transitions and non-zero ∆∆CP (among other things)
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have been reported; and these have been applied to analyze measured DSC denaturation curves of HSA [21–24]. Alternative approaches to modeling non-two state
transitions of HSA alone and extracting evaluated thermodynamic parameters from
DSC data have also been reported; and their results are generally congruent with
ours [22].
Consistency and accuracy of results obtained with our relatively simple analytical
process argues that application of more complicated models is not required to obtain
quantitatively accurate results for HSA ligand binding from DSC [25].

2.2.13

Dose-Response Curves

Experimentally determined thermodynamic parameters as a function of ligand
concentration provided a means for estimating values of the association binding con◦

stant, KA . For this purpose, ligand concentrations served as the doses and ∆Gcal (37 C)
or Tm the responses measured for HSA in mixtures with ligand at increasing doses.
The Hill equation was employed to fit the binding data. Evaluated fitting parameters provided quantitative estimates of the EC50 for ligand binding to HSA as
follows [26–29]

Response = min +

max − min
1 + 10(Log(EC50 −x ))M

(2.1)

Where max and min are the maximum and minimum points on the measured
◦

curves of ∆Gcal (37 C) or Tm , respectively, as a function of ligand concentration. x
values are the ratios of [ligand]/[protein]. M and EC50 are the slope and midpoint of
the measured response.
Using this relatively simple ligand binding model analysis provided evaluated EC50
in good agreement with reported KD = 1/KA values for NAP and BCG (and many
other ligands, examined thus far). Strictly speaking for more complicated binding
equilibria than assumed here EC50 may not be equal to KD [27, 29].
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CHAPTER 3: CAPTURE REAGENT AND STRATEGY
FOR RETRIEVING ALBUMIN-BOUND LIGANDS FROM
PLASMA

3.1

Introduction
Human plasma is a complex fluid comprised of a variety of molecular cellular com-

ponents constantly perfusing tissues throughout the entire body [1]. Included in this
process is distribution of exogenous therapeutic compounds and endogenous circulating components released in the interstitial fluid. Endogenous compounds might
include metabolic and cellular degradation products that can be associated with
health status. For example in cancer, tumors constantly shed cell remnants releasing
disease-specific proteins and protein fragments into plasma. Endogenous circulating
components might interact with HSA and alter thermograms. In addition to being
a transport medium for exogenous compounds, plasma contains an enormous repository of endogenous cellular components that can bind HSA and also can be directly
reflective of collective physiological status and indicative of normal health.
The process of pre-clinical drug development efforts require that new chemical
entities (NCE) identified as potential drug candidates be both potent and bioavailable. To be potent an NCE must have specific and sufficient binding strength to
its desired target. Bioavailability of the NCE requires the compound be properly
Absorbed, Distributed, Metabolized, Excreted and not Toxic, or that it possesses favorable ADME/Tox characteristics. An essential part of meeting these requirements
is how the NCE interacts with Human Serum Albumin, HSA.
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A key facet of bioavailability of an NCE is the ability to delay metabolism by
the liver, or clearance from the body by the kidneys. Both pharmaceuticals and
biomolecules utilize protein binding to protect them from clearance [2]. Specifically,
plasma proteins are primarily responsible for binding these entities to protect them
from clearance and to distribute them throughout the body. One of the challenges is
finding ways of manipulating the ability of an NCE to bind plasma proteins and this
has become a key aim in improving pharmacokinetics of short lived biomolecules [3].
In this regard, any attempt to manipulate the ability of an NCE to bind plasma proteins must first begin by gaining a firm understanding of the strength and specificity
of interactions between the compound and components of the plasma proteome.
At the center of any approach to plasma protein analysis is HSA since it is the
primary component of plasma by mass and comprises 60% of the total protein in
plasma [4]. HSA is a circulating sponge and transporter of many components in the
blood [5]. Central to its function, HSA binds a variety of ligands (peptides, proteins,
lipids, etc.) and serves to circulate entities that bind it (cargo) in the blood to various
locations, organelles and organs throughout the body. Associated with these functions
there are a multiplicity of reactive sites on HSA with a known binding affinity for a
large variety of different ligands [4, 6, 7].
The secondary structure of HSA contains multiple helical subdomains suitable
for binding a variety of ligands. Sudlow designated and characterized the primary
drug binding sites on the HSA structure as sites I and II [8]. Binding capacity of
HSA allows it to accommodate quantities of ligands exceeding their solubility limit in
plasma [9]. A variety of analytical methods have been employed to study the binding
sites on HSA and their interactions with ligands. Methods that have been employed
include but are not limited to; affinity chromatography [10], capillary electrophoresis [5, 11] fluorescence and UV/vis spectroscopy [6, 12], nuclear magnetic resonance
(NMR) [13], and mass spectrometry [14, 15]. Most of these methods have been hindered by their limited ability to only analyze simple solutions of individual proteins or
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protein fragments; providing little insight into interactions of these molecules within
the wider network of the plasma proteome.
Over the past decade, a number of groups have pursued a unique approach to
plasma analysis based on differential scanning calorimetry (DSC) [16–20]. This novel
approach provides an extremely attractive means of plasma analysis. Plasma thermograms measured by DSC are sensitive to mass, abundance, and effects of ligand
(exogenous and endogenous) binding. In essence, plasma thermograms provide a
system-wide snapshot of the status of the plasma proteome (and ligands therein) in
terms of thermodynamic stability of the major plasma proteins and circulating ligands
that bind them. Classification of plasma using DSC contrasts with more standard
methods based on charge, molecular weight (MW), or antigenic activity and provides
a new perspective from which to analyze plasma. The readout of a DSC experiment
is the plots of the heat capacity, ∆Cp versus temperature, or thermogram. As the
most abundant plasma protein (60%) the fractional contribution of HSA comprises a
significant portion of the overall signal making up the plasma thermogram.
The present study was undertaken as part of an effort to investigate and perhaps
more clearly define, from a physical perspective, the underlying mechanism responsible for specific perturbations of plasma thermograms brought about by ligand interactions. The current hypothesis is that ligand interactions with HSA in plasma
and their associated effects on HSA thermostability have a major impact on perturbations of the plasma thermogram. Both exogenous ligand binding and binding of
endogenous ligands associated with various disease states can bind to HSA inducing
perturbations of the plasma thermogram [21–24]. Verifying this supposition requires
a means to isolate ligands that bind HSA in plasma as supplied by the capture strategy. Results presented here clearly show for four different types of ligands that bind
HSA in plasma, that these ligands can be captured and retrieved. In addition, that
thermograms of mixtures of plasma or HSA with the same HSA-binding ligands are
significantly different than thermograms of plasma or HSA alone.
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The aim of the capture strategy is to isolate retrieved material (from interesting
plasma samples) in sufficient quantities for extensive follow-on analysis, in particular
DSC measurements. Effects of the retrieved, isolated material on just the HSA thermogram would directly demonstrate contributions of HSA/ligand interactions on the
measured perturbed plasma thermogram. The degree to which the HSA thermogram
is affected defines the extent of the plasma thermogram perturbation attributable to
binding of HSA.

3.2

Capture Strategy
In this isolation scheme, biotinylated HSA acts as an affinity reagent for ligands

in plasma that bind HSA. In the capture step, streptavidin coated magnetic beads
are attached to biotinylated HSA then inserted into a plasma solution. With application of a magnetic field ligand-bound biotinylated HSA is retrieved. Captured
HSA contains bound plasma components (ligands). Bound ligands are washed off the
retrieved biotinylated HSA and subjected to further characterization and analysis by
gel electrophoresis and MS.

3.2.1

Components

There are several components used in the capture strategy as depicted in Fig
3.1. The capture moiety (Fig 3.1a) is comprised of HSA with biotin attached to
the surface. The capture moiety acts as an affinity reagent for capturing molecular
components from plasma sample solutions. The retrieval moiety in Fig 3.1b is a magnetic bead, surface-coated with streptavidin. Coupling of the capture and retrieval
moieties is achieved through the biotin-streptavidin linkage, resulting in the fully
complete capture reagent shown in Fig 3.1c. Coupled reagents are separated from
uncoupled reactants using a magnet while pulling off the supernatant; the magnet
is removed, and the retained coupled capture reagent is re-suspended in appropriate
buffer.
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Figure 3.1.: Components of the Capture Reagent. (a) Biotinylated HSA is the Capture Moiety. (b) Streptavidin coated magnetic beads comprise the Retrieval Moiety.
(c) Biotinylated HSA and magnetic beads are coupled through the biotin-streptavidin
bond forming the Capture Reagent. Of course, the precise morphology of the capture
reagent is determined by the level of HSA biotinylation and the standard density of
streptavidin coating for the commercial magnetic beads

3.2.2

The Capture Moiety

The capture moiety is biotinylated HSA (HSAB ) made using the N-Hydroxy Succinate Biotin (N-HS) reagent, which attaches biotin to primary amines of lysine resides [25]. Previous studies indicated that biotin attachment has a small but measureable effect on HSAB thermodynamic stability [25]. Relative levels of HSA biotinylation were evident on respective thermograms and produced small incremental
changes with increased biotinylation. With increased biotinylation, thermodynamic
stability incrementally increased up to a ratio of 10:1 biotin:HSA. These results verified sensitivity of DSC to detect the difference in relative amounts of biotinylation
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and indicated that protein stability is not greatly affected by biotinylation up to a
ratio of about 10:1 (biotin:HSA) [25]. Also, the biotinylated HSA species have a
very similar structure to natural HSA, and therefore should have comparable ligand
binding affinities. Capture experiments for capture moieties prepared at incubation
ratios (biotin:HSA) of approximately 10:1, 5:1, and 1:1, suggested the intermediate
coverage produced the best capture (not shown). For the capture moiety used in this
study, HSAB ,was prepared at an estimated coverage of 5:1.
AUC measurements concur with DSC measurements that modest levels of biotinylation do not greatly perturb overall structural stability of HSA [25]. MW determinations by AUC were found to be accurate to within +/- 5 kDa [26]. Thus, an increase
of 2.443 kDa (corresponding to attachment of 10 biotins) HSAB would have a MW
within the error of the measurement. AUC measurements indicated for HSAB at a
1:10 HSA:biotin attachment ratio a MW of 56.7 kDa; at a 1:5 attachment ratio MW
of 64.6 kD and at a 1:1 attachment ratio MW = 63.3 kD. These MW values are
essentially the same within the error of AUC measurements for unmodified natural
HSA. For the biotinylated species monomer/dimer ratios were approximately 90%
monomer, 10% dimer indicating no change in dimerization dissociation constant with
increased biotinylation. Monomer frictional ratios were also quite similar indicating
no differences in shape. Overall, results of AUC analysis were consistent with DSC
measurements; and also indicated biotinylation of HSA does not alter gross conformation, stability, or binding capacity of the protein.

3.2.3

The Retrieval Moiety

The second component is the retrieval moiety (Fig 3.1b) comprised of streptavidin
coated magnetic beads. The complete capture reagent is made by coupling the capture
and retrieval moieties through the biotin-streptavidin bond (Fig 3.1c).
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3.2.4

Capture Process

In the capture process, HSA-bound components are washed off the capture reagent.
The wash protocol employs a mixture of weak acid and organic solvent. For DNA,
high salt washes were used. With this combination of solvents the HSA-bound components are presumably washed off the capture reagent. Given the milieu of plasma
molecular components and ligands such as proteins, peptide fragments, nucleic acids,
fatty acids and lipids that can potentially be bound, it is not surprising diverse solvent
washes might be required to dislodge bound components of various types [5, 14, 27].
The procedure for the capture process is depicted in Fig 3.2.

3.3

Results

3.3.1

Binding and Capture of Naproxen and Bromocresol Green

NAP and BCG (Sigma Aldrich) were used as received from the supplier without
further purification. For these reactions 1 mL solutions containing 1 mg/mL human
◦

plasma and 100 µM of either NAP or BCG were incubated at 4 C for 24 hours.
Plasma/ligand solutions were then added to the capture reagent and incubated an
◦

additional 24 hours at 4 C. A magnetic field was applied and the supernatant removed.
Before retrieval of the ligands, beads were washed with 300 µL of 0.1% Tween
20. The retrieval wash contained acetonitrile, acetic acid, and water in a ratio of
50:0.1:49.9 (v/v%) with 150 mM NaCl at pH 3.5. The capture reagent was washed
with 100 µL retrieval wash solution and vortexed for 10 seconds. This was repeated,
and aliquots were combined for a total volume of 200 µL. Results for NAP are displayed in Fig 3.3. The mass spectrum measured for the captured material is shown in
Fig 3.3a. Isotope simulation for NAP is shown Fig 3.3b. As indicated by the results
in Fig 3.3 a component with precisely the mass of NAP was effectively captured and
retrieved. The measured result shows a -12.2 ppm difference from theoretical. At a
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Figure 3.2.: Summary of the capture process. The general procedure is comprised of
six steps (a)-(f) as shown. (a) A plasma sample containing exogenous (and endogenous) ligands. (b) Capture reagent added to plasma sample and mixture incubated.
(c) Capture reagent isolated using a magnet to pull down attached HSAB capture
moiety with (presumably) bound components. While the magnet was applied, the
supernatant was withdrawn. (d) Following isolation wash, supernatant was removed,
retrieval wash performed by adding a mixture of solvents intended to elute bound
analytes off the capture moiety. (e) While applying magnet field, supernatant was
retrieved. (f) Retrieved supernatants collected from the low (isolation) and high salt
(retrieval) washes were subjected to characterization by LC/MS analysis (NAP, BCG)
or gel electrophoresis (DNA).

mass of 230 m/z, this results in a 0.28% uncertainty in identification. From comparison with a NAP sample of known concentration it was estimated from the ion count
that NAP concentration in the retrieval wash was approximately 2 µM. Accounting
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Figure 3.3.: Mass spectrometry analysis of naproxen isolated from plasma using the
capture process. (a) High resolution mass spectrum showing the presence of naproxen
at m/z 230.09094. (b) Isotope simulation for predicted naproxen peaks.

for dilution of the washed sample, 400 nM of NAP was recovered from the sample,
an approximately 0.4% recovery.
Binding and capture experiments for BCG were precisely the same as those done
for NAP. The supernatant from each step was collected for further analysis. Results
are shown in Fig 3.4; where results of LC/MS analysis in Fig 3.4a and isotope simulation in Fig 3.4b demonstrate effective retrieval of BCG. Using the primary isotope
peak calculation of the measured result shows only a 2.2 ppm difference from the
theoretical m/z for BCG. With an m/z = 696, there is an approximately 0.15% uncertainty in proper identification of this molecule. Similar to NAP, the concentration
of BCG in the wash solution was estimated to be 2-3 µM; 400-600 nM was recovered
from the original sample with 0.4-0.6% recovery. Recovery values for these experiments appear low. However based on protein coverage of the magnetic beads, there
is estimated to be 417 nM of HSAB attached to the capture reagent available for
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Figure 3.4.: Mass spectrometry analysis of bromocresol green isolated from plasma
using the capture process. (a) High resolution mass spectrum of captured material
showing the presence of bromocresol green at m/z 696.71552. (b) Isotope simulation
for predicted bromocresol green.

retrieving ligands from plasma; resulting in a roughly 1:1 ratio of HSAB to retrieved
ligands.

3.3.2

Binding and Capture of DNA

Given the multiplicity of reactive sites on HSA and its known affinity for a variety
of ligands it seemed logical that HSA might also bind DNA. We chose DNA as an
“unknown” test ligand and investigated HSA binding of short ssDNA and dsDNA in
plasma. It turns out DNA provides an important test example for effectiveness of the
capture strategy with a weakly binding ligand.
Results of analysis of DNA binding and capture are shown in Fig 3.5. Experiments
with ssDNA were performed using ∼1 mg/mL low-salt solution of plasma containing
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◦

3 µM 25R ssDNA in 400 µL incubated at 4 C for at least 24 hours. The incubated
◦

sample was added to the capture reagent and the mixture was again incubated at 4 C
overnight. The tube containing the incubated solution sample was then placed under
a magnetic field; and the capture reagent along with (presumably) bound ssDNA was
pulled to the bottom of the reaction tube. The excess supernatant was removed. To
isolate bound components, contents of the tube were subjected to three subsequent
washes, each using 100 µL of low-salt buffer. This was followed by two retrieval wash
steps, each using 100 µL of high-salt buffer. Supernatant fractions from all washes
were collected for subsequent analysis. Results in Fig 3.5a clearly show ssDNA was
effectively captured using the capture strategy and isolated with a high salt retrieval
wash. This is indicated on the gel (lane vi) shown in Fig 3.5a.
For binding and capture reactions with dsDNA a ∼1 mg/mL standard plasma
low salt solution containing 33.3 µM cy5’-25MER dsDNA in 300 µL was prepared
◦

and incubated at 4 C for at least 24 hours. Conditions differed slightly from those
for ssDNA. Since under similar conditions dsDNA appeared to be a relatively weaker
binder, and more difficult to visualize, a higher concentration of hot-labeled duplex
DNA was employed. Incubated plasma/DNA solutions were subjected to capture
procedures carried out in similar fashion as described above for ssDNA. Results are
shown in Fig 3.5b where evidently a slight amount of bound dsDNA was effectively
captured and washed off the reagent. In summary, gel analysis indicated ssDNA and
dsDNA binding to HSA was detectable, but weak.

3.3.3

Thermogram Analysis of Mixtures of Plasma and HSA with Different Ligands

Naproxen
Thermograms (∆Cp versus T) of mixtures of plasma and NAP are shown in Fig
3.6a. Concentrations for these experiments were 1 mg/mL of plasma with NAP at
100 µM. Clearly, the presence of NAP perturbs the plasma thermogram, shifting the
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Figure 3.5.: Gel electrophoresis analysis of DNA capture. (a) Gel results for isolated
25 base single strand DNA derived from the capture strategy. Migration positions
of HSA and single strand DNA are indicated. Lane assignments are: (1) Plasma +
DNA; (2) Remaining supernatant following capture reagent incubation with plasma;
(3) First low salt wash; (4) Second low salt wash (5) Third low salt wash. Note, in
these low salt washes after the first low salt wash there is no material present. (6)
First high salt wash; (7) Second high salt wash. Note, DNA is apparently washed
off with high salt; (8) HSA standard; (9) First supernatant after HSA and capture
reagent incubation. (10) Biotinylated HSA cleaved from the capture reagent. (b) Gel
results of isolated 25 base pair cy5-labeled double stranded DNA. Lane assignments
are the same as for single strand DNA capture experiments. (c) Isolation of lanes 3 7, contrast correction and enhancement were performed to remove interference from
the DNA standard bands in lanes 1 - 2. What is notable is the decreased intensity of
the DNA band in lanes 3, 4 and 5 which correspond to the low salt washes. Lane 6
and 7 are the high salt washes in which intensity of the band in lane 6 for the first
high salt wash increases from lane 5 (the last low salt wash). This increase reveals
that DNA was captured and isolated.

◦

curve to higher temperatures (∼5 C). The shift of the plasma thermograms due to
NAP apparently has much to do with binding of NAP to HSA in plasma. This is
demonstrated by the effect of NAP on the HSA thermogram shown in Fig 3.6b. In
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Figure 3.6.: Thermograms of plasma and HSA in mixtures with naproxen. (a) Thermograms of whole plasma () plasma and NAP mixture (•). Clearly the plasma
thermogram of the mixture is shifted up in temperature in the presence of NAP compared to the thermogram of plasma alone. (b) Thermograms of HSA () and the
HSA and NAP mixture (•). Again, the thermogram of the mixture is shifted up in
temperature.

these experiments HSA was present at 2 mg/mL (28µM) and NAP at 100 µM. The
thermogram for the HSA/NAP mixture was approximately the same intensity and
◦

shifted up by ∼5 C. Separate DSC experiments for HSA at the same concentration
in different mixtures with greater concentrations than 100 µM of NAP indicated
saturation was not obtained at 100 µM (shown in Chapter 4). Thus, there is not
expected to be an excess of free NAP in these mixtures. Effects of NAP on the
thermogram of HSA are clear; at this concentration of NAP (100 µM) the HSA
◦

thermogram is shifted to higher temperature (5 C), with ∆Hcal = 181.7 kcal/mol for
the HSA/ligand mixture compared to 155.0 kcal/mol for HSA alone. This measured
value of standard HSA was within expected error of previously published results [25].
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Figure 3.7.: Thermograms of plasma and HSA in mixtures with bromocresol green.
(a) Thermograms of whole plasma () plasma and BCG mixture (•). Clearly the
plasma thermogram of the mixture is shifted up in temperature in the presence of
BCG compared to the thermogram of plasma alone. (b) Thermograms of HSA ()
and the HSA and BCG mixture (•). Again, the thermogram of the mixture is shifted
up in temperature.

Bromocresol Green
Under similar conditions, 1 mg/mL plasma and 100 µM BCG, the thermogram
(∆Cp versus T) for the mixture of BCG and plasma (shown in Fig 3.7a), is shifted
◦

to higher temperature ∼7 C compared to the plasma thermogram. This is quite
similar to effects of NAP. Since BCG is known to bind HSA, effects of BCG binding
on the plasma thermogram seen in Fig 3.7a are also surely because the ligand binds
HSA in plasma and thereby alters the plasma thermogram. In concurrence, the
thermogram of HSA at 2 mg/mL in a mixture with 100 µM BCG, shown in Fig 3.7b,
indicates a similar effect of BCG. The thermogram for the HSA mixture with BCG is
approximately 20% lower in intensity, a little broader and shifted up in temperature
◦

by ∼7 C compared to the thermogram of HSA alone. The calorimetric enthalpy is
∆Hcal = 165.6 kcal/mol for the HSA/ligand and only slightly higher than HSA alone.

67

DNA
For mixtures of DNA with plasma or HSAB it was necessary to explore origins of
the perturbed thermogram and verify that what was captured was actually responsible
for the observed disturbance of the thermogram. This required knowledge of whether
the mere presence of the ligand and/or significant binding of the ligand (in this case
dsDNA) to HSA was responsible for observed perturbed thermograms of plasma and
HSAB in mixtures with DNA. Thus, it was necessary to dissect thermograms of the
DNA/plasma and DNA/HSAB mixtures.
Analysis of thermograms of mixtures of plasma with NAP or BCG presented no
problems since the ligands themselves have an essentially insignificant ∆Cp over the
temperature range of the plasma thermogram (not shown). However, the case is different for mixtures of plasma or HSA with either ssDNA or dsDNA because both
ssDNA and dsDNA individually display a very significant ∆Cp over the temperature
range of the plasma thermogram. In the case of DNA, a direct comparison of the µW
versus T curves was preferable. The analysis was required to determine whether thermograms measured for mixtures of plasma or HSAB with DNA were equivalent to the
calculated composite curves constructed from the numerical sums of thermograms for
the individual components i.e plasma or HSA and DNA. Essentially, identical measured and calculated composite curves reveal there is little effect of the “interaction”
of DNA with plasma or HSAB . At least the interaction is not significant enough to
affect the plasma or HSAB thermogram.
Baseline corrected µW versus T thermograms for the individual components and
the measured composite curves of mixtures of plasma and HSAB with ssDNA and
dsDNA are shown and compared in Figs 3.8 and 3.9. Calculated composite curves
were constructed from individual curves using a linear combination of the respective
thermograms of the individual components, measured at exactly the same concentrations as in the mixtures. Experimentally measured composite curves were normalized
to the µW versus T thermogram for HSAB alone.
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Single Strand DNA

Figure 3.8.: Thermograms of plasma in mixtures with single strand and double
stranded DNA. (a) Thermograms of plasma alone () and the 25 base ssDNA alone
(•). (b) Thermograms of the plasma and ssDNA mixtures; () Measured thermogram
of plasma and ssDNA; (•) Thermogram calculated from the sum of the individual
thermograms of plasma and ssDNA in (a). (c) Thermograms of plasma alone ()
and the 25 base pair dsDNA alone (•). (d) Thermograms of plasma and dsDNA mixtures; () Measured thermogram of plasma and dsDNA; (•) Composite thermogram
calculated from the sum of the individual thermograms of plasma and dsDNA in (c).
All curves were normalized to the thermogram of plasma alone.

Thermograms (µW versus T plots) for plasma and DNA alone and their mixtures
are shown in Fig 3.8. Those for ssDNA and plasma are shown in Fig 3.8a. The ther69

mogram for ssDNA alone displays a small ∆Cp that spans the early low temperature
◦

region (45-75 C) of the plasma thermogram. Results of independent experiments with
the ssDNA alone and energetic analysis of the sequence (not shown) suggested this
transition likely corresponds to melting of a relatively stable intramolecular hairpin
loop structure that forms in the short ssDNA oligomer. Displayed in Fig 3.8b, are the
measured thermograms for the ssDNA/plasma mixture and composite thermogram
calculated from the sum of the individual thermograms. Two notable observations
emerge from the comparison in Fig 3.8b. The thermogram for the plasma/ssDNA
mixture is not very different from the plasma thermogram alone in Fig 3.8a and; the
calculated composite thermogram in Fig 3.8b is also very close to the measured composite thermogram with only very minor differences. It is tempting to equate these
small differences to low level interactions of ssDNA with plasma. If such an interaction does exist, it does not involve substantial changes in thermodynamic stability
sufficient to significantly affect the plasma thermogram. Thermograms for ssDNA
and HSAB alone are shown in Fig 3.9a. Measured and calculated composite curves,
just as determined for plasma and ssDNA (Fig 3.8b), are shown in Fig 3.9b. Again,
there are only small differences between measured and calculated composite curves
for the mixtures.
Measured and calculated thermograms for mixtures of plasma and ssDNA are
◦

nearly quantitatively identical with only minor differences around 48-60 C and 70◦

◦

77 C. The major peak on plasma thermograms at ∼65 C is attributed primarily
◦

to HSA. The much smaller peak around 53 C has been attributed to melting of
fibrinogen [28–31]. Since the influence of ssDNA alone has been subtracted out,
◦

this higher peak seen at 53 C could be due to ssDNA interactions with fibrinogen in
plasma, but this remains speculative until verification. Regarding the slight difference
◦

at ∼65 C, this region of the plasma thermogram primarily corresponds to melting of
immunoglobulins such as IgG and IgA, and may reveal interactions of them with
ssDNA.
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Double Strand DNA

Figure 3.9.: Thermograms of HSAB in mixtures with single strand and double
stranded DNA. (a) Thermograms of HSAB alone () and the 25 base pair ssDNA
alone (•). (b) Thermograms of the HSAB and ssDNA mixtures; () Measured thermogram of HSAB and ssDNA; (•) Thermogram calculated from the sum of the individual thermograms of HSAB and ssDNA in (a). (c)Thermograms of HSAB alone
() and the 25 base dsDNA alone (•). (d) Thermograms of HSAB and dsDNA; ()
Measured thermogram of HSAB and dsDNA; (•) Composite thermogram calculated
from the sum of the individual thermograms of HSAB and dsDNA in (c). All curves
were normalized to the thermogram of HSAB alone.

Thermograms of dsDNA and plasma alone are shown in Fig 3.8c. Unlike ssDNA,
dsDNA displays a significant melting transition that overshadows much of the high
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◦

temperature region (65-85 C) of the plasma thermogram. Given that the curves are
normalized to the plasma thermogram, apparently under these conditions the DNA
has a relatively larger ∆Cp compared to plasma. Measured and constructed composite curves are shown in Fig 3.8d. Just as seen for ssDNA, calculated composite curves
for dsDNA constructed from the sum of the individual thermograms of plasma and dsDNA (measured under precisely the same conditions as in plasma mixtures) were not
greatly different. Also consistent with weak, inconsequential (in the thermodynamic
sense) binding of dsDNA to HSA, there is a small difference from approximately 60◦

70 C which corresponds to the HSAB transition region suggesting perhaps a small
contribution from HSAB /dsDNA interactions. Thermograms of dsDNA and HSAB
alone are shown in Fig 3.9c. The measured and calculated composite curves constructed from the individual thermograms measured under the same conditions are
shown in Fig 3.9d.
Measured composite curves versus calculated constructed composites in Figs 3.8d
and 3.9d show for both ssDNA and dsDNA, with the minor differences stated above,
there is little variation over the entire temperature range. Thus, indicating these
ligands interact very weakly in the sense of having an insignificant effect on the
thermogram.
NAP and BCG are known to bind HSA and this activity clearly manifests on
thermograms of mixtures of the ligands with plasma. Heretofore, binding activity
of HSA with ssDNA or dsDNA has not (to our knowledge) been reported. Results
showed that although thermograms of plasma alone and mixtures of plasma with
DNA were very different, after proper analysis little evidence for binding was actually
obtained. Captured DNA (presumably previously associated with HSA in plasma)
was detected on gels. From results of independent gel experiments, binding could be
detected with an estimated binding constant less than mM. For a binding constant in
the micromolar range, it is expected that HSA would be 50% saturated with DNA;
this binding should be easily detectable by AUC. Weak binding of DNA to HSAB is
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consistent with lack of binding results in AUC experiments, implying that the DNA
concentration is at least 100-fold lower than the binding constant.
Despite low binding activity of ssDNA and dsDNA to plasma, DNA is an ideal
example ligand for several reasons. DNA is not really an exogenous ligand per se as
similar molecules could actually be encountered endogenously. In this regard DNA
is an example of an actual unknown analyte with relatively weak binding to HSA.
Experiments with DNA provided a practical test of the efficacy of the capture strategy on such an unknown analyte in plasma. Analysis of DNA plasma thermograms
revealed special considerations that must be taken into account for proper analysis
of thermograms of the mixtures.

3.3.4

Binding of Captured Ligands to Unmodified HSA

In this relatively simple (one ligand) system it was clear that the added ligand
caused the perturbed plasma and HSA thermograms. For situations where the ligand
is unknown or there are more than one ligand it would be essential to verify that
the captured ligand(s) was responsible for the perturbed thermogram. Addition of
captured ligands to unmodified HSA provides the means to verify that both the targeted ligands were captured and that they were responsible for the original perturbed
thermogram.
Ligands were captured according to the procedure described in Chapter 2. Both
retrieval wash solutions containing ethanol and acetonitrile were used. The capture
and retrieval process was repeated by reintroduction of the capture reagent to the
sample, incubating for 6 hours, and retrieving ligands. Individual washes were combined, for each solvent, to generate a pooled retrieval solution. This pooled retrieval
solution is not desirable since acetic acid and ethanol/acetonitrile have deleterious effects on native HSA structure [4, 32, 33]. Thermograms for the effect organic solvents
and pH have on HSA structure are shown in Appendix A and Chapter 4, respectively.
To remove harmful acid and organic solvents, pooled wash solutions were concentrated
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using a vacuum concentrator. Thermograms were measured for solutions prepared
from the solvent-free ligand and unmodified HSA. Results of thermograms generated
from ethanol and acetonitrile retrieval solutions are shown in Figure 3.10.

Figure 3.10.: Addition of captured ligands to unmodified HSA. (a) Thermograms for
HSA with naproxen (NAP) washed from the capture reagent with different organic
solvents. (n) Standard HSA at 28 µM, (l) HSA with NAP pooled from five ethanol
washes, (s) HSA with NAP pooled from five acetonitrile washes, (t) HSA with NAP
pooled from a single ethanol wash. (b) Thermograms for HSA with bromocresol green
(BCG) washed from the capture reagent with different organic solvents. (n) Standard
HSA at 28 µM, (l) HSA with BCG pooled from five ethanol washes, (s) HSA with
BCG pooled from five acetonitrile washes.

Thermograms of HSA with retrieved ligands were not greatly different from normal
HSA with ligands. However, even with combining retrieval washes, the concentration
of ligand remained relatively low. The larger difference in naproxen thermograms
compared to bromocresol green can be accounted for by the greater sensitivity of
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HSA thermograms to naproxen at lower concentrations than for bromocresol green.
This greater sensitivity to naproxen binding compared to bromocresol green was again
verified in Chapter 4. The ability to add retrieved ligands to unmodified HSA and
observe quantifiable thermogram shifts demonstrate the diagnostic power of DSC for
analyzing abnormal plasma samples.

3.4

Discussion
Results demonstrate the ability and application of the capture strategy to isolate

four different types of ligands from plasma, two of which NAP and BCG are wellknown HSA binders. The others are short ssDNA and dsDNAs (25 nucleotides,
25 base pairs, respectively), not previously known to have significant HSA binding
activity. In individual experiments these ligands were added to plasma and subjected
to the capture scheme. Captured products were analyzed by MS or gel electrophoresis.
First and foremost, results revealed that binding occurred as demonstrated by effective
capture of added ligands. Mixtures of the different ligands with plasma and HSA were
also subjected to DSC analysis. Individual thermograms of plasma (w/o ligands),
HSA, and biotinylated HSA (HSAB ) provided an analytical basis for comparison and
characterization of measured thermograms of the plasma/ligand mixtures. This was
an essential requirement since in all cases plasma/ligand thermograms were different
than that of plasma alone.

3.4.1

Applications of Thermogram Analysis in Diagnostics

DSC has been employed for many years as the method of choice for quantitative
thermodynamic studies of protein and DNA denaturation [31, 34, 34–39]. In DSC
experiments excess heat capacity of thermally induced unfolding of proteins is directly
measured and provides evaluation of the calorimetric enthalpy, ∆Hcal [29, 40, 41].
Over the past decade, applications of DSC in the realm of proteomic diagnostics
have been reported [1, 14, 15, 20, 42–44]. Reportedly, the primary basis for diagnostic
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applications lies in observations for a number of diseased states that plasma thermograms are systematically and statistically different from the average normal plasma
thermogram. Diseased states and stages can manifest as specifically distinct patterns
on thermograms. Based on these observations robust statistical analysis has demonstrated utility of plasma thermogram analysis for disease monitoring and response to
therapy [19, 22, 28, 45, 46].
It would seem these observations make compelling arguments for the potential
power of DSC analysis in diagnostic applications. Unfortunately, that potential diagnostic power has not been realized due to difficulties in identifying specific components
of diseased plasma responsible for the observed disease-specific perturbed patterns on
plasma thermograms. There is lack of understanding of the precise mechanism underlying observed perturbations of plasma thermograms which provokes the lingering
essential question: What disease specific entities in plasma cause the thermogram
shifts? An operative hypothesis has been that in diseased states, endogenous low
molecular weight proteins, peptide fragments, lipids and circulating nucleic acids (generally referred to as analytes or ligands) characteristic of that disease (and therefore
indicative of its presence), increase in concentration in diseased plasma [5, 14, 15, 47].
The prevailing opinion is that such analytes form complexes with the most abundant proteins in plasma (specifically HSA and immunoglobulins). These interactions
alter thermodynamic stabilities of the proteins they bind, which in turn affects the
recorded plasma thermograms. But little actual proof of this has been reported.
Our major contention is that most significant perturbations of plasma thermograms, brought on by ligand binding, can primarily be attributed to interactions
with HSA. These interactions affect HSA thermodynamic stability which is directly
reflected in the plasma thermogram. Perturbations of the plasma thermograms arise
from thermodynamically significant interactions between circulating analytes and the
most prominent plasma proteins, primarily HSA. These effects manifest on plasma
thermograms producing characteristic patterns for specific diseases that differ from
the average “normal” signature [12, 16–24, 28–31, 40, 41, 45, 46, 48–67]. In this way,
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plasma thermograms can be more sensitive to binding interactions than standard
techniques such as electrophoresis and mass spectrometry. Changes in plasma thermograms resulting from binding (for example) of small peptides to a larger receptor
are far more dramatic than changes in either mass or charge associated with the
binding event.
Although DSC thermograms can be highly sensitive to binding interactions, thermograms themselves are mere indicators of binding presence and provide, on their
own, little insight into actual identities of the specific binding ligands involved. Thermogram analysis in combination with the capture strategy provides a direct, fast,
and simple means to quantitatively validate the aforementioned operative hypothesis by providing the link between causative agents circulating in blood that bind
to plasma proteins, and specific perturbations of plasma thermograms. Using the
capture strategy, likely candidates can be isolated from plasma and their effects on
the HSA thermogram independently assessed. By identifying circulating ligands in
plasma specifically responsible, the capture approach provides a novel means to begin
to unravel features of the molecular mechanism(s) underlying observed specific DSC
plasma thermogram patterns, and their association with human disease.

3.5

Conclusion
With further development, the capture strategy may become an invaluable bio-

marker discovery and proteomics analysis screening tool. Using this strategy will
enable classification of important ligands, based on their associated perturbations of
the plasma thermogram. With sufficient training sets of data, the process could be
used to provide relevant characterizations of captured ligands and classification of
their type and character based on their specific effects on plasma thermograms alone.
Once this is accomplished the true diagnostic power of this method can be realized.
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[61] Pawel Góralski, Malgorzata Rogalińska, Jerzy Z. Bloński, Edyta Pytel, Tadeusz
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CHAPTER 4: ANALYSIS OF LIGAND BINDING TO
NATURAL AND MODIFIED HUMAN SERUM ALBUMIN
BY DIFFERENTIAL SCANNING CALORIMETRY

4.1

Introduction
Human serum albumin (HSA) is a multi-domain, multifunctional protein molecule

comprised of a single polypeptide chain. At 60% by mass HSA is the most prominent
protein in blood plasma [1, 2]. In vivo, HSA functions as a circulating sponge with
the principal role as ligand transporter. Inherent to its function, HSA binds both
reversibly and covalently to a broad spectrum of endogenous and exogenous ligands.
Not surprisingly, with such diverse binding potential, multiple reactive sites on HSA
have been identified. Primary, ligand-specific binding sites hypothetically proposed
based on modeling studies have been experimentally confirmed [3–5]. There are 585
amino acids in the HSA primary structure [2]. X-ray crystal analysis of HSA indicated
the monomer (molecular weight 66.5 kD) has a heart-shaped 3-D structure. In the
HSA tertiary structure there are three domains, I, II and III each with sub-domains
A and B; all arranged in 27α-helices. Named after Sudlow two major binding sites
for many ligands are tucked within the tertiary structure [2, 6–8]. These are Drug
site 1 located in subdomain IIA (Sudlow Site-I) and Drug site 2 in subdomain IIIA
(Sudlow Site-II).
Thermodynamic stability of HSA structures cannot be determined by x-ray crystal
analysis. Moreover, structural models based solely on x-ray data provide little insight
into thermodynamic aspects of ligand binding, or effects of local binding on the overall
structure and stability of HSA. Alternatively, DSC measures the thermostability of
84

HSA global structure, manifested in the thermal denaturation curve (or thermogram).
Thus, thermograms of HSA can be sensitive to structural modifications, isomerization
and binding interactions conveyed through their effects on thermodynamic stability
of the protein.
Sudlow Site-I comprises three sub-sites within a pocket able to bind multiple
ligands [6, 7, 9]. Around the structural framework of Site-I there are a number of
strategically placed charged resides able to support hydrogen bonding interactions
within the pocket (between lysine, tyrosine, etc.); and with ligands that bind there.
Consequently, these interactions are sensitive to pH and can effect protein structure
upon binding [10, 11]. Lysine residues in the HSA structure are also primary targets
for chemical modifications (including biotinylation) of the protein.
Biotinylation is a naturally occurring modification associated with several metabolic processes [12, 13]. It is also an analog of glycosylation, another similarly-adducted
HSA modification [14–16]. As prepared using the N-HS reagent, biotin binds and
covalently attaches to primary amines of lysine residues in HSA [17]. In a recently
published study biotin was attached to lysine residues in varying amounts and DSC
thermograms were measured for the differentially biotinylated protein molecules,
HSAB [18]. That study investigated effects of increasing amounts of random but
site-specific biotinylation on global thermodynamic stability of HSAB . Increased biotinylation caused incremental increases in thermodynamic stability of the structure,
indicated by concomitant increases of measured melting transition temperatures and
transition enthalpies of HSAB thermograms. These results showed DSC can be a
sensitive method for quantitatively assessing effects of different levels of biotinylation
on the conformation and stability of HSAB .
The intrinsic functional activities and physio-chemical attributes of HSA can be
exploited for directed applications. For example, biotinylation of HSA provides a
means for attachment to a solid support to make ligand capture reagents [19]. Effectiveness of these reagents depends on the extent to which attachment affects activities
and capacities of essential binding domains, e.g. Sudlow Site-I and Site-II. Since co-
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valent modification of lysine residues via biotin attachment could affect the ligand
binding properties of HSA it was essential to gauge effects of increased biotinylation
on ligand binding. This was a primary aims of the present study.
Unlike Site-I, Site-II is physically much smaller and is comprised of a single hydrophobic cleft in the binding domain. Site-II is primarily comprised of uncharged
residues and void of lysine residues. Consequently, ligand binding to Site-II is relatively less sensitive to pH. However, several lysine residues do reside proximal to
Site-II and these could affect the surrounding chemical environment. Biotinylation of
external lysines near Site-II could affect ligand binding, but likely to a lesser extent
than Site-I.
To more fully characterize effects on ligand binding, this study endeavored to
thermodynamically characterize site-specific ligand binding to HSA and HSAB . For
this purpose, thermograms collected as a function of ligand concentrations were used
to make estimates on ligand binding constants for HSA and HSAB as a function of pH.
Effects of ligand binding on protein structure and thermostability were also evaluated.
Ideal ligands used in this study were bromocresol green (BCG) and naproxen (NAP);
both known to bind selectively to Site-I or Site-II on HSA, respectively [2, 3]. NAP
and BCG are considered “ideal” ligands in the sense that their preferable binding
sites on HSA, and binding constants for those sites are well known [3–5, 20].
Our efforts are motivated by the desire to manipulate, enhance and exploit ligand
binding properties of HSA for several specific applications. These include HSA-based
capture reagents and drug delivery systems [19,21–23]. Success in this pursuit requires
a detailed understanding of the structural and thermodynamic features of HSA, and
how these are related to ligand binding activity and capacity.
Results demonstrate DSC analysis can be a powerful and convenient means for
probing inter-relationships between molecular conformation and thermodynamic stability of HSA bound by ligands.
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4.2

Results & Discussion

4.2.1

Overview

In three pH environments DSC thermograms were measured for standard HSA
and HSAB (prepared from HSA) alone; and in various mixtures of the proteins in
the presence of titrated amounts of either NAP or BCG. This definition of standard
HSA is strictly applicable in our in vitro system where fatty acids (FA) are not
present [24]. In vivo, the natural state of HSA is most certainly bound to some
extent by FA [2, 14, 25–27]. In this regard our results pertain to ligand binding in
the absence of FA. The linkage between binding and stability was demonstrated for
NAP and BCG in binding to HSA and HSAB . These ligands were chosen because
their binding constants and stoichiometries for HSA, under conditions similar to ours,
are well known [2, 3, 5]. Both ligands have multiple binding sites on HSA, but each
preferentially binds to one of two different high affinity sites termed by Sudlow as
Site-I and Site-II [2–5, 28, 29].

4.2.2

Stability of HSA and HSAB Alone as a Function of pH

Protein samples for all DSC measurements were prepared with commercially available, 99% pure HSA. This definition of standard HSA is strictly applicable in our in
vitro system where fatty acids (FA) are not present [24]. In vivo, the natural state
of HSA is most certainly bound to some extent by FA [2, 14, 25–27]. FA binding
constants can be orders of magnitude higher than drug ligands and consequently
dominate the ligand binding process. The presence of ”FA- and globulin-like contaminants” in less pure HSA commercial preparations can strongly contribute to the HSA
thermogram [18]. In order to isolate effects of ligand binding alone, it was necessary
to examine binding of ligands to HSA in the absence of FA.
Measurements determined how thermodynamic stability of HSA was affected by
covalent attachment of biotin. DSC analysis was demonstrated to be clearly capable of
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detecting the presence of modifications and differentiate, from standard HSA, effects
of increasing amounts of covalent modification. Multiple site modification of HSA
caused an incremental temperature shift up with increasing amounts of biotinylation
[18]. For the present study HSAB was prepared in precisely the same fashion as
previously described.
Thermodynamic parameters derived from DSC experiments for the newly prepared HSAB molecules were in precise agreement (within experimental error) with
reported values from our earlier study [18]. Evaluated parameters Tm and ∆Gcal
◦

(37 C) determined for HSAB∶1 were used as metrics for calibrating stability changes
associated with attachment of a single biotin. As described below, with the same
◦

proportional increases in Tm and ∆Gcal (37 C) as previously observed for increased
biotinylation up to saturation; the corresponding increases for the biotinylated HSA
samples prepared and examined here were consistent with HSAB∶X (X=1,5,10) samples, prepared as intended.
Prior to analysis of ligand binding to the HSA and HSAB substrates as a function
of pH, the thermodynamic stabilities of the substrates alone at pH = 6.0, 7.4 and 8.0
were examined by DSC. These pH values were chosen to bracket the known pKa of
lys199 (∼7.5) which resides in binding site I and with a reported role in structural
stabilization that depends on ionization state [10, 11]. Although the explicit thermograms are not displayed, quantitative parameters derived from DSC measurements
for HSA and HSAB∶X (X =1, 5, 10) as a function of pH are listed in Table 4.1. These
results can be summarized as follows.
(1) Tm is the primary indicator of thermodynamic stability. For both HSA and
HSAB the Tm values increased with decreasing pH. Further, increased biotinylation
induced increased stability. ∆Tm values in Table 4.1 are the differences between the
measured Tm ’s for HSA and HSAB∶X (X =1, 5, 10) at pH 6.0, 7.4 and 8.0 and HSA
at pH = 7.4. From the ∆Tm values listed in Table 4.1, the order of stability for HSA
and HSAB∶X (X =1, 5, 10) as a function of pH is 6.0

7.4

8.0. Results for HSA

and HSAB at pH = 7.4 are identical to those previously reported [18]. That study
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Table 4.1.: Stability parameters determined from DSC measurements for HSA and
HSAB alone. ∆∆H is the extra enthalpy contribution of biotinylation and pH isomerization to the denaturation reaction compared to the standard state (HSA and
HSAB∶X pH 7.4).
HSA

◦

∗

◦

Tm ( ) ∆Tm ( )

∆G (kcal/mol) ∆H (kcal/mol) ∆∆H

∗∗

(kcal/mol)

HSA pH 8.0

61.4

-1.1

10.0

136.4

-19

HSA pH 7.4

62.5

0

12.0

154.9

0

HSA pH 6.0

68.3

5.8

15.8

172.6

18

HSAB1∶1 pH 8.0

65.2

2.7

12.8

154.2

-39

HSAB1∶1 pH 7.4

67.3

4.8

17.2

192.7

0

HSAB1∶1 pH 6.0

69.3

6.8

19.9

211.2

18

HSAB1∶5 pH 8.0

71.1

8.6

17.2

173.6

-27

HSAB1∶5 pH 7.4

72.5

10

20.6

200.6

0

HSAB1∶5 pH 6.0

75.5

13

25.5

231.4

31

HSAB1∶10 pH 8.0

71.7

9.2

18.2

181.2

-26

HSAB1∶10 pH 7.4

72.5

10

21.2

206.6

0

HSAB1∶10 pH 6.0

76.1

14

26.2

234.0

27

For HSA and HSAB

*:∆Tm = Tm (pH) - Tm (7.4)

**: ∆∆H (pH) = ∆H(pH) -

∆H(7.4)

showed that the greater the level of biotinylation of HSA the greater the increase in
stability. Values of ∆Tm in Table 4.1 for HSA and HSAB∶X (X =1, 5, 10) show this
trend persists at pH = 6.0 and 8.0.
◦

(2) The values of ∆G = ∆Gcal (37 C) and ∆H = ∆Hcal in Table 4.1 provide
quantitative significance to the observed trends of ∆Tm for HSA and HSAB∶X (X =1,
5, 10) at pH 6.0, 7.4 and 8.0. These values are consistent with the observed order of
stability, as a function of pH. In Table 4.1, values of ∆G and ∆H for HSA and HSAB
at 7.4 are in precise agreement with findings of our prior study [18]. The spread of
∆G values vary for HSA and HSAB∶X (X =1, 5, 10) from 5.8 kcal/mol (for HSA) to
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between 7.1 and 8.3 kcal/mol for HSAB∶X (X =1, 5, 10). Effects of pH on protein
stability were greater for HSAB∶X (X =1, 5, 10) than HSA. Similarly, ∆∆H ranges
over the pH range from 36 kcal/mol for HSA, and from 52.8 to 57.8 kcal/mol for
HSAB∶X (X =1, 5, 10).
(3) The relative enthalpic contributions of pH, ∆∆H summarized in Table 4.1 are
differences between ∆H values measured for each of the HSA and HSAB samples at
pH = 6.0 and 8.0 from ∆H measured at pH = 7.4. These values indicate for HSA,
∆∆H (-19 kcal/mol) is lower at pH = 8.0 and (18 kcal/mol) higher at pH = 6.0
than at 7.4. These values are greater for HSAB∶X (X =1, 5, 10) where ∆∆H values
range from -26 to -39 kcal/mol at pH = 8.0 and from 18 to 31 kcal/mol at pH =
6.0. Effects of biotinylation are to decrease ∆H at pH = 8.0 and increase ∆H at pH
= 6.0; both to a greater extent than the analogous pH dependent changes observed
for HSA. Clearly, denaturation of the HSAB∶X (X =1, 5, 10) molecules is much more
sensitive to changes in pH than unmodified HSA. In HSAB molecules the biotins are
attached to lysine residues. The observed relatively greater influence of pH for the
biotinylated HSA molecules directly implicates the role of lysine residues in the pH
dependence of HSA denaturation.
As shown in Table 4.1 stability of HSA and HSAB varied with pH in the order
pH = 6.0 > 7.4 > 8.0. Potential origins of heightened stability of the HSA structure
at lower pH have been proposed to be due to protonation of lysine residues 199
(pKa ∼7.5–8) [10, 11] 195 (pKa ∼8.9) [10, 11] within the HSA tertiary structure.
When protonated these residues form hydrogen bonds with proximal residues Gln 196
and His 242 residing on a neighboring helix of site I, resulting in hydrogen bonding
between sub-motifs. At pH = 6.0, it is expected that both Lys 199 and Lys 195
are fully protonated. The amount of stabilization resulting from a tightening of the
of tertiary structure afforded by the suspected additional hydrogen bonds at pH =
6.0 was 20 kcal/mol; in precise agreement with the greater ∆Hcal measured here at
pH = 6.0 for HSA (18 kcal/mol) compared to HSA at pH = 7.4. And also in good
agreement with results from modeling studies of protonation of HSA structure where
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the global enthalpy change was estimated to be 14.7 kcal/mol, and associated with
significant effects on stability of the protonated structure [10]. Biotinylation of lysine
residues amplifies the differences in pH 8.0 and 6.0. At pH = 8.0 biotinylation of
lysines negatively effects the interaction observed at pH = 7.4. Conversely, at pH =
6.0 biotinylation of lysines enhances this interaction. Results can be summarized as
follows.
These results for HSA and HSAB∶X (X = 1, 5, 10) alone established the basis for
comparisons of results of ligand binding experiments conducted with them over the
same pH range.

4.2.3

pH Dependent HSA Structure

As described in Chapter 1, HSA is known to adopt different structural forms
depending on pH. Thermograms measured for HSA at pH values ranging from 3.0 to
8.0 are displayed in Fig 4.1. Corresponding thermodynamic parameters can be found
in Appendix A. Note, the thermograms at pH 6.0 to pH 4.5 show the emergence of
two peaks. The ”F” form of HSA occurs at pH ∼4.5 and is characterized by unfolding
of the native structure through cleavage of disulfide bonds. In this form subdomains
I and III of HSA appear to maintain some of their native structure, as shown in Fig
1.2.
The observation of two peaks on the pH=4.5 thermogram is consistent with ribbon
structures generated for HSA at pH 4.5 [2, 30]. A potential application utilizing this
observation would be isolation and analyzing ligand binding to particular individual
regions of the HSA structure in a label free way. Currently, the method of choice
to determine primary ligand binding sites on HSA is using fluorescent probes in
competitive exclusion experiments [31]. However, these probes can only identify a
single HSA binding site out of the many available sites. Use of thermograms at
pH=4.5 could provide a label free means to analyze ligand binding at specific locations
on HSA.
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Figure 4.1.: Thermograms for pH structures of HSA. 28 µM HSA at: (n) pH 7.4,
(l) pH 6.0, (s) pH 8.0, (t) pH 4.5, (u) pH 5.5, (◀) pH 3.0.

4.2.4

Reversibility of HSA pH Structure

The structural dependence of HSA on pH, described above, should be readily
reversible with changes in pH. To verify the reversible structural isomerization of
HSA, a solution of HSA was prepared at pH 3.0. The resulting thermogram HSA
solution at pH=3.0, displayed in Fig 4.2, showed little of the native structure of HSA
is present. HSA solutions at pH 3.0 were then brought to pH ∼7.2 by addition of
pH 8.0 buffer (Chapter 2) and melted. The resulting HSA thermogram at pH ∼7.2,
is shown in Fig 4.2, and indicates recovery of the native HSA structure at pH=7.4.
Slight differences might be due to the slightly lower pH of the reversed solution. This
result is consistent with the data above, in Section 4.2.2, where lower pH structures
of HSA displayed larger values of ∆G and ∆Tm .
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Figure 4.2.: Reversibility of pH structures of HSA (n) Standard HSA at 28 µM, (l)
HSA at pH 3.0, (s) HSA at pH 3.0 returned to pH ∼7.2.

4.2.5

Binding of NAP and BCG to Normal HSA

Fig 4.3 displays typical DSC thermograms measured for a constant amount of
HSA, at pH = 7.4, in the presence of increasing amounts of either NAP (a) or BCG
(b). There are clearly measurable variations of the thermograms with increasing
ligand concentrations. These data provided quantitative evaluations of essential ther◦

modynamic parameters ∆Hcal , ∆Scal , and ∆Gcal (37 C) at each ligand concentration.
Thermodynamic parameters for thermal denaturation of HSA bound by NAP and
BCG at pH = 7.4, are summarized in Table 4.2. At least two thermograms were measured for every sample. Average standard error on ∆Hcal values was approximately
◦

5%. Replicate experiments produced ∆Gcal (37 C) values within ± 0.2 kcal/mol and
◦

Tm ’s within ± 0.15 C.
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Figure 4.3.: Binding data for HSA in mixtures with NAP and BCG. (a) Titration
thermograms for HSA with NAP as a function of concentration. (n) Standard HSA
at 2mg/mL plus NAP at: 1 µM ( ), 10 µM (▶), 50 µM (◀), 100 µM (u), 175 µM
(t), 200 µM (s), 225 µM (l). (b) Titration thermograms for HSA with BCG as a
function of concentration. (n) Standard HSA at 2mg/mL plus BCG at: 10 µM ( ),
50 µM (▶), 75 µM (◀), 150 µM (u), 200 µM ((t), 225 µM (s).
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Table 4.2.: Thermodynamic parameters evaluated for HSA thermal denaturation in
mixtures with increasing amounts of the ligands naproxen (NAP) and bromocresol
green (BCG) at pH = 7.4.
Naproxen
[NAP] (µM) ∆Hcal (kcal/mol)
HSA

HSAB1∶1

HSAB1∶5

HSAB1∶10

Bromocresol green
0
∆G37

Tm

0

[BCG] (µM) ∆Hcal (kcal/mol) ∆G37

Tm

0

154.9

12.0

62.5

0

154.9

12.0

62.5

1

184.4

14.4

63.2

1

170.1

13.1

62.9

10

208.7

16.4

63.5

10

177.0

13.8

63.3

25

211.1

17.0

64.2

25

182.1

14.4

63.6

50

208.6

17.9

66.1

50

189.8

15.2

64.0

75

204.5

17.9

66.8

75

187.8

15.3

64.6

100

192.5

17.6

68.2

125

182.3

16.2

67.2

150

193.6

18.0

68.7

150

178.8

16.7

69.0

175

192.5

17.90

68.8

175

169.8

15.9

69.1

200

192.0

17.90

68.9

200

167.4

16.2

70.3

225

167.2

16.4

70.8

0

192.7

17.2

67.3

0

192.7

17.2

67.3

25

218.7

20.6

69.3

50

195.5

18.5

69.4

75

214.6

21.0

70.7

75

205.9

20.0

70.3

150

225.6

22.8

71.8

150

210.8

20.9

71.2

0

200.6

20.6

72.5

0

200.6

20.6

72.5

25

213.0

22.8

71.8

50

202.9

21.3

73.3

75

229.2

25.1

75.2

75

210.7

22.5

74.0

150

232.0

25.9

76.0

150

210.6

23.1

75.1

0

206.6

21.2

72.5

0

206.6

21.2

72.5

25

211.1

22.7

74.3

50

213.4

22.4

73.3

75

216.6

23.7

75.0

75

215.2

22.9

74.0

150

223.2

25.5

77.0

150

214.7

23.5

75.1

Error

5%

± 0.2

± 0.2

Error

5%

± 0.2

± 0.2
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NAP is known to primarily bind in the hydrophobic cleft of Sudlow Site-II. The
reported binding dissociation constant, KD (=1/KA ) ranges from 0.3 to 2.6 µM, with
stoichiometry n = 1. The curves in Fig 4.3a and data in Table 4.2 indicate when NAP
interacts with HSA at increasing concentrations there is a continual shift up in Tm
◦

(by as much as ∼6.5 C). BCG is a Sudlow Site-I binder with a reported KD ∼1.4 µM,
stoichiometry n = 3 [2, 5, 6]. Including warfarin, Site-I is known to bind a number
of therapeutic ligands. Thermograms in Fig 4.4b and data in Table 4.2 shows HSA
binding with increasing concentrations of BCG induced shifts up in Tm (by as much
◦

as ∼9 C).
Examination of the sets of curves in Fig 4.3 reveals clear differences between the
binding behaviors of NAP (n=1) and BCG (n=3); differences likely due to their
different binding stoichiometries and primary binding sites. Since Tm is a direct
measure of overall thermodynamic stability, changes in Tm with increased ligand
concentration provide a measure of the relative strength of ligand binding, through
measured changes in HSA denaturation. Comparable thermograms and data were
also obtained for binding of NAP and BCG to HSA at pH 6.0 and 8.0 shown in
Appendix A.

4.2.6

Binding of NAP and BCG to HSAB

In precisely the same manner as for the ligand binding experiments of HSA with
NAP and BCG, binding mixtures of the ligands with HSAB∶X (X = 1, 5, 10) were
also analyzed by DSC. Corresponding sets of thermograms are displayed in Appendix
0

A. In Fig 4.4 values of the differences ∆∆G37 determined for binding of ligands to
HSAB at pH = 7.4 are plotted versus ligand concentration for NAP (a) and BCG
(b), in mixtures with HSA or HSAB . Due to the different binding stoichiometries
for NAP and BCG, NAP concentrations were 25, 75 and 150 µM and BCG concentrations were 50, 75 and 150 µM. Plots in Fig 4.4 demonstrate effects of different
levels of biotinylation on ligand binding. Compared to HSA, biotin attachment to
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Figure 4.4.: Binding data for HSA and HSAB with (a) NAP and (b) BCG at pH 7.4.
Curves drawn through the data resulted from optimized model fits that produced
estimates on the ligand binding constant, KA and isomerization constant, KI , for HSA
and HSAB (see text). Displayed curves are for HSA (n), HSAB∶X , X=1 (l), X=5
(s), X=10 (t). Results of the comparative analysis in the three pH environments
are compared in Table 4.2.

0

HSA increases the melting free-energy, ∆G37 , by as much as 6 kcal/mol [18]. Values
0

of ∆∆G37 for ligand binding to HSAB∶X (X =1,5,10) at pH = 7.4 were progressively
smaller with increased biotinylation. Similar data were also obtained for HSA and
HSAB at pH 6.0 in Fig 4.5, and 8.0 in Fig 4.6 with similar findings. Results derived
from them are compared and summarized in Table 4.3.
Preferential binding of ligands to the native HSA structure (as opposed to the
denatured form), directly increases the relative concentration of native compared to
denatured protein species, resulting in an observed increase in thermostability. This
resulted in an increase of the transition temperatures, Tm , of HSA and HSAB . In all
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Figure 4.5.: Binding data for HSA and HSAB with (a) NAP and (b) BCG at pH 6.0.
Curves drawn through the data resulted from optimized model fits that produced
estimates on the ligand binding constant, KA and isomerization constant, KI , for
HSA and HSAB . Displayed curves are for HSA (n), HSAB∶X , X=1 (l), X=5 (s),
X=10 (t).

cases for both ligands, Tm values were higher for HSA than for HSAB with increased
ligand concentrations, indicating stronger ligand binding for HSA than for HSAB .
Additionally, ligand binding itself can affect protein structural stability and thereby
contribute measurably to the observed ∆Hcal of denaturation in the presence of ligands. As seen there, in the three pH environments, ∆Hcal values were significantly
different from zero in all cases examined and ranged from one to 53 kcal/mol.
As discussed later, these observations indicated a departure from the standard
mass-action/LeChatlier’s principle treatment for simple ligand binding [32]. According to our model, the additional enthalpy in the presence of the ligands represents
perturbations of protein structural thermodynamic stability associated with ligand
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Figure 4.6.: Binding data for HSA and HSAB with (a) NAP and (b) BCG at pH 8.0.
Curves drawn through the data resulted from optimized model fits that produced
estimates on the ligand binding constant, KA and isomerization constant, KI , for
HSA and HSAB . Displayed curves are for HSA (n), HSAB∶X , X=1 (l), X=5 (s),
X=10 (t).

binding. Thus, DSC thermograms measured as a function of ligand concentration
displayed more than a simple Tm shift.

4.2.7

Reversibility of Melting Transitions for Free and Ligand-bound
HSA and HSAB

As previously reported for the reversibility of the melting transition of highly pure
HSA (same preparation used here), analogous melting experiments were performed
on HSAB alone and HSA, or HSAB complexed (at saturation) with either NAP or
BCG [18]. As in previous experiments for HSA alone, new experiments measured ther◦

mograms for different samples first heated to temperatures from 25 to 60 C, cooled
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◦

at the same rate, and then re-heated from 25 to 80 C [18]. As previously reported
for HSA, when the HSAB and ligand-bound samples were first heated to tempera◦

tures up to 60 C, just at the edge of the melting transition, cooled and re-melted,
recorded thermograms were indistinguishable from those of the unheated samples,
displayed in Fig 4.7a. They displayed a single peak, with Tm in precise agreement
with the corresponding previously unheated samples. As before, this observation was
◦

taken to indicate that up to at least 60 C, corresponding to early onset of the melting
transition, measured thermograms were unaffected by prior heating and cooling, and
reversible [18, 33–35].

Figure 4.7.: Reversible and irreversible melting transitions for free and ligand-bound
◦

HSA. (a) Thermograms for HSA after initial heating to 60 C with naproxen (NAP)
and bromocresol green (BCG). (n) HSA at 28 µM, (l) HSA at 28 µM with 25 µM
NAP, (s) HSA at 28 µM with 75 µM BCG. (b) Thermograms for HSA after initial
◦

heating to 80 C with NAP and BCG. (n) HSA at 28 µM, (l) HSA at 28 µM with
25 µM NAP, (s) HSA at 28 µM with 75 µM BCG.

100

In contrast, when HSA, HSAB or ligand-bound samples were pre-heated to tem◦

peratures above Tm i.e. up to 80 C, cooled and re-melted, thermograms for the
pre-heated samples were quite different from normal (not previously heated) thermograms, shown in Fig 4.7b. These results were also entirely consistent with published
◦

studies of HSA, that have shown HSA melting is mainly reversible up to ≈62 C, but
not much higher [36–38]. It was also reported that the rate of irreversible denatu◦

ration reaction was considerably slower at lower temperatures (below 74 C). Under
experimental conditions comparable to ours [18,34,39,40], these authors asserted that
◦

even up to 74 C the HSA denaturation reaction is predominantly reversible [38]. Behaviors of thermograms for the heated and re-melted protein solutions of HSA and
HSAB were essentially the same, in the presence or absence of ligands (at all ligand
concentrations), providing evidence for minimal effects of ligand interactions with the
denatured protein. In light of these reports it was assumed the measured and analyzed melting transitions of HSA and HSAB alone or complexed with ligands were
(for the most part) reversible. Finally, in the analyses that were performed, the denatured state of the protein was chosen as the “universal” reference state. With this
choice, the possibility of heterogeneous denatured states and ligand binding to them
was presumably small and not explicitly considered. These were major operative
assumptions in the present study.

4.2.8

Data Analysis Strategy

Meaningful analysis of ligand binding to HSA by DSC is challenging for several
reasons. First, the thermogram of HSA is relatively simple in character, single peaked
and nearly symmetric. From an informatics perspective there is insufficient complexity (“information”) in an individual thermogram to support very detailed analytical
models, with reliable predictive accuracy. Second, data reduction and analysis of
primary DSC data is highly dependent on choice of baselines and uncertainties associated with same. Third, interpretation of results is highly model dependent and
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difficult; with marginal accuracy and limited reliability. For these reasons and other
considerations, we have implemented the Ligand Binding Isomerization (LBI) model
(as described in Appendix A) to analyze, interpret and compare results; the expressed
intent being evaluation of effects of biotinylation and pH on ligand binding to HSA.

4.2.9

Dose-Response Curves

Experimentally determined thermodynamic parameters as a function of ligand
concentration provided a means for estimating values of the association binding constant, KA . For this purpose, ligand concentrations served as the doses and ∆Gcal
◦

(37 C) or Tm the responses measured for HSA in mixtures with either NAP or BCG
at increasing doses. Dose Response (D-R) curves shown in Fig 4.8 generated from
DSC primary data for HSA at pH = 7.4 enabled quantitative evaluation of the ligand
binding constants, KA , for NAP and BCG binding to HSA. [37, 38].
Using the range established by the values summarized in the table inset of Fig
4.8, D-R analysis provided semi-quantitative estimates on HSA dissociation binding
constants for NAP (0.21-2.27 µM) and (1.64-4.97 µM) for BCG. The mean values
of KD were 1.24 µM for NAP and 3.31 µM for BCG. These values were in precise
agreement with the range of reported consensus values for NAP (0.3-2.6 µM) and BCG
(1.4 µM) [4,5]; and used as the basis for relative comparisons with other results. Even
◦

though Tm is evaluated directly by DSC while ∆Gcal (37 C) requires more detailed
◦

analysis, the curves for Tm and ∆Gcal (37 C) versus ligand concentration in Fig 4.8
are comparable. The range of reported values for the binding constants of NAP and
BCG spans the differences displayed for them in Fig 4.8. For this reason, the average
◦

values of the binding constants determined from Tm and ∆Gcal (37 C) were used for
further analysis; since the whole of that analysis involved relative comparisons.
D-R curves were not constructed for HSAB∶X (X=1,5,10) because only four data
points were collected for each of the HSAB samples. These data were unable to
support construction of D-R curves that could support reliable fits.
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Figure 4.8.: Dose Response (D-R) curves constructed from experimentally derived
0

∆G37 (l) and Tm (n) plotted versus log for([ligand]/[protein]) for NAP (a) and
BCG (b) binding, pH = 7.4. Inset: Tables summarize binding parameters derived
from D-R curves constructed from the data in (a) and (b). Displayed values are in
excellent agreement with those reported in the literature [2, 5–8].

4.2.10

Analysis of Binding Curves

Initially, binding constants were evaluated by fitting the data assuming mass action was the sole source of the observed increases in stability with increased ligand
concentration, i.e. increased ligand concentration and binding to the native structure resulted in increased thermodynamic stability of ligand-bound protein. Simply
assuming a single determinant (ligand concentration) for observed stability increases
resulted in evaluated binding constants approximately two orders of magnitude higher
than actually found for NAP and BCG from their D-R curves. This disparity suggested factors in addition to mere mass action (Le Chatlier’s Principle) might also
be responsible for observed increases in stability of HSA with increased ligand con103

centration [41]. In consideration of these factors, the LBI model was employed (see
Appendix A).
To compare ligand binding of HSA with that for HSAB , as a function of increased biotinylation and pH, binding curves were constructed by plotting ∆∆Gobs
T otal

= ∆∆Gobs

HSA

- ∆Gobs

as a function ligand concentration. As described in Appendix

A, binding curves were calculated using the expression for ∆∆Gobs derived from the
LBI model,
∆∆G = RT (ln(1 + [L]KA (1 + KI )) − lnKN D )

(4.1)

Binding curves of ∆∆Gobs versus ligand concentration that were generated at
pH=7.4 are shown in Fig 4.4. Values of KA or KI were evaluated by varying them
to fit the measured binding data as shown in Fig 4.4. Similar data were obtained
at pH = 6.0 and pH = 8.0 and also fit as described (not shown). Fits of the data
obtained by varying both KA and KI simultaneously as adjustable parameters were
prone to produce inconsistent, non-unique solutions; indicating the binding data in
Fig 4.4 might only support a single parameter fit. Justification for fitting with a single
parameter required assuming that biotinylation and pH primarily effected different
aspects of HSA structural stability and binding. Owing to this constraint, fits of the
same data (Fig 4.4) were performed in two different scenarios. First, to define effects
of pH on binding, data for HSA were fit varying KI while holding KA constant at
their independently determined values for NAP and BCG (Fig 4.4). Then, effects of
biotinylation were assessed by fixing KI determined for HSA, and varying KA in fits
of the data.

4.2.11

Binding Curves (pH)

In fits the binding constant, KA was fixed at the average values for either NAP
and BCG independently determined from D-R curve analysis as summarized in Fig
4.8. Isomerization constants, KI , were evaluated as the sole adjustable parameter to
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minimize the sum of the Chi-squared of the fits (shown in Fig 4.4) [42, 43]. Resulting
values of KI evaluated at pH = 6.0, 7.4, and 8.0 are displayed in Table 4.3. The analysis assumed values of the binding constants, KA , at pH 6.0 and 8.0 were essentially
identical to that at pH = 7.4, the designated reference state. Different conformational
isomers of HSA adopted in different pH environments have been reported [2, 10, 11].
Presumably structural changes induced by binding contribute to a portion of the
measured ∆∆Gobs . This part is represented by KI and assumed to capture collective
effects of pH on binding and HSA structure. Values of KI in Table 4.3 are from 11 to
16 times higher for NAP binding compared to BCG. This corresponds to free energy
differences associated with differences in KI for the two ligands that range from 1.50
to 1.75 kcal/mol over the pH range from 6.0 to 8.0. Thus, values of KI in Table 4.3
revealed (1): stability of the ligand-bound HSA structure as a function of pH was
6.0>7.4>8.0 consistent with reports for native HSA structure [10, 11]. (2) Compared
to BCG, NAP binding had a relatively greater effect on HSA stability as a function
of pH.
Table 4.3.: Values of the isomerization constant, KI , determined from fits of the
binding curves as shown in Fig 4.8. As described in the text, KI , corresponds to
the change of HSA thermodynamic stability that accompanies ligand binding. Note:
the effect is much greater for NAP binding compared to BCG at all pH examined.
Isomerization as a function of pH is strongest for pH = 6.0>7.4>8.0.

HSA-NAP

KI

HSA-BCG

KI

HSA NAP pH 8.0

51.3

HSA BCG pH 8.0

4.0

HSA NAP pH 7.4

141.6 HSA BCG pH 7.4

12.5

HSA NAP pH 6.0

244.2 HSA BCG pH 6.0

14.7
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4.2.12

Binding Curves (Biotinylation)

Biotinylation also has a measurable effect on HSA structural stability. Because
it is a covalent modification of the structure it presumably can more directly affect
ligand binding than pH [18]. With this consideration KA was varied as the single
adjustable parameter to fit the corresponding set of data points as shown in Fig 4.4
for pH 7.4. Values of KI determined in the three pH environments (as summarized in
Table 4.3) were fixed in the fitting procedure. Determined values of KA for HSAB∶X
(X=1,5,10) at pH 6.0 and 8.0 are summarized and compared in Fig 4.4.
Relative comparisons were based on the average dissociation binding constants
for NAP and BCG determined from the D-R curves in Fig 4.8 and converted to KA
values. Specifically, values used in subsequent comparative analysis were: for NAP,
5

−1

KA =8.06 x 10 M

5

−1

and for BCG, KA =3.02 x 10 M . The experimental protocol

revealed baselines had essentially the same structure for HSA and HSAB , in the three
pH environments. Thus, inter-comparison of relative differences of fitted binding constants for the HSAB molecules at pH 6.0 and 8.0 provided a reasonably accurate and
semi-quantitative metric. Relative values obtained from this comparison, summarized
in Fig 4.4, reveal effects of biotinylation and pH on ligand binding.
Ratios for NAP and BCG listed in Fig 4.4 were determined by dividing the binding
constants (evaluated from curve fitting) by the average values of KA determined from
the D-R analysis for NAP and BCG (summarized in Fig 4.8). Relative values of the
ratios summarized in Fig 4.4 provided a semi-quantitative indication of effects of HSA
biotinylation and pH on NAP and BCG binding. Results revealed that compared to
HSA, biotinylation results in reduction of binding constants for both NAP and BCG
by as much as 100-fold for HSAB∶X . Regardless of pH or level of biotinylation, binding
appears to be greatly suppressed.
This was not unexpected considering that lysine residues prominently reside in and
around critical positions in the binding pockets defined by Sudlow Site-I and Site-II.
Biotinylation of lysine residues could certainly affect ligand binding (as observed);
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Table 4.4.: Effects of biotinylation and pH on NAP and BCG binding for HSAB .
Ratios that are listed for NAP and BCG are binding constants determined from
curve fitting divided by the average values of KA determined from D-R analysis for
NAP and BCG binding to HSA = 7.4 summarized in Fig 4.8.

HSA-NAP

Ratio

HSA-BCG

Ratio

HSAB1∶1 NAP pH 8.0

0.26

HSAB1∶1 BCG pH 8.0

0.29

HSAB1∶5 NAP pH 8.0

0.31

HSAB1∶5 BCG pH 8.0

0.02

HSAB1∶10 NAP pH 8.0

0.15

HSAB1∶10 BCG pH 8.0

0.01

HSAB1∶1 NAP pH 7.4

0.11

HSAB1∶1 BCG pH 7.4

0.25

HSAB1∶5 NAP pH 7.4

0.15

HSAB1∶5 BCG pH 7.4

0.05

HSAB1∶10 NAP pH 7.4 <0.01 HSAB1∶10 BCG pH 7.4

0.04

HSAB1∶1 NAP pH 6.0

0.01

HSAB1∶1 BCG pH 6.0

0.20

HSAB1∶5 NAP pH 6.0

<0.01

HSAB1∶5 BCG pH 6.0

0.02

HSAB1∶10 NAP pH 6.0 <0.01 HSAB1∶10 BCG pH 6.0

0.03

and it would be expected that this effect might increase with additional numbers of
biotins attached (also observed). Results in Table 4.3 further indicate that pH = 8.0
may be optimum for ligand binding of HSAB .

4.3

Conclusion
DSC analysis has been proven to be both a relatively fast and simple means to

assess ligand binding and quantitatively evaluate effects of ligand binding on HSA
stability. These features combined with quantitative success achieved in evaluation of
ligand binding parameters for NAP and BCG with HSA and HSAB are encouraging

107

and support the claim that DSC analysis can be a practical tool for screening ligand
interactions with HSA.
Binding of ligands to HSA is a critical determinant of effective drug efficacy impacting bioavailability, potency, delivery and metabolism [44–46]. A critical step in
pre-clinical drug discovery involves assaying how drug candidates interact with HSA
and other plasma proteins. Through the binding-stability linkage as exploited here,
DSC measurements of mixtures of “unknown” test ligands with HSA can provide a
direct means of evaluating ligand binding constants. High throughput capabilities of
DSC combined with simplicity and speed of the measurement make real the possibility
of DSC-based high-throughput drug screening.
Results convincingly demonstrated utility of the binding-stability relationship in
characterizing interactions of NAP and BCG with HSA. Further, general applicability of this approach to study interactions of a number of other different ligands
with HSA has also been demonstrated. In Chapter 5, a larger body of data of the
type shown here has been accumulated for 29 additional ligands of different types
and aqueous solubilities. These data provide additional supporting evidence for the
general nature of the binding-stability linkage and demonstrate its utility for characterizing HSA/ligand binding interactions. Results from these endeavors are the
subject Chapter 5. Also, this same binding-stability linkage relationship was recently
employed to characterize ligand binding with HSA and whole plasma [19].
In general, there are a number of important applications for capabilities of manipulating and enhancing ligand binding to HSA. These could play major roles in advancing pre-clinical drug discovery of pharmaceuticals, ADMET analysis and pharmacokinetics. Applications include engineering of modified HSA derivatives as specially
designed affinity capture reagents for the directed purpose of binding and isolating
ligands from plasma as described in Chapter 3 [19, 47]. In addition, modern design
strategies for effective, HSA-based therapeutic delivery systems in blood could benefit greatly from detailed knowledge of HSA ligand binding thermodynamics and the
binding-stability linkage described here [44, 45, 47, 48].
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CHAPTER 5: EVALUATION OF 29 DRUG/LIGAND
BINDING CONSTANTS FOR HUMAN SERUM
ALBUMIN USING DIFFERENTIAL SCANNING
CALORIMETRY

5.1

Introduction
Methods for analyzing binding of ligands to proteins are crucial for a number

of applications. One of central importance is analysis of drug/ligand binding to
Human Serum Albumin (HSA). Assessment of plasma protein binding (PPB) of new
drug candidates is an integral component of pre-clinical drug discovery and protein
engineering. For the purpose of this study, the terms ligand and drug are used
interchangeably to mean binding entities. In essence, all drugs are ligands but not all
ligands are necessarily drugs.
At 60% by mass of all plasma proteins HSA is the most prominent [1–4]. Intrinsic
to its biological activities, HSA is directly involved in transport and distribution of
therapeutic drugs in the blood. This activity can directly impact desired pharmacological effects of a therapeutic drug. A multiplicity of reactive sites on HSA have
been identified, and several with known binding affinities for a variety of different
drugs [5–7]. The pharmacokinetics (ADME properties) of administered therapeutic
agents can be greatly impacted by the enormous binding capacity of HSA, and binding
of other plasma proteins. Both experimental and computer studies have extensively
analyzed site-specific drug binding in HSA [8–10]. The prominence of HSA among
plasma proteins and the central role HSA plays in bioavailability of drugs, makes it
an important screening target. Screening of new drug candidates for HSA binding
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and analysis is central to their pre-clinical evaluation and development. Supply of
new drug candidates exceeds current screening capacity. This is primarily due to
the use of ineffective high-throughput screening methods. The result is bottlenecks
in the development pipeline and ultimately lower availability of potentially effective
drug candidates. Improved methods for rapid, quantitative screening of new drug
candidates for their PPB activity, could aid considerably in loosening disruptive bottlenecks and expediting the drug discovery process [11]. At least 90% of all new
drug candidates fail. Improved screening methodologies capable of rapidly evaluating protein binding properties are needed to provide deeper insight into relationships
between molecular and chemical characteristics of targets and drug candidates. This
information provides the means to establish correlations between specific physical and
chemical attributes of drugs and their targets. Such correlations can then be employed
in the functional design and optimization of biochemical properties of new drug candidates. These improvements could aid to reduce the failure rate of new drugs and
could have significant impact on the early pre-clinical drug discovery process.
Generally, when a drug/ligand recognizes and binds to a protein, depending on
the nature of binding (electrostatic, polar, hydrophobic, etc.) it can either stabilize
or destabilize the protein with respect to thermal or chemical denaturation. Thus,
relative to the unbound protein, when bound the melting temperature (or concentration of denaturant) required to unfold the protein is either increased or decreased.
Interactions between circulating drug/ligands in plasma with HSA can affect protein
thermodynamic stabilities, thereby influencing the shape of the melting curve or thermogram of drug/ligand-bound HSA [12–14]. In this sense, thermograms measured by
differential scanning calorimetry (DSC) are highly sensitive to drug/ligand binding
interactions, as shown in Chapter 4.
This enhanced sensitivity of ligand-bound HSA compared to free HSA is due to a
direct linkage between ligand binding and thermodynamic stability of the protein [15].
The nature of this linkage is two-fold. Ligand binding to a protein as a function
of increased ligand concentration results in increases in melting transition tempera-
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tures, Tm , of ligand-bound protein complexes. Not unexpected this observation is
simply a well-known manifestation of Le Chatelier’s principle as applied to proteinligand binding [16, 17]. That is if a ligand binds preferentially to the native rather
than denatured state the thermal stability will be increased. Provided the measured
calorimetric enthalpy of the heat-induced denaturation transition of the ligand-bound
protein remains constant, as ligand concentration is increased, the observed shift in
stability with ligand binding forms the foundation of any standard temperature shift
assay [16].
However, if the measured melting enthalpy of the ligand-bound protein does
change with increased ligand concentrations then (as has been observed) this is an indication that the equilibrium thermodynamic stability of the native protein structure
has also changed due to ligand binding [15]. Therefore, observed changes in thermal
stability also reflect directly on thermodynamic consequences of structural (perhaps
subtle or not so subtle) perturbations of the protein conformation and stability associated with ligand binding.
Depending on the type and strength of binding interactions, temperature shifts on
thermograms of proteins in the presence of ligands can be dramatic (easily tens of degrees). These “T-shifts” along with increases in the melting enthalpies of drug/protein
complexes that are associated with binding of ligand can be far more significant than
detectable variances in either mass or charge that accompany binding. Consequently,
compared to other standard methods, DSC derived thermograms can be more sensitive to binding interactions.
DSC is a well-known physical technique commonly used for detailed quantitative
analysis of protein stability. Thus, it is surprising that relatively little attention has
been given to application of DSC for analysis of drug/protein interactions. This
because previous attempts to utilize DSC for drug binding analysis have met with
limited success [18–20]. Chapter 4 described a fast, reliable and accurate procedure
using DSC measurements that enables evaluation of thermodynamic parameters for
ligand bound protein. There are a number of favorable features of this analytical
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approach. These include: (1) ease of sample preparation and experimental execution,
(2) small volume of sample required (∼500 µL), (3) no prior knowledge of binding
activity required, (4) short processing time (less than 90 minutes), (5) Fully amenable
to automated, high-throughput format for parallel screening applications.
Collective features of the process provide a promising alternative approach with
which to interrogate drug/protein interactions, and argue that DSC could prove to
be a potentially superior screening alternative.

5.2

Results and Discussion

5.2.1

Drug/Ligand Samples

Chemical compounds chosen for DSC analysis of HSA binding were selected to
be representative of a broad variety of drugs; all with known clinical utility. A few
compounds with no reported binding activity, or poor aqueous solubility were also
examined. In total, HSA binding reactions of 29 different compounds were analyzed.

5.2.2

Binding of 29 drugs to HSA

Typical binding data for HSA in the presence of drugs were comprised of DSC
thermograms measured for a constant amount of HSA in the presence of increasing
amounts of drug. The complete sets of thermograms collected for HSA in the presence
of increasing concentrations and D-R curves derived from them for the 29 drugs are
given in Appendix B.
For drugs that exhibited detectable binding to HSA there were clearly measurable variations of the HSA-bound thermograms with increasing drug concentrations.
From these data quantitative values of Tm and thermodynamic parameters ∆Hcal ,
◦

◦

∆Scal =∆Hcal /Tm , and ∆Gcal (37 C)=∆Hcal -T(37 C)∆Scal were determined at each
◦

drug concentration. The values of ∆Hcal , Tm and ∆Gcal (37 C) evaluated for thermal
denaturation of HSA bound by the 29 drugs are summarized in Table 5.1 (a more
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detailed description can be found in Table B.1 of Appendix B). These results are
discussed subsequently.

Figure 5.1.: Measured (◦) binding constants compared with literature (□). Literature
values are given in Table 1. *Insoluble or sparingly aqueous soluble compounds.

Out of the 29 drugs examined, 19 of the drugs had binding data reported in the
literature. For six of the drugs, no binding data was available. Four of the drugs
did not display any binding activity. Evaluated binding constants for the 19 drugs
are plotted along with their reported literature values in Fig 5.1. Evaluated binding
constants and stoichiometries for the 29 drugs with HSA are displayed in Table 5.1
along with their average literature values. Additional information (literature values
and experimental techniques for their evaluation) can be found in Appendix B. As

117

shown in Fig 5.1, KD values ranged over five orders of magnitude from 10 nM to 1
mM and agreed with reported values within the error.
To prospect for HSA binding activity for the four drugs with no reported binding
activity, thermograms of the drug/HSA mixtures were measured at a drug concentration of 100 mM. This relatively high drug concentration would be expected to evoke
some sort of a response in the form of shifted HSA thermograms induced by drug
binding. The measured thermograms of these drug mixtures of HSA with 100 mM
drug concentration were identical to that of HSA alone, providing no evidence for
HSA binding (Appendix B).
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Table 5.1.: HSA-Drug binding constants and stoichiometries.
Drug

Avg. Measured

Measured

Avg. Literature

KD (10 M)

Stoichiometry

KD (10 M)

Stoichiometry

3.31 ± 1.7

3

1.43 [21]

3 [21]

Naproxen (NAP)

1.24 ± 1.0

10.8

1.33 ± 0.5 [9, 22–25]

1-10 [9, 22–25]

Chloroquine (CQ)

33.97 ± 4.6

1.3

62.40 ± 37.1 [26–28]

1 [26, 28]

Multihance (MH)

1335 ± 45

1.1

1948 ± 1532 [29, 30]

1 [29, 30]

Ablavar (AB)

36.61 ± 14.7

2.3

60.40 ± 43.4 [29–32]

1 [29–32]

Dotarem (DOT)

N/A 1.0

–

N/A [30]

–

Prohance (PRO)

N/A

–

N/A [30]

–

Magnevist (MAG)

N/A

–

N/A [30]

–

Gadovist (GAD)

N/A

–

N/A [30]

–

Tetracaine (TET)

26.13 ± 2.5

0.8

59.80 ± 13.2 [33, 34]

1 [33, 34]

Captopril (CAP)

3.75 ± 1.7

2.7

191.59 ± 188.4 [35, 36]

1.7 [35, 36]

Caffeine (CAF)

247

–

696.2 ± 201.2 [37–40]

1 [37, 38, 40]

Thimerosal (TMS)

1) 3.13 ± 0.43

1) 0.8

339 [41]

1 [41]

2) 317.50 ± 63.5

2) 0.7

Fluorescein (FSC)

3.31 ± 1.7

1.4

212.03 ± 106.2 [42, 43]

1-4 [42, 43]

Metformin (MET)

1) 2.01 ± 0.43

0.6

26.73 ± 3.6 [44, 45]

1 [44, 45]

−6

Bromocresol

−6

Literature

Green (BCG)

2) 24.5
Metoprolol (MEP)

11.14 ± 8.1

0.2

74.07 ± 72.4 [46, 47]

1-2 [46, 47]

Bupropion (BPR)

1) 0.25 ± 0.04

1) 1.3

172.2 ± 165.8 [48, 49]

1 [48, 49]

2) 19.51 ± 9.3

2) 2.8
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Table 5.1 continued
Drug

Avg. Measured
−6

Measured

Avg. Literature
−6

Literature

KD (10 M)

Stoichiometry

KD (10 M)

Stoichiometry

DM1157 (DM1)

0.91 ± 0.01

1.0

N/A

-

BP-DOTA (side)

8.55 ± 0.7

1.2

N/A

-

BP-DOTA (corner)

11.41 ± 1.0

0.9

N/A

-

NBAM-DO3A

70.20 ± 1.8

1.0

N/A

-

BPAM-DO3A

16.58 ± 5.0

1.9

N/A

-

DOTFA

19.37 ± 9.1

2.8

N/A

-

Digitoxin (DTX)*

14.86 ± 0.3

1.0

21.27 ± 9.1 [50–52]

1 [50]

Ibuprofen (IB)*

2.30 ± 1.3

3.7

1.89 ± 0.8 [52–54]

3 [53]

Decanoic Acid (DCA)*

8.42 ± 0.4

0.9

6.70 ± 3.3 [55–57]

1 [55–57]

∆9-tetrahydrocannabinol

0.04 ± 0.02

2.0

0.05 ± 0.1 [58]

1 high affinity [58]

(THC)*

1 low affinity [58]

β-Estradiol (BST)*

17.94 ± 8.9

3.2

9.98 ± 6.7 [59–62]

”assumed n=1” [59, 63]

Bilirubin (BIL)*

0.33 ± 0.1

1.6

0.07 ± 0.1 [64–66]

1 [66]

5.2.3

Drug/Ligand Binding Constants
◦

For 23 of the drugs, D-R curves constructed with either ∆Gcal (37 C) or Tm displayed typical binding behavior where increasing dose concentrations led to a sigmoidal increase in response. These curves were fit well with a single D-R curve and
provided evaluations of binding constants in agreement with the literature. Five of
the binding curves were atypical and displayed a bi-dose response or destabilization
with increased drug concentration. These specific examples are described below.
Two of the drugs (thimerosal and bupropion) displayed bi-D-R curves for both
◦

∆Gcal (37 C) and Tm . Analysis of the bi-D-R curves yielded two KD values suggestive
of two distinct binding reactions. As shown in Table 5.1, two binding constants
were evaluated for thimerosal, KD1 = 3.13 µM and KD2 = 312 µM (see Table 5.1).
The latter is consistent with the reported literature value, KD = 339 µM [41]. The
120

former requires additional considerations. One of those is that thimerosal contains an
organomercury moiety; with HSA binding likely corresponding to KD1 . Interestingly,
binding of small organomercury compounds to the free sulf-hydryl at cys34 on HSA
has been reported to be 0.1-1 µM (with n=4 required for accurate fits). This range
of values is very close to our evaluated KD1 = 3.13 µM [67, 68]. Thimerosal rapidly
decomposes in the presence of HSA to yield organo-Hg(II) fragments that can also
bind HSA [67]. Detection of two binding reactions for thimerosal is consistent with
HSA binding of both whole thimerosal and an un-mercurated thimerosal fragment at
its specific site on HSA [67].
An analogous situation likely exists for bupropion for which the t-butylamino
group is reportedly cleaved yielding two products in solution, i.e. a chlorophenyl
product and t-butylamino [69]. The observed bi-D-R curve likely corresponds to
separate binding of the two degradation products to HSA, in a manner similar to
thimerosal. The result is the observation of two separate binding constants, KD1
= 0.25 µM and KD2 = 19.5 µM (see Table 5.1). The average of these is 9.8 µM in
excellent agreement with the reported HSA binding constant of 6.37 µM [48].
For metformin, only the Tm D-R curve was bi-phasic. This observation is possibly
due to HSA binding of both metformin and a decomposition moiety. Metformin is a
biguanide compound. Generally, in aqueous solutions biguanide compounds decompose to urea and other amines [45, 70]. These amine compounds can bind to HSA,
while urea is a known protein denaturant. The bi-D-R curve for Tm displayed a
destabilizing trend for HSA as a function of drug concentration, possibly due to urea,
◦

while ∆Gcal (37 C) displayed a single D-R curve with KD = 2.44 µM. The destabilizing bi-D-R curve for Tm yielded two separate binding constants, KD1 = 1.58 µM
and KD2 = 24.52 µM (see Table 5.1). The latter is in excellent agreement with the
reported average value for metformin, KD =26.73 µM [44,45]. Presumably the former
corresponds to binding of amine degradation products. Although consistent with our
results this interpretation is by no means conclusive.
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◦

Finally, captopril and metoprolol displayed a single D-R curve for ∆Gcal (37 C)
and a destabilizing D-R curve for Tm . Averages of evaluated binding constants
for captopril and metoprolol were KD = 3.75 µM and 11.14 µM, respectively (see
Table 5.1). These binding constants were consistent with the reported literature
values [35, 36, 46, 47]. As discussed above for metformin the presence of urea as a
degradation product obviously can destabilize the protein. Origins of the destabilizing D-R curves for captopril and metoprolol are less obvious. For captopril it has
been reported that, compared to unbound protein, the observed binding to HSA
encourages formation of aggregates at lower temperatures [71]. This could lead to
destabilization of the native HSA structure with increasing captopril concentrations.
For metoprolol, although not conclusive, circular dichroism measurements at increasing concentrations of metoprolol, led to spectroscopic changes interpreted to indicate
a decrease in α-helical structure for bound HSA which likely could destabilize the
native structure [46].
For the majority of compounds, quantitative drug binding analysis was performed
using simple D-R analysis. For the exceptions described above, quantitatively accurate KD values were obtained along with additional qualitative insight generated from
HSA binding thermograms. These results were encouraging and demonstrated that
our DSC approach was able to detect destabilizing behavior due to drug binding, and
provide accurate drug binding constants from a single set of experiments. Further, as
described below semi-quantitative estimates of the binding stoichiometry were also
obtained.

5.2.4

Binding Stoichiometry

In some cases, differences between the D-R curves constructed using either ∆Gcal ◦

(37 C) or Tm were observed. As described below semi-quantitative estimates on
the ligand binding stoichiometry could be estimated by comparison of the differ◦

ent binding constants evaluated from fitting the ∆Gcal (37 C) and Tm D-R curves.
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For single site binding, stoichiometry n=1, binding constants evaluated using either
◦

∆Gcal (37 C) or Tm were in quantitative agreement. However, for ligands with n
◦

> 1, i.e. 2-10, ratios of the binding constants determined from ∆Gcal (37 C) or Tm
doses differed, semi-quantitatively, by a factor of n. The rationale for this observation
follows.
◦

∆Gcal (37 C) was obtained from the measured ∆Hcal and Tm . ∆Hcal is comprised
of enthalpy changes of the drug and protein target that accompany binding, and
effects of binding on the thermodynamic stability of the protein. This includes intermolecular interactions of different types between drug and target. Also included in
◦

∆Gcal (37 C) are changes in entropy due to conformational changes in the drug and
◦

target upon binding. Therefore, ∆Gcal (37 C) was imminently more sensitive than Tm
to individual binding events as well as overall effects of binding on HSA structure.
For binding sites able to accommodate more than a single ligand, i.e. with binding
stoichiometry n > 1, effects of binding each ligand in the site are directly reflected in
◦

the evaluated ∆Hcal and consequently ∆Gcal (37 C) [15].
For ligand binding where n=1, Tm shifts with increased concentrations of ligands
that preferentially bind the intact native protein structure, are a natural occurrence
due to Le Chatelier’s principle [16, 17]. This leads to an increase in Tm of the ligandbound native structure and agrees with our results for ligands with n=1 stoichiometry.
Conversely, observed behavior for ligands with n > 1 is not simply explained by Le
Chatelier’s principle. Accordingly, at high ligand concentrations (above stoichiometric
amounts) the release of ligand by denaturation of the protein effects the melting equilibrium. However, at low ligand concentrations (below stoichiometric amounts) prior
to occupation of all possible binding sites (in an equilibrium sense), re-distribution
of the ligand among available binding subsites within the binding pocket can occur.
For example bromocresol green has been reported to occupy all three subsites (Ia, Ib,
Ic) within Sudlow Site I [21].
Consequently, for n > 1, ligand binding at the lowest sub-stoichiometric ligand
concentrations effectively decreases the actual observed site-specific binding constant
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for subsequent ligand binding events. In this scenario two competing reactions are
operative. The first being primary binding of ligand(s) in the binding pocket. The
second being redistribution of the ligand(s) within the pocket. Once ligand concentration is high enough to decrease likelihood of redistribution, and the primary binding
reaction dominates the process, then titratable increases in Tm are observed.
An alternative possibility is that the ligand can bind at more than one site with
relatively high affinity; but binding at some of these binding sites may not be sufficient
to affect the melting transition of ligand-bound HSA. In which case, binding of one
(or all) of the available sites, either individually or in concert, may be necessary to
affect HSA stability as detected by a shift in Tm . For example, naproxen has up to
10 binding sites on the HSA structure with binding constant values within an order
of magnitude of one another [9]. This was consistent with our observed stoichiometry
for naproxen of n = 10.8. Note, that these binding effects need not be exclusive and
could occur simultaneously.
Thus, for single ligand binding at a single site, KD values obtained using either
◦

Tm or ∆Gcal (37 C) would be expected to be essentially the same (as observed).
However, for binding multiple ligands at a single site prior to saturation, measured
Tm may be largely unaffected until several binding events have taken place at the
site and saturation binding is approached. The result was observation of a shifted
D-R curve for Tm (by a factor of n, the binding stoichiometry) compared to those for
◦

∆Gcal (37 C). This resulted in differing values for the binding constants obtained from
◦

the analysis of Tm or ∆Gcal (37 C) D-R curves as a function of ligand concentration.
In effect, there were actually two binding constants, i.e. KD(Tm ) and KD(∆Gcal (37◦ C))
evaluated. The ratio KD(Tm ) ⁄KD(∆Gcal (37◦ C)) provided semi-quantitative estimates of
the binding stoichiometry, n. As shown in Table 5.1 the very good agreement between
estimated n values with those reported in the literature for the same ligands supports
◦

validity of the above proposition. KD values derived from ∆Gcal (37 C) comprised
the ensemble of thermodynamic contributions of ligand binding to HSA. Individual
evaluated thermodynamic parameters for binding obtained from thermograms can
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also yield additional insight and provide a means for further classification of drug
interactions with HSA.

5.2.5

Binding Thermodynamics

Formation of drug/protein complexes requires several specific events. These include: disruption of non-covalent interactions with water for both the drug and target
molecule i.e. de-solvation; conformational changes in the target and drug and formation of non-covalent interactions between them required for complexation; exchange,
association, or dissociation of ions, protons and small molecules that also accompany
drug binding. Each of these events can contribute to binding affinity in different
ways, but all manifest in values of binding contributions to the enthalpy ∆HB and
entropy, ∆SB . In our analysis ∆HB =∆HHSA⋅L -∆HHSA . ∆HHSA is the melting enthalpy of HSA alone and ∆HHSA⋅L = ∆Hcal is the denaturation enthalpy measured
◦

for the HSA-ligand complexes. ∆Gcal (37 C) for the ligand-bound complexes and HSA
◦

alone were derived from values of ∆Hcal , ∆Scal and Tm . Then ∆GB (37 C)=∆GHSA⋅L
◦

◦

◦

(37 C)-∆GHSA (37 C). It should be noted that ∆GB (37 C) does not necessarily equal
◦

∆GB =-R(310K)lnKD . ∆GB (37 C) contains energetic contributions to binding mentioned above that effect thermal denaturation of the ligand-bound protein. Therefore
′

◦

∆Gcal (37 C) calculated from D-R curves was considered to be the energy only due to
ligand binding, not including other thermodynamic effects that might also contribute
◦

to the measured ∆GB (37 C). To denote Tm changes caused by ligand binding ∆Tm
is used where ∆Tm = Tm (HSA⋅L) - Tm (HSA).
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Table 5.2.: HSA-Drug thermodynamic binding parameters.
−1

Drug

∆HB (kcal mol

)

−1

∆GB (kcal mol

)

◦

∆Tm ( C)

Test Compounds
bromocresol green

23.21

3.82

6.29

naproxen

44.67

5.68

5.52

chloroquine

64.36

5.25

1.43

Multihance

49.36

4.37

1.75

Ablavar

51.71

6.85

6.53

tetracaine

41.68

4.37

3.16

captopril

57.44

4.56

-0.41

caffeine

94.13

8.00

0.47

thimerosal

73.93

14.30

16.67

fluorescein

62.97

8.89

7.95

metformin

52.57

4.27

-0.31

metoprolol

50.60

4.06

-0.40

buproprion

44.25

3.99

0.62

Unknown Compounds
DM1157

60.24

4.70

0.60

BP-DOTA (side)

25.18

4.05

6.10

BP-DOTA (corner)

50.76

7.37

7.80

NBAM-DO3A

35.54

3.92

4.87

BPAM-DO3A

71.99

7.74

4.55

DOTFA

18.98

1.67

0.35

Insoluble or Poorly Soluble Compounds
digitoxin

32.62

4.74

3.92

ibuprofen

119.54

23.59

19.53

decanoic acid

147.52

30.28

24.56

∆9-tetrahydrocannabinol

51.40

4.45

0.28

β-Estradiol

47.60

4.53

0.92

bilirubin

47.27

4.15

0.30

Error

± 7%

± 0.15

± 0.15
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Thus, a direct link exists between structural stability of HSA and melting stability of ligand-bound HSA complexes. Our approach involves exploiting this linkage by
evaluating binding constants through measurements of the effects of ligand binding
on the thermodynamics of ligand-bound protein denaturation. An added benefit of
our DSC-based analytical process is the enhanced insight that can be gained into relationships between specific physical (stereochemical) and chemical (functional group)
features and their effects on protein binding. In particular, as shown below, dissecting
the effects on binding activity of different derivatives with specific modifications of a
central compound can prove to be most insightful.
Examination of thermodynamic binding parameters listed in Table 5.2 provides
three examples highlighting how semi-quantitative thermodynamic measurements can
inform on specific features that might be considered in drug design choices. These
are: (1) BP-DOTA (side) and (corner), (2) NBAM-DO3A and BPAM-DO3A, and
(3) chloroquine and DM1157. Selected compounds contain examples of stereoisomers
and two functional isomers.
First, consider several novel analogs of commercially available gadolinium-based
contrast agents used for in vivo NMR imaging (generous gifts of Professor Mark
Woods and Dr. Lauren Rust). DSC measurements of these compounds provided a
quantitative metric by which to gauge effects of different specific chemical modifications of the drugs on HSA binding. Specifically, Dotarem (DOTA) and Prohance
(DO3A) have been reported to not bind measurably to HSA [30]. Our analysis concurred and thermograms of drug/HSA mixtures were identical to HSA alone with
no binding detected. In contrast, functional and stereochemical modifications of
these compounds conferred appreciable HSA binding activity; seen through unique
responses of the measured thermograms of their mixtures with HSA, and corresponding evaluated thermodynamic parameters as described below.
Modified forms, BP-DOTA (side) and (corner) are novel stereoisomers of Dotarem
[72] (generous gift of Professor Mark Woods and Dr. Lauren Rust, Portland State
University). For these compounds, the DOTA structure was modified with a biphenyl
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thiourea functional group [72]. The primary difference between the side and corner
isomers of BP-DOTA is the different regiochemistry of the BP functional substituents
on the chelate structure [72]. Binding data in Table 5.1 for the BP-DOTA compounds
indicated little difference in the average binding constants KD of 8.6 µM and 11.4
µM, for the side and corner isomers, respectively. However, measured thermodynamic
binding parameters were significantly different.
Even though BP-DOTA (side) and BP-DOTA (corner) displayed very similar
binding constants for HSA, the enthalpic contributions to binding, ∆HB , were significantly different at 25.18 kcal/mol for BP-DOTA (side) and 50.76 kcal/mol for
BP-DOTA (corner). Likewise, BP-DOTA (corner) displayed greater ∆GB and ∆Tm
than BP-DOTA (side). These significant differences suggested a potentially important role of stereochemical structure on HSA binding of drugs within this compound
family. These results highlighted how apparently identical compounds with similar
binding constants could display significantly different thermodynamic contributions
of drug binding to HSA thermostability. It would be much more difficult to obtain
comparable results using other methods (NMR, ITC and SPR) commonly applied to
assay ligand/protein binding. Our method provided unique information, i.e. both
compounds displayed essentially the same binding constants, but very different thermodynamic contributions of binding to HSA thermostability.
Second, consider NBAM-DO3A and BPAM-DO3A, novel functional isomers of
Prohance (unpublished, generous gift of Professor Mark Woods and Dr. Lauren Rust,
Portland State University). NBAM-DO3A contains a nitrobenzyl group and BPAMDO3A contains a biphenyl located at the same position on the chelate (DO3A). In
contrast to the BP-DOTA compounds above, these DO3A derivatives displayed significantly different average binding constants. With KD = 70.2 µM and 16.58 µM
for NBAM and BPAM, respectively. Notably, for the weaker binder NBAM, ∆HB
= 35.54 kcal/mol, half the ∆HB of BPAM at 71.99 kcal/mol. Similarly, ∆GB for
NBAM (3.92 kcal/mol) was approximately 50% of that for BPAM (7.74 kcal/mol).
Both compounds had similar ∆Tm values. Evaluated stoichiometries were n=2 for
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BPAM and n=1 for NBAM. After accounting for differences in estimated stoichiometry for BPAM-DO3A and BP-DOTA, the compounds displayed remarkably similar
binding constants. This despite differences in the DOTA and DO3A chelates. Thus,
the functional biphenyl modification conferred ∼11 µM binding to the chelates that
otherwise did not bind HSA. In this case the functional derivates (NBAM and BPAM)
showed differences in both HSA binding and thermodynamic stability.
Third, consider chloroquine, an antimalarial drug, and DM1157 a novel reversed
chloroquine compound consisting of a chloroquine backbone with an attached reversal agent (Generous gift from Professor David Peyton and Dr. Katherine Liebman,
Portland State University) [73–75]. Unlike the DOTA and DO3A examples above,
chloroquine and DM1157 displayed essentially identical thermodynamic contributions
of binding to HSA thermodynamic stability, i.e. ∆HB = ∼60 kcal/mol, ∆GB = ∼5
◦

kcal/mol, and ∆Tm = ∼1 C for both compounds. It might be expected given the similar thermodynamic behaviors of the compounds they would display similar binding
constants. However, this was not the case. For Chloroquine KD = 33.97 µM while
KD = 0.91 µM for DM1157. The binding constants differ by almost two orders of
magnitude! These results indicated that attachment of the reversal agent conferred
a much stronger binding constant compared to the unmodified chloroquine. Even
though binding of the bulky reversal agent did not significantly affect thermostability
of bound HSA. This was consistent with the general observation for these compounds
as ligand size did not necessary correlate with thermodynamic stability.
Of 29 drug compounds examined 22 were reported to be soluble in water. Six
were reportedly insoluble. Generally, between 40 and 70% of new chemical entities
entering the drug development pipeline potentially face bioavailability issues due to
low aqueous solubility [76]. Difficulties and limitations imposed by poor solubility can
compromise binding reactions in aqueous environments where most binding experiments were conducted. As an alternative, binding measurements can be performed
in organic solvents but could have potentially deleterious effects on the structure
and stability of the protein substrate. The organic environment could also adversely
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affect the stability of ligand/substrate complexes [77]. To avoid potential problems
associated with poor solubility, a novel sample preparation methodology was invoked.
Minimum amounts of drug sample (milligrams) are required with complete avoidance
of organic solvents in drug/HSA solutions. The method leverages one of the truly
remarkable intrinsic properties of HSA. That is the ability of the protein to accommodate extraordinary levels of ligand binding and actually increase ligand solubility in
plasma up to seven times higher than the normal solubility limit [78]. This ubiquitous
binding proclivity of HSA forms the basis for the HSA-assisted sample preparation
method that was used. It enabled the solubility of normally insoluble compounds
in aqueous mixtures with HSA. Effectiveness of the HSA-mediated solubility process
was clearly demonstrated for six poorly aqueous soluble compounds denoted by an
asterisk in Fig 5.1 and Table 5.1. Evaluated binding constants for these compounds
with HSA were in excellent agreement with literature reports. Application of this
process expands capabilities of DSC for screening potential drug/ligand candidates.

5.3

Conclusion
A number of techniques have been applied to evaluate protein/ligand binding

constants and assess drug-HSA binding. These include equilibrium dialysis, ultrafiltration, absorbance and fluorescence spectroscopy, isothermal titration calorimetry
(ITC) and Surface Plasmon Resonance (SPR). Of these, ITC and SPR are most
comparable (label-free) with our method.
ITC can provide precise evaluation of binding thermodynamics and binding constants at specific temperatures. Despite the sensitivity of ITC, the experiment is not
easily scalable for applications in preclinical drug discovery. ITC requires a skilled
practitioner to perform experiments, and large sample volumes at high concentrations. In the standard format ITC is incapable of high-throughput applications.
Despite being able to deliver perhaps the most quantitatively accurate binding information, because of the inherent drawbacks, ITC has been sparingly employed for
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drug screening [11]. Alternatively, the use of SPR for drug binding assays has become
a popular screening technique in the drug development industry.
SPR is a label-free detection scheme purported to provide important information
about binding of ligands and small molecules to plasma proteins. In fact, SPR has
become a method of some choice to examine equilibrium and kinetics of ligand/drug
binding. Although potentially quite informative, SPR has short comings and is not
without attendant difficulties. SPR does not provide complete information. For
example, SPR cannot supply any insight into binding stoichiometry. Another major
deficiency of SPR is that proteins or ligands must be immobilized to a surface. For
HSA binding, the protein is affixed using a sulfo-NHS reagent [79, 80]. In Chapters
3 and 4 this reagent was used to modify HSA with NHS-biotin [15]. Modification
of HSA molecules acted to decrease measured ligand binding constants by factors
from three to 100 [15]. Although SPR is able to quite accurately detect the presence
of ligand binding to surface-bound HSA, effects of modifications of HSA (required
for surface attachment) on ligand binding can be difficult to gauge. Thus, it can be
difficult to evaluate quantitatively accurate binding constants, for natural proteins,
from SPR measurements alone. A comparable label-free alternative that uses natural
HSA could provide more quantitatively accurate assessment of ligand binding. Ours
is such a method.
In this chapter we employed the DSC-based process, reported in Chapter 4, to
evaluate HSA binding parameters for 29 different drugs [15]. Four of the compounds
did not display any detectable binding activity; and six were insoluble in aqueous
solutions. Results demonstrated quantitatively accurate evaluations of drug-HSA
binding constants and semi-quantitative estimates of binding stoichiometries. For all
compounds examined, regardless of aqueous solubility, the near universal agreement
with published data for known drug/HSA binding constants attests to the general
accuracy and robustness of the approach. Results demonstrated a number of many
attractive advantages of our method over more laborious and labor intensive, less
accurate, slower and less informative ligand screening techniques such as ITC and
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SPR. Advantages of the method have the potential to considerably improve the preclinical drug screening process. More effective preclinical screening can reduce drug
development costs, and lead to production of more successful drugs with lower prices;
a major goal of modern healthcare management.
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Isis M Figueiredo, and Josué Carinhanha Caldas Santos. Thimerosal changes
protein conformation and increase the rate of fibrillation in physiological conditions: spectroscopic studies using bovine serum albumin (BSA). International
Journal of Biological Macromolecules, 113:1032–1040, 2018.
[42] Osama K Abou-Zied and Saba AJ Sulaiman. Site-specific recognition of fluorescein by human serum albumin: A steady-state and time-resolved spectroscopic
study. Dyes and Pigments, 110:89–96, 2014.
[43] John T Penniston. Fluorescence polarization measurement of binding of fluorescein to albumin. Experimental Eye Research, 34(3):435–443, 1982.
[44] Elaheh Rahnama, Maryam Mahmoodian-Moghaddam, Sabra KhorsandAhmadi, Mohammad Reza Saberi, and Jamshidkhan Chamani. Binding site
identification of metformin to human serum albumin and glycated human serum
albumin by spectroscopic and molecular modeling techniques: a comparison
study. Journal of Biomolecular Structure and Dynamics, 33(3):513–533, 2015.
[45] Deepti Sharma, Himanshu Ojha, Mallika Pathak, Bhawna Singh, Navneet
Sharma, Anju Singh, Rita Kakkar, and Rakesh K Sharma. Spectroscopic and
molecular modelling studies of binding mechanism of metformin with bovine
serum albumin. Journal of Molecular Structure, 1118:267–274, 2016.
[46] Osman Duman, Sibel Tunç, and Bahar Kancı Bozoğlan. Characterization of
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CHAPTER 6: ALLOSTERIC LIGAND BINDING OF
UNMODIFIED AND BIOTINYLATED HUMAN SERUM
ALBUMIN

6.1

Introduction
Human serum albumin (HSA) is a multi-domain, multifunctional protein molecule.

At 60% by mass HSA is the most prominent protein in blood plasma [1, 2]. In vivo,
HSA functions as a circulating sponge with the principal role as ligand transporter.
Inherent to its function HSA binds both reversibly and covalently to a broad spectrum
of endogenous and exogenous ligands. To name a few, classes of HSA binding ligands
include carbohydrates, fatty acids, peptides, hormones, MRI contrast agents and
drugs [2–4]. Not surprisingly, with such a diverse binding potential, multiple reactive
sites on HSA have been identified. Primary, ligand-specific, binding sites have been
hypothetically proposed based on modeling studies and some of these have been
experimentally confirmed [2, 5–7].
There are 585 amino acids on a single polypeptide chain of the HSA primary
structure [2]. In the x-ray crystal structure HSA monomer (molecular weight 66.5
kD) has a heart-shaped 3-D structure. In the HSA tertiary structure there are three
domains, I, II and III each with sub-domains A and B; all arranged in 27 α-helices.
Tucked within this tertiary structure are two major binding pockets for many ligands,
named after Sudlow [2, 3, 8, 9]. These are site IIA located in subdomain IIA (Sudlow
Site I) and site IIIA in subdomain IIIA (Sudlow Site II). A third site in subdomain
IB, site III, has also been proposed to be a minor consensus binding site [10].
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Atomic coordinates acquired via x-ray structures, in silico molecular modeling,
and docking/binding simulations have led to the proposition of allosteric interactions
that occur in HSA when site-specific ligands are simultaneously bound at their respective primary sites [5, 11–15]. These model analyses provide little insight into the
actual consequences of ligand binding on the thermodynamics of the global structure of HSA. This is relevant since modifications of the protein, which affect global
stability, can also affect local ligand binding which can further affect HSA global
stability.
Thermodynamic stability of HSA structures cannot be determined by x-ray structure analysis. Models based solely on them provide little insight into thermodynamic
aspects of the overall structure, stability and effects of local ligand binding. Direct
relationships between thermodynamic stabilities of standard and modified HSA and
site-specific ligand binding have not been established. Results of this study begin to
address this deficiency.
DSC analysis measures the thermostability of HSA global structure, manifested
in the thermal denaturation curve (or thermogram). Through this linkage, DSC thermograms of HSA are sensitive to structural modifications, isomerization and binding
interactions from their effects on thermodynamic stability of the protein. Thermodynamic characteristics of covalently modified HSA and their relative effects on ligand
binding have been investigated by DSC [16–18].
Biotinylation is a naturally occurring modification [19, 20]. Although this modification is important in several metabolic processes, more importantly it is assumed
to be an analog of glycosylation, another similarly-adducted HSA modification [11,
21, 22]. As prepared using the N-HS reagent, biotin binds and covalently attaches
to primary amines of lysine residues in HSA [23]. In Chapters 3 and 4 biotin was
attached to lysine residues in varying amounts and DSC thermograms were measured
for the differentially modified protein molecules, HSAB [16, 18].
That study investigated effects of increasing amounts of site-specific biotinylation
on global thermodynamic stability of HSA and HSAB . The effect of increased bi141

otinylation was an incremental increase in thermodynamic stability of the structure,
indicated by concomitant increases in melting transition temperatures of the thermograms. As described in Chapter 4 there is a direct linkage between HSA structural
modifications (biotinylation) and thermodynamic stability measured by DSC.
A direct linkage also exists between ligand binding and thermodynamic stability.
This binding-stability linkage provides a means for quantitative interpretation of thermodynamic parameters evaluated from DSC thermograms measured for ligand/HSA
mixtures. Previous experiments in Chapters 4 and 5 demonstrated the direct linkage
between thermodynamic stability and; binding constant and stoichiometry [18].
The aim of this study was thermodynamic characterization of site-specific ligand
binding with standard and modified structures of HSA. Early on in this endeavor,
the linkage between ligand binding and stability was clearly evident. This bindingstability linkage was then exploited to enable quantitative evaluation of effects of sitespecific ligand binding for unmodified versus biotinylated HSA, on thermodynamic
stability. Ligands chosen were bromocresol green (BCG) and naproxen (NAP); both
known to bind selectively to sites I or II and III, respectively [2,5]. They are considered
“ideal” ligands in the sense that their preferable binding sites on HSA, and binding
constants for those sites are well known [5–7, 24].
Our efforts were motivated by desires to manipulate, enhance and exploit the ligand binding capacity of HSA. Intrinsic to this pursuit is a fundamental understanding
of both structural and thermodynamic features of HSA related to its ligand binding
capacity. This is necessary for the purpose of engineering modified HSA as specially
designed affinity reagents. Such reagents can be used for the directed purpose of
binding and isolating ligand analytes from plasma. They can also form the basis of
HSA-based therapeutic delivery systems in blood [25–28].
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6.2

Results and Discussion

6.2.1

Overview

DSC thermograms were measured for various mixtures of highly pure (99%), unmodified “standard” HSA and HSAB (prepared from standard HSA) in the presence
of titrated amounts of either NAP or BCG alone or selected mixtures of both. This
definition of standard HSA is strictly applicable in our in vitro system where fatty
acids have been removed [29]. In vivo, the standard state of HSA is most certainly
bound to some extent by fatty acids [2, 11, 13, 15, 30]. The binding-stability linkage was demonstrated in Chapter 4 for NAP and BCG in their binding to standard
and biotinylated HSAB . These ligands were chosen because their stoichiometries and
binding constants for HSA have been reported [2,5,7]. Both ligands are known to have
multiple binding sites on HSA, but each preferentially binds to one of two different
high affinity sites (Sudlow sites I and II).

6.2.2

Thermograms of Standard HSA in Mixtures with Ligands

DSC derived binding data for HSA in the presence of NAP and BCG are displayed in Fig 6.1. Primary data shown are the DSC thermograms measured for a
constant amount of standard HSA in the presence of increasing amounts of either
NAP (Fig 6.1a) or BCG (Fig 6.1b). Plots in Figs 6.1a and 6.1b are clearly different. From displayed thermograms in Fig 6.1, semi-quantitative evaluations of the
0

thermodynamic parameters ∆Hcal , ∆Scal , and ∆G37 were obtained at each ligand
concentration. These evaluated thermodynamic parameters for thermal denaturation of HSA bound by NAP and BCG are summarized in Table 6.1. Standard error
0

on ∆Hcal and ∆Scal values was approximately 5%. ∆G37 values were within ± 0.2
◦

kcal/mol and Tm ’s were ± 0.15 C Examination of these results revealed significant
differences for the two ligands as a function of concentration.
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Figure 6.1.: Binding data for HSA in mixtures with NAP and BCG. (a) Titration
thermograms for HSA with NAP as a function of concentration. (n) Standard HSA
at 2mg/mL plus NAP at: 1 µM ( ), 10 µM (▶), 50 µM (◀), 100 µM (u), 175
µM (t), 200 µM (s), 225 µM (l). (b) Titration thermograms for HSA with BCG
as a function of concentration. (n) Standard HSA at 2mg/mL plus BCG at: 10
µM ( ), 50 µM (▶), 75 µM (◀), 150 µM (u), 200 µM ((t), 225 µM (s). (c)
Differences in Tm (∆Tm ) and calorimetric entropy (∆∆S) between ligand bound HSA
and normal HSA as a function of ligand concentration. ∆Tm : NAP (△), BCG (◦);
∆∆S: NAP (▲), BCG (l) Vertical lines denote reported saturation concentrations
for NAP and BCG primary site binding. (d) Dose response curves constructed from
0

experimentally derived ∆G37 : BCG (l), NAP (n). Inset: Table summarizes binding
parameters derived from Dose-Response curves constructed from the data in (a) and
(b). Displayed values are in good agreement with those reported in the literature
[2, 5–8].
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Table 6.1.: Thermodynamic parameters of ligand binding.
Naproxen
[NAP] (µM)

Bromocresol green

∆Hcal (kcal/mol) ∆Scal (cal/mol K)

0

∆G37

Tm

[BCG] (µM)
0

154.94

0

154.94

460.93

11.98

62.5

∆Hcal (kcal/mol) ∆Scal (cal/mol K)

0

∆G37

Tm

460.93

11.98

62.5

1

184.38

548.18

14.36

63.2

1

170.12

506.23

13.11

62.9

10

208.65

619.86

16.40

63.5

10

176.99

526.08

13.83

63.3

25

211.07

625.67

17.02

64.2

25

182.05

540.59

14.39

63.6

50

208.56

614.86

17.86

66.1

50

189.75

562.81

15.19

64.0

75

204.50

601.63

17.90

66.8

75

187.76

555.95

15.33

64.6

100

192.45

563.76

17.60

68.2

125

182.33

535.71

16.18

67.2

150

193.64

566.45

17.96

68.7

150

178.84

522.66

16.74

69.0

175

192.52

563.00

17.90

68.8

175

169.77

496.04

15.92

69.1

200

192.04

561.41

17.92

68.9

200

167.42

487.44

16.24

70.3

225

167.24

468.25

16.43

70.8

Error

5%

5%

± 0.2

± 0.2

Error

6.2.3

5%

5%

± 0.2

± 0.2

Binding of NAP and BCG to Standard HSA

NAP primarily binds to the hydrophobic pocket in Sudlow site II, with a reported
binding dissociation constant, KD ≈ 0.3 to 2.6 µM, stoichiometry n = 1 [2,5,6]. DSC
analysis of standard HSA in mixtures with increasing concentrations of NAP are
shown in Fig 6.1a. Data indicate NAP interacts with HSA causing a continual shift
◦

up in Tm (by as much as ≈6.5 C) with increasing ligand concentrations. Differences
between Tm of HSA/ligand mixtures at each ligand concentration and standard HSA
alone, Tm , are plotted versus concentration of NAP in Fig 6.1c. For NAP Tm increases
in a linear manner up to about 100 µM and then levels off thereafter at higher ligand
concentrations. This observation suggests a single (primary) binding site for NAP on
HSA, in agreement with numerous reports [5, 6, 24].
BCG is a Sudlow site I binder, with a reported KD ∼1.4 µM, stoichiometry n =
3 [2, 7, 8]. Including warfarin, site I is known to bind a number of other therapeutic
ligands. Thermograms for mixtures of HSA with increasing concentrations of BCG
are shown in Fig 6.1b. BCG binds HSA altering stability of the DSC thermogram
◦

with a shift up in Tm (by as much as ≈9 C) with increasing ligand concentration.
Here again, the linkage between binding and stability in HSA is clearly observed. As
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derived from the thermograms in Fig 6.1b, Tm values in Fig 6.1c also increase with
increasing ligand concentrations of BCG, but in a different manner than observed for
NAP. For NAP Tm increases in a linear manner before plateauing. In contrast Tm
for BCG seems to display two plateaus. One up to about 150 µM that levels off only
to increase again up to 200 µM before reaching a second plateau at and above 250
µM.
The observed difference in behaviors is likely due to the higher binding stoichiometry of BCG (n=3) compared to NAP (n=1) and binding of more than one BCG
molecule in site I, compared to binding of a single NAP molecule in site II. The
bi-phasic behavior of Tm for BCG is consistent with additional binding of BCG
molecules, with the effect of increasing stability of bound HSA. Since Tm is a direct measure of overall thermodynamic stability, changes in ∆Tm provide a relative
measure of the extent to which ligand binding induces significant (in the thermodynamic sense) structural changes of HSA. Under this criterion both NAP and BCG
binding demonstrate measurable effects on HSA structure.
Plotted in Fig 6.1c are differences between measured calorimetric entropies, ∆Scal
for ligand-bound HSA and ligand-free unbound HSA, i.e.∆∆Scal as a function of
ligand concentration. Recall, ∆Scal and Tm are inversely related through the enthalpy
(∆Hcal /Tm ≈ ∆Scal ). Generally, ∆∆Scal is a measure of the relative difference in
order between ligand-bound and unbound HSA. That is, if the bound state is more
ordered than the unbound native state of standard HSA, with a corresponding larger
∆Scal , then a larger∆∆Scal would also be observed.
If ligand-bound HSA forms a more stable, ordered structure (compared to standard HSA), the expectation would be an increased ∆Scal with increased ligand concentration until saturation is reached; and a maximum occurring at approximately
the site-specific binding stoichiometry, n. In Fig 6.1c the behavior of ∆∆Scal versus
ligand concentration for NAP shows a single peak at approximately 25 µM corresponding to the binding stoichiometry, n=1; then decreases and levels off at higher
ligand concentrations. The plot of ∆∆Scal versus BCG concentration displays a broad
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transition from 25 to 150 µM. From this plot saturation occurs around 50-60 µM. Although less than the expected saturation value for BCG, peaks on the plots of ∆∆Scal
versus ligand concentration in Fig 6.1c provide semi-quantitative indications of the
ligand binding stoichiometries. It is known that NAP binds at 1:1 to site II and BCG
binds site I at 1:3. Examination of the plots in Fig 6.1c reveals for both ligands that
∆∆Scal peaks are close to the known saturation binding stoichiometries (indicated
by the dotted vertical lines) for NAP and BCG with HSA.
Ideally saturation would correspond to the point where ∆∆Scal peaked and ∆Tm
ceased to change with increasing ligand concentrations. That the curves of ∆∆Scal
in Fig 6.1c decrease after the peak and level off at higher concentrations might reveal
the presence of additional binding activity (binding to additional sites, possibly site
III for example) that results in a less ordered ligand-bound state and correspondingly
smaller ∆∆Scal . That ∆Tm ceased to change at higher concentrations argues that if
secondary binding activity was present, it apparently had a relatively small effect on
overall stability of the protein.
◦

Using ligand concentration as the dose and ∆Gcal (37 ) as the response Dose Response (D-R) curves shown in Fig 6.1d were constructed and analyzed in the typical
manner [31, 32]. As summarized in the table inset of Fig 6.1d, D-R analysis provided
semi-quantitative estimates on HSA binding constants for NAP (0.25 ± 0.20 µM),
and BCG (1.70 ± 0.89 µM). These values were in good agreement with reported
consensus values for NAP (0.3-2.6 µM) and BCG (1.4 µM) [6, 7]. Good agreement of
binding constants evaluated from experimentally derived D-R curves further attested
to robustness of the direct linkage between binding and stability in HSA.

Biotinylated HSA
In Chapter 4, results of DSC measurements were reported that provided a quantitative measure of thermodynamic effects due to site-specific biotinylation of HSAB
[16]. There, a methodology and analytical process were developed and applied to
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quantitatively evaluate thermodynamic contributions associated with specific modifications (biotinylation) of HSA. Results demonstrated DSC to be a sensitive method
for monitoring conformation and stability of HSAB with different levels of biotinylation; and provided the primary analytical foundation employed to interpret results of
the present study.
Samples for all DSC measurements were prepared with commercially available,
99% pure HSA. Measurements determined how thermodynamic stability of HSA (an
indirect measure of HSA structural integrity) was affected by covalent attachment of
biotin. DSC analysis was demonstrated to be clearly capable of detecting the presence
of modifications and differentiate from standard HSA, effects of increasing amounts
of covalent modification. Multiple site modification of HSA caused an incremental
temperature shift up with increasing amounts of biotinylation.
For the present study biotinylated HSAB was prepared in precisely the same fashion as described in Chapter 2 [16, 17]. Thermograms of the newly prepared HSAB1∶1 ,
HSAB1∶5 and HSAB1∶10 and thermodynamic parameters derived from them were in
precise agreement (within experimental error) with reported values from the earlier
◦

study. Evaluated parameters Tm and ∆Gcal (37 ) determined for HSAB1∶1 were used
as metrics for calibrating stability changes associated with attachment of a single
◦

biotin. With proportional increases in Tm and ∆Gcal (37 ) as previously observed
for increased biotinylation up to saturation; the corresponding increases for the biotinylated HSA samples prepared and examined here were consistent with HSAB1∶1 ,
HSAB1∶5 and HSAB1∶10 samples prepared as intended.

6.2.4

Binding of NAP and BCG to Biotinylated HSAB

In precisely the same manner as for the ligand binding experiments of standard
HSA with NAP and BCG, binding mixtures of ligands with HSAB1∶1 , HSAB1∶5 and
HSAB1∶10 were also analyzed by DSC. Corresponding specific thermograms are dis0

played in Appendix A with ∆G37 for binding of NAP and BCG evaluated from them
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0

Figure 6.2.: ∆G37 values for mixtures of HSAB with NAP (a) and BCG (b). (a) (n)
standard HSA + NAP, (l) HSAB1∶1 + NAP, (s) HSAB1∶5 + NAP, (t) HSAB1∶10 +
NAP. (b) (n) standard HSA + BCG, (l) HSAB1∶1 + BCG, (s) HSAB1∶5 + BCG,
(t) HSAB1∶10 + BCG.

summarized in Fig 6.2, and plotted versus ligand concentration in Fig 6.2. For HSAB
binding experiments, thermograms were measured at three different concentrations
0

of NAP and BCG. In Fig 6.2 values of ∆G37 are plotted versus the molar ratio of
NAP (Fig 6.2a) or BCG (Fig 6.2b) in mixtures with HSA or HSAB .
Due to the different binding stoichiometries of NAP and BCG, NAP concentrations were 25, 75 and 150 µM and BCG concentrations were 50, 75 and 150 µM.
Plots in Fig 6.2(a,b) demonstrate effects of different levels of HSA biotinylation on
ligand binding and again clearly exhibited the binding-stability linkage persists in
HSAB . Compared to standard HSA (Fig 6.2a and Fig 6.2b) biotinylation resulted in
0

an increase in ∆G37 by as much as ∼6 kcal/mol.
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Dose response curves were not constructed for the HSAB samples because only four
data points were collected for each of the modified protein samples. These data were
unable to support construction of sufficiently meaningful D-R curves that consistently
produced reliable fits.
0

Table 6.2.: ∆G37 (kcal/mol) for biotinylated HSA.
0

0

NAP ∆G37 (kcal/mol)

BCG ∆G37 (kcal/mol)

[NAP]

WT

HSAB1∶1

HSAB1∶5

HSAB1∶10

[BCG]

WT

HSAB1∶1

HSAB1∶5

HSAB1∶10

0

11.98

17.16

20.61

21.24

0

11.98

17.16

20.61

21.24

25

17.02

20.63

22.82

22.66

50

15.13

18.49

21.27

22.37

75

17.90

21.04

25.14

23.65

75

15.33

19.95

22.47

22.94

150

17.96

22.77

25.91

25.49

150

16.74

20.93

23.05

23.51

Error

6.2.5

± 0.2 kcal/mol

Two Ligands Binding to HSA and HSAB

Up to this point binding experiments with HSA and HSAB contained a single
ligand, i.e. either NAP or BCG. The first series of two-ligand binding experiments
focused on standard HSA. A subset of analogous binding experiments for HSAB were
also conducted.
Initial experiments examined solutions of standard HSA pre-incubated with a set
concentration (25, 50 or 75 µM) of either NAP or BCG; with the other ligand added
subsequently in a titratable fashion over the concentration range from 25 to 150 µM.
These experiments investigated whether pre-bound ligand at one specific site affected
binding of the second ligand to a different site, compared to binding of the ligand
alone to that site. Measured thermograms of experiments with two-ligand mixtures
are displayed in Appendix C. Results of DSC measurements for the various mixtures
are summarized in Table 6.3 and plotted for comparison in Fig 6.3.

150

0

Figure 6.3.: ∆G37 values determined for two-ligand binding to HSA. (a) NAP
binding in the presence of 25, 50 or 75 µM BCG: (n) HSA + NAP (control),
(l) HSA+BCG(25 µM)+NAP, (s) HSA+BCG(50 µM)+NAP, (t) HSA+BCG(75
0

µM)+NAP, (:) Composite (additive) ∆G37 values for NAP and BCG alone plus
HSA. (b) BCG binding in the presence of 25, 50 or 75 µM NAP: (n) HSA+BCG
(control), (l) HSA+NAP(25 µM)+BCG, (s) HSA+NAP(50 µM)+BCG, (t)
HSA+NAP(75 µM)+BCG (:) Composite of both NAP and BCG binding alone
(same as in (a) plus HSA alone.
Note: In (a) there is apparently little difference between NAP binding alone or in the
presence of 25, 50 or 75 µM BCG; and these curves are far less than the composite
curve of NAP+BCG. This reveals the allosteric effect of BCG binding on NAP binding in HSA. In (b) curves for BCG binding are much higher in the presence of NAP
at 25, 50 and 75 µM. Also, these curves are much closer to the composite curve of
NAP+BCG+HSA. This further reveals the allosteric effect of NAP on BCG binding
is relatively much smaller.
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In Fig 6.3a, binding curves are displayed for the two-ligand mixtures that contained pre-bound BCG at three different concentrations and in each case with NAP
added in a titratable fashion. Also shown in Fig 6.3a are the binding curves for NAP
alone and the “composite curve” constructed by addition of the individual contributions to binding from NAP and BCG, plus that of HSA alone. Consequently, if
pre-binding of BCG, and subsequent binding of NAP were completely independent
the expectation for two-ligand mixtures would be binding curves approximating the
composite curve. Examination of the curves in Fig 6.3a indicates this is clearly not
0

the case. As seen in Fig 6.3 binding curves of ∆G37 versus NAP for NAP alone,
and those for NAP in the presence of 25, 50 and 75 µM BCG were not significantly
different; and certainly much less than the composite curve. This indicated NAP
binding was greatly diminished by pre-bound BCG and revealed the presence of a
strong allosteric effect of BCG on NAP binding.
In Fig 6.3b more pronounced differences were observed between binding curves
of BCG and those with HSA pre-bound by NAP. With increased concentrations of
pre-bound NAP, binding curves for BCG were much greater than the binding curve of
BCG alone. This contrasts the much smaller effect of pre-bound BCG on subsequent
NAP binding. Thus, in contrast to the observations in Fig 6.3a, pre-bound NAP
has a relatively much smaller effect on further BCG binding. As a result, associated
allosteric effects of NAP on BCG binding were much less, and binding curves in Fig
6.3b approached the composite curve.
Finally, the next series of two ligand binding experiments were designed to compare effects of binding one ligand on subsequent binding of the other for standard
HSA and for each of the differentially biotinylated forms of HSAB . For these experiments a pre-bound ligand concentration of 50 µM was chosen because it was the
intermediate concentration of those examined in previous two-ligand binding experiments (Fig 6.3, Table 6.3). DSC thermograms, shown in Appendix C, measured for
the various mixtures revealed sensitivity of the binding-stability linkage and divulged
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0

Table 6.3.: Binding chemical potentials (∆G37 ) (kcal/mol) for two-ligand binding of
HSA.
NAP Binding

BCG Binding

[NAP] (µM)

HSA25BCG

HSA75BCG

HSA150BCG

[BCG] (µM)

HSA25N AP

HSA50N AP

HSA150N AP

0

14.00

15.13

15.33

0

16.45

16.92

17.38

25

15.65

17.12

16.50

50

18.33

18.27

19.51

75

17.81

17.62

18.23

75

19.49

18.47

20.42

150

18.78

18.96

19.38

150

19.61

19.29

21.08

Error

± 0.2 kcal/mol

the presence of allosteric interactions in both ligand-bound standard and biotinylated
HSA samples.
0

To illustrate this finding, consider ∆G37 values determined from DSC thermograms for standard HSA or each of the three differentially modified HSAB molecules
in mixtures with a fixed amount (50 µM) of either BCG or NAP, and at titrated concentrations of the other ligand (NAP or BCG). Measured thermograms are shown in
Appendix C Results of these experiments for standard HSA and HSAB are displayed
in Fig 6.4 and summarized in Table 6.4 and plotted in histogram form in Fig 6.5.
0

0

Specifically, ∆∆G37 values in Fig 6.5 correspond to differences in measured ∆G37
0

for two-ligand mixtures compared to ∆G37 determined from single ligand binding
experiments.
In Fig 6.5a histograms for HSA and HSAB are only slightly above zero at all
titrated values of NAP when BCG was pre-bound; clearly indicating NAP binding was
significantly affected by BCG. This contrasts behavior in Fig 6.5b where histograms
are noticeably higher and revealed pre-bound NAP had a relatively smaller effect on
titrated BCG binding.
Differences between Figs 6.5a and 6.5b reveal differences in additive effects of
binding BCG and NAP at saturation on global stability of HSA or HSAB . If prebound ligand had no effect, differences would be expected to be nearly equivalent to
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Figure 6.4.: Effects of two-ligand binding to HSAB . (a) Standard HSA, (n) HSA with
NAP, (l) HSA with NAP in the presence of 50 µM BCG, (s) HSA with BCG, (t)
HSA with BCG in the presence of 50 µM NAP. (b) HSAB1∶1 , (n) HSAB1∶1 with NAP,
(l) HSAB1∶1 with NAP in the presence of 50 µM BCG, (s) HSAB1∶1 with BCG,
(t) HSAB1∶1 with BCG in the presence of 50 µM NAP. (c) HSAB1∶5 , (n) HSAB1∶5
with NAP, (l) HSAB1∶5 with NAP in the presence of 50 µM BCG, (s) HSAB1∶5 with
BCG, (t) HSAB1∶5 with BCG in the presence of 50 µM NAP. (d) HSAB1∶10 , (n)
HSAB1∶10 with NAP, (l) HSAB1∶10 with NAP in the presence of 50 µM BCG, (s)
HSAB1∶10 with BCG, (t) HSAB1∶10 with BCG in the presence of 50 µM NAP.

that of the pre-bound ligand alone (leftmost black histograms in Fig 6.5a and 6.5b).
Fig 6.5a reveals this was clearly not the case for pre-bound BCG with subsequent
NAP binding clearly diminished. Thus, a sizable destabilizing allosteric effect is
associated with BCG binding (at site I) that affected NAP binding (at site II). Higher
histograms in Fig 6.5b correspond to differences in two-ligand binding versus single
ligand binding for BCG. Although not totally additive combined effects of pre-bound
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0

0

Figure 6.5.: Differences in ∆G37 for two ligand mixtures (Table 4) from ∆G37 for one
ligand mixtures with HSA and HSAB (from Table 6.3). (a) NAP binding to HSA
or HSAB in the presence of 50 µM BCG, (X= 25-150 µM). ∆∆G37 = ∆G37 (X ⋅
0

0

BCG + N AP ) − ∆G37 (X + N AP ) : () standard HSA, (⧄) HSAB1∶1 , (⧅) HSAB1∶5 ,
0

(⊠) HSAB1∶10 . (b) BCG binding to HSA or HSAB in the presence of 50 µM NAP.
∆∆G37 = ∆G37 (X ⋅N AP +BCG)−∆G37 (X +BCG): in the presence of 50µM NAP:
0

0

0

() standard HSA, (⧄) HSAB1∶1 , (⧅) HSAB1∶5 , (⊠) HSAB1∶10 . The left-most group
of histograms in (a) correspond to 50 µM BCG, 0 NAP; in (b) they correspond to 50
µM NAP, 0 BCG. These histograms correspond to differences between the curves in
Fig 6.3a and 6.3b

NAP and subsequent BCG binding were not as strongly linked. Differences in Fig
6.5b indicate binding by BCG was only slightly affected by pre-bound NAP; and the
(allosteric) effect of pre-bound NAP binding on BCG binding was not nearly as large
as that for the effect of pre-bound BCG on NAP binding in Fig 6.5a.
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Table 6.4.: Binding chemical potentials (∆G37 ) (kcal/mol) for two-ligand binding of
HSAB .
NAP Binding

BCG Binding

[NAP] (µM)

WT

HSAB1∶1

HSAB1∶5

HSAB1∶10

[BCG] (µM)

WT

HSAB1∶1

HSAB1∶5

HSAB1∶10

0

15.19

18.49

21.27

22.37

0

16.92

20.84

23.97

23.15

25

17.12

21.35

23.10

23.00

50

18.38

21.76

24.12

25.04

75

17.62

21.92

25.45

24.03

75

18.74

22.56

25.60

25.30

150

18.96

23.32

26.36

25.93

150

19.86

22.96

25.06

24.99

Error

6.2.6

± 0.2 kcal/mol

Thermodynamic Analysis of Results

This approach is analogous to that previously described [16]. Consider the following reaction in which ligand-bound native HSA is assumed to melt to denatured
HSA and free-ligand, i.e.
0

Kobs

−−
⇀
HSAN ⋅L ↽
−−
−
− HSAD + L

(6.1)

There are several underlying operative assumptions. The melting transition occurs
in a pseudo two-state manner from the native intact ligand-bound structure, HSAN ⋅L ,
to the denatured state, HSAD , and free ligand, L. This reaction occurs with an
0

observed standard state equilibrium constant, Kobs⋅L . The observed standard-state
0

0

free-energy is given by ∆Gobs⋅L = −RT lnKobs⋅L . At temperatures below Tm the
0

standard state free-energy, ∆Gobs⋅L > 0 and the native ligand-bound structure is
favored. All ligand binding reactions are assumed to occur at equilibrium.
Other than effecting HSA stability through binding, the free ligand is assumed
to not make an appreciable contribution to the observed thermogram for ligandbound HSA. Further, consequences of free ligand binding to the denatured state are
assumed to not contribute significantly to the measured thermogram of ligand-bound
HSA. Within the boundaries established by these assumptions, the equilibrium in
Eqn 6.1 can be represented in terms of the corresponding chemical potentials,
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0
0
−
⇀
µN ⋅L −
↽
−−
−
− µD
0

(6.2)

0

Where µN ⋅L and µD are the hypothetical standard state chemical potentials for
the ligand-bound native state (N⋅ L) and the denatured state (D), respectively. The
0

standard state free energy, ∆Gobs⋅L , is defined in terms of the differences between
the standard state chemical potentials of the ligand-bound native and ligand-free
denatured states,
0

0

0

∆Gobs⋅L = µD − µN ⋅L

(6.3)

The observed standard state equilibrium constant for the reaction is also given
by the ratio of the mole fractions of denatured (χD ) and native ligand bound (χN ⋅L )
forms,
0
0
χD
0
−(µ −µ
)/RT
Kobs⋅L = χ
= e D N ⋅L
N ⋅L

0

(6.4)

0

−(∆Gobs⋅L )/RT

Kobs⋅L = e

(6.5)

Since ∆Gobs⋅L > 0, at temperatures below Tm , (µD − µN ⋅L ) > 0, (µD = ∆Gobs⋅L +
0

0

0

0

0

µN ⋅L . Arbitrarily designating the denatured state as the reference state, (µD = 0,
0

0

0

◦

the measured values of ∆Gobs⋅L determined at 37 C, i.e. ∆G37 are the standard state
0

0

0

chemical potentials for ligand-bound HSA, µN ⋅L = ∆Gobs⋅L . Values of ∆G37 for the
various ligand/HSA mixtures are summarized in Table 6.1.
From these data, ligand-specific contributions from binding for mixtures of NAP
and BCG with HSA and HSAB were extracted. Binding was investigated for four
different HSA species. The same process was applied in each case. Central to the
entire process are the standard state chemical potentials of standard intact, native
HSA, (µHSA ); and standard HSA bound by ligand, (µHSA⋅L ); and analogous quantities
0

0

for the HSAB molecules.
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Further it was assumed that the “contribution” of ligand binding to HSA thermo0

dynamic stability can be parsed into an independent “ligand effect” term denoted, µL ,
0

0

0

0

µHSA⋅L = µHSA + µL . With these definitions and the experimentally measured µHSA⋅L
0

0

0

and µHSA , individual µL values were determined. In a generic sense, µL denotes the
standard state chemical potential of the ligand assumed to include specific stability
0

contributions from ligand binding. Precise values of µL depend on the particular lig0

0

and and associated binding mode(s). In consideration of this distinction µL = µN AP
0

or µBCG are specifically designated.
Kobs⋅L = −RT (∆Gobs⋅L ) is the observed equilibrium constant for denaturation of
0

0

0

the ligand-bound protein complex. Thus, µL is a measure of the stability provided
by ligand binding in thermal denaturation of ligand-bound HSA.
0

0

Values of ∆G37 (∆Gobs⋅L ) for standard ligand-bound HSA are given in Table 6.1
for NAP and BCG over a wide range of ligand concentrations. These data form the
basis of our analysis and conclusions drawn therefrom. Data in Table 6.1 were used
0

0

to derive estimates on the individual values of µN AP or µBCG . In an identical fashion,
similar parameters were also evaluated for HSAB .

6.2.7

Evaluated Binding Parameters

Measurements were made for mixtures of HSA with ligand (L) as a function of
ligand concentration(CL ). It was assumed the measured standard state chemical
potential can be expressed as the sum of the individual standard state chemical potentials for HSA alone and the ligand dependent standard state chemical potential of
components present in the mixture at concentration, (CL ).
0

0

µHSA⋅L (CL ) = µHSA + µL (CL )

(6.6)

0

The value of µHSA⋅L was independently measured. DSC binding experiments of
HSA in the presence of either NAP or BCG, measured as a function of CL from
below to well above saturation provided determination of µHSA⋅L (CL ) (corresponding
0
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0

to −∆G37 values in Table 6.1). These measured quantities then provided evaluations
(using Eqn 6.6) of µL (CL ) as a function of CL .
0

Effects of biotinylation on ligand binding were similarly analyzed utilizing analogous experimental results presented in Fig 6.2. Specific details of an identical process
carried out for HSA, and three HSAB molecules (HSAB1∶1 HSAB1∶5 HSAB1∶1 ) are not
explicitly described. That analysis provided evaluation of the standard state chemical
potentials for binding of BCG and NAP binding (alone) at saturation to HSA; designated µBCG (CBCG ) and µN AP (CN AP ). Analogous values of these quantities were
0

0

also determined for HSAB1∶1 , HSAB1∶5 , and HSAB1∶10 and are also summarized in Fig
6.2.

6.2.8

Allosteric Analysis

Results for mixtures of HSA with both ligands, L1 = BCG and L2 = NAP, are
summarized in Table 6.3. Recall, in the first of these experiments BCG (L1 ) was
titrated into a mixture of HSA pre-incubated with 25, 50 or 75 µM NAP(L2 ). The
measured standard state chemical potential for the HSA⋅NAP+BCG complex is generally defined as,
µHSA⋅L2 +L1 (CL2 , CL1 ) = µHSA + µN AP (CL2 ) + µBCG (CL1 )
◦

◦

◦

◦

(6.7)
◦

For independent binding events, the experimentally measured value for µHSA⋅L2 +L1
(CL2 , CL1 ) should be equivalent to the sum of the individual values of µHSA , µN AP
◦

◦

(CL2 ), and µBCG (CL1 ) each independently determined for BCG and NAP bind◦

ing to HSA, at their respective concentrations. However, since measured values of
µHSA⋅L2 +L1 (CL2 , CL1 ) were not equal to the sum of their individual values, the fol◦

lowing modified standard state chemical potential for binding was introduced,
µBCG (CL1 ) = µHSA⋅L2 +L1 (CL2 , CL1 ) − µHSA − µN AP (CL2 )
◦

∗

◦

◦

◦

(6.8)
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Which is different than µBCG (CL1 ) and accounts for effects of pre-bound NAP
◦

on subsequent BCG binding, which is an allosteric effect. Second, for the case where
NAP was titrated into a pre-incubated mixture of HSA with BCG, the standard state
chemical potential of the HSA⋅BCG+NAP complex is given by,
µHSA⋅L1 +L2 (CL2 , CL1 ) = µHSA + µBCG (CL1 ) + µN AP (CL2 )
◦

◦

◦

◦

(6.9)

And if the calculated sum of µHSA , µBCG (CL1 ), and µN AP (CL2 ), experimentally
◦

◦

◦

measured values are not equal then,
µN AP (CL2 ) = µHSA⋅L2 +L1 (CL2 , CL1 ) − µHSA − µBCG (CL1 )
◦

∗

◦

◦

◦

(6.10)

Which is again potentially different than µN AP (CL2 ) and accounts for the allosteric
◦

effect associated with pre-bound BCG on subsequent NAP binding.

Figure 6.6.: Generic scheme for allosteric ligand interactions with HSA.
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The generic allosteric scheme is presented in graph form in Fig 6.6 where BCG
(site I binder) is designated as ligand L1 ; and NAP (site II binder) is ligand L2 . In
Fig 6.7, the allosteric diagram for the four binding reactions have vertical distances
scaled according to their evaluated standard state chemical potentials for binding
given in Table 6.5. Displayed standard state chemical potentials are drawn to scale.
For the binding reaction involving BCG binding alone, µBCG (CL1 ) = A; and for BCG
◦

binding after NAP binding, µBCG (CL1 ) = B. Likewise, the standard state chemical
◦

∗

potentials for binding NAP alone, µN AP (CL2 ) = α and for NAP binding following
◦

BCG binding, µN AP (CL2 ) = β, are also designated.
◦

∗

Strictly speaking for an unlinked system ligand binding events are independent
and not influenced by binding of other ligands. In an unlinked system, binding of
BCG or NAP should not vary regardless of whether NAP or BCG was bound first
and necessarily, A = B and α = β. Conversely for true allosteric linkage, if α > β
then A > B, and reciprocal effects would be expected for one ligand binding on the
other. That is, if binding L1 decreases binding of L2 then necessarily in a fully linked
system, binding of L2 must also decrease binding of L1 . For perfectly allosterically
linked ligand binding events, A − B = α − β. These differences provide for informative
comparisons of the relative allosteric effects of ligand binding in HSA.
Table 6.5.: µL (kcal/mol) for individual binding events with ligands.

Protein[L]

A

B

A-B

α

β

α−β

HSA (25 µM)

-2.41 -2.23 -0.18 -5.04 -1.69

-3.35

HSA (50 µM)

-2.96 -2.40 -0.56 -4.94 -1.13

-3.81

HSA (75 µM)

-3.35 -3.11 -0.24 -5.92 -1.17

-4.75
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Figure 6.7.: Evaluated standard state chemical potentials µ = µHSA⋅L (CL ) [(A),(α)]
◦

◦

and µ = µHSA⋅L (CL ) [(B),(β)] for two-ligand binding to HSA. The generic reaction
◦

◦

∗

diagram shows different ligand binding events. These are denoted A: binding of BCG
(L1) alone to HSA site I. α: binding of NAP(L2) alone to HSA site II. B: binding of
BCG to site I on HSA pre-bound with NAP at site II (L2+L1). β: binding of NAP
at site II on HSA pre-bound with BCG at site I (L1+L2). Reactions at different
pre-bound ligand concentrations are denoted as vertical bars, i.e. (n) 25 µM, (l) 50
µM, (s) 75 µM.

Similar to the example with unmodified HSA in Fig 6.7, the three HSAB molecules
were analyzed using the allosteric scheme in Fig 6.8. Unlike unmodified HSA, the
HSAB molecules were pre-bound with 50 µM ligand and 50 µM of NAP or BCG was
added to the pre-bound complex. Standard state chemical potentials for allosteric
interactions of the three HSAB molecules, as summarized in Table 6.6.
In Fig 6.9 the allosteric schemes diagrammed in Figs 6.7 and 6.8 were converted
to histogram form. Depth of the histograms correspond to standard state chemical
162

potentials as displayed in Figs 6.7 and 6.8. Fig 6.9a corresponds to values of the
standard state chemical potentials given in Table 6.5. In Fig 6.9b values of the
standard state chemical potentials given in Table 6.6 for standard HSA and the three
HSAB molecules are displayed for comparison. For the allosteric parameters A, B, α,
β units are kcal/mol.

Figure 6.8.: Evaluated standard state chemical potentials µ = µHSA⋅L (CL ) [(A),(α)]
◦

◦

and µ = µHSA⋅L (CL ) [(B),(β)] for two-ligand binding to HSAB . The generic reac◦

◦

∗

tion diagram shows different ligand binding events. These are denoted A: binding
of BCG (L1) alone to HSA site I. α: binding of NAP(L2) alone to HSA site II. B:
binding of BCG to site I on HSA pre-bound with NAP at site II (L2+L1). β: binding
of NAP at site II on HSA pre-bound with BCG at site I (L1+L2). Pre-bound ligand
concentrations were 50 µM for both NAP and BCG. (n) HSAB1∶1 , (l) HSAB1∶5 , (s)
HSAB1∶10
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Table 6.6.: µL (kcal/mol) for individual binding events for HSAB with 50 µM ligand.

Protein

A

B

A-B

α

β

α−β

HSA

-2.96 -2.40 -0.56 -4.94 -1.13

-3.81

HSAB1∶1

-2.79 -1.72 -1.07 -3.47 -2.86

-0.61

HSAB1∶5

-1.86 -1.63 -0.23 -2.21 -1.83

-0.38

HSAB1∶10

-1.70 -2.15

-0.84

0.45

-1.47 -0.63

Examination of the values in Table 6.5 reveal that the pure linkage criterion is
not strictly met in our system. For example, in Table 6.5 and Fig 6.9a, at 50 µM the
difference in chemical potentials for BCG binding alone and BCG binding following
NAP binding is small: A − B = −2.96 − (−2.40) = −0.56. In contrast, the difference
between standard state chemical potentials of NAP binding alone and binding of NAP
following pre-bound BCG is significantly larger at: α − β = −4.94 − (−1.13) = −3.81.
This says that binding of BGC is only very weakly linked to NAP binding. As a result
BCG binding to HSA pre-bound with NAP is only slightly less than BCG binding
alone, i.e. A − B = −0.56. In contrast, NAP binding to HSA pre-bound with BCG is
considerably less than binding of NAP alone binding to HSA, and α−β = −3.81. This
indicates the allosteric effect of binding of NAP to HSA pre-bound with BCG is nearly
a factor of nearly seven times greater than the effect of pre-bound NAP on subsequent
binding of BCG. Potential origins for these linkage differences are discussed below.
Plots in Fig 6.9 also reveal more subtle features of ligand binding and associated
allosteric effects. For example, Fig 6.9 demonstrates the allosteric effects of BCG
binding on NAP binding and NAP binding on BCG. In Fig 6.9a, the family of histograms at each pre-bound concentration clearly shows the nearly independent effect
of pre-bound NAP on BCG binding, i.e. the parameter values representative of BCG
binding alone (A) or with pre-bound BCG (B) were essentially the same at all pre164

bound concentrations of NAP. In contrast, parameters for binding NAP alone (α) and
NAP binding following pre-bound BCG (β) were very different, clearly demonstrating
the destabilizing allosteric effect of pre-pound BCG on NAP binding, regardless of
pre-bound BCG concentration.

Figure 6.9.: Standard state chemical potentials for the two-ligand binding reactions.
(a) Binding potentials for standard HSA pre-bound ligand concentrations of 25 µM
(), 50 µM (⧄), and 75 µM (⧅). (b) Binding potentials for biotinylated HSAB
species pre-bound by 50 µM of ligand () standard HSA, (⧄) HSAB1∶1 , (⧅) HSAB1∶5 ,
(⊠) HSAB1∶10 . Note: the binding parameters α and β have significant values for
the HSAB molecules indicating persistence of the allosteric effects in the biotinylated
HSA species.

Fig 6.9b emphases difference in the effects of biotinylation on ligand binding. The
BCG binding events alone (A) or with pre-bound NAP (B) are essentially the same
for standard HSA or HSAB , indicating biotinylation has little effect on binding of
BCG. In contrast, for the corollary reactions of NAP binding to HSA and HSAB ,
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binding parameters (α) and (β) reveal two remarkable behaviors. First, the allosteric
effects of pre-bound BCG binding on subsequent NAP binding (α) are preserved in
HSAB and the group of histograms for (α) and (β) in Fig 6.9b are different, although
the differences become smaller with more biotinalytion, i.e. HSAB1∶5 and HSAB1∶10 .
Second, the group of histograms displayed for binding of NAP alone (α) are strongly
affected by biotinylation. So much so that for HSAB1∶10 there is very little difference
in the NAP binding events, and pre-bound BCG has little effect on subsequent NAP
binding.

6.3

Discussion
Results iteratively demonstrated a direct linkage between site-specific ligand bind-

ing and thermodynamic stability of ligand-bound HSA or HSAB .

The binding-

stability linkage was explicitly demonstrated for binding of NAP and BCG alone;
and it was exploited to quantitatively evaluate binding parameters for NAP and
BCG (both well-known HSA binding ligands). Evaluated parameters were in good
agreement with known, published values for the binding stoichiometry and binding
constant, KD , for both ligands with HSA. Two levels of linkage between ligand bind0

ing events and HSA stability were observed. Measured values of ∆Gobs⋅L differ for the
two ligands; and binding of the ligands together are clearly linked through allosteric
interactions within the HSA structure.
A major function of HSA is the transport of fatty acids (FA) to and from the
liver [15,30]. Intrinsically, for this purpose there are a number of binding sites for FA
of different lengths on HSA. These sites can also bind many other ligands, including
drugs [5,11,13–15,30]. Allosteric effects on ligand binding have largely been discussed
in the context of FA binding. Published results found site specific binding of FA to
Sudlow sites I and II and other minor binding sites depended on the length of the FA.
Longer FA preferentially bind site I, while smaller FA prefer binding site II [2,13,15].
FAs can additionally bind in one of the seven additional FA specific binding sites [13].
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Ligand binding to specific sites on HSA can be influenced by FA binding in two
ways. (1) Directly (by competing for the same site bound by FA) or; (2) If the drug
does not preferentially bind to the same site as FA, FA binding at its preferable site
can allosterically affect specific binding of the drug at their preferred (and possibly
distant) sites on HSA. These allosteric interactions in HSA that have been studied
primarily involved interactions between HSA bound by fatty acids (FA) or heme, two
naturally occurring and biologically very important ligands [11, 33–37]. Allosteric
effects associated with other ligands have not been nearly as widely studied; nor has
their range and magnitude been determined.
Here in our ideal in vitro system no heme or FA was present enabling a closer
examination of allosteric effects of other ligands between different primary binding
sites. Ability to observe allosteric interactions between site-specific binding ligands
at sites I and II, as done here, was likely made possible by the comparative binding
strengths of the ligands chosen (in the absence of heme or FA).
Data showed that HSA pre-bound by NAP had a small effect on subsequent
binding of BCG; but pre-bound BCG had a large effect on subsequent NAP binding.
The stronger allosteric effect seems to be mostly associated with the influence of prebound BCG on NAP binding. This is consistent with what has been reported for
FA binding at site I that has been shown to allosterically affect heme binding at site
III, i.e. there are demonstrated allosteric interactions between sites I and III [35].
Similar structural rearrangements to those induced by FA binding at site I have not
been found when a short FA preferentially binds site II [35].
We are not aware of any reports of FA binding at site I exerting an allosteric effect
on binding of other ligands at site II, as observed here for the effect of BCG binding
on NAP.
Other possibilities exist, but the most obvious scenario consistent with these observations is an allosteric linkage between sites I and II that has not been previously
observed. Published studies of allosteric interactions with HSA have primarily examined interactions between a strong binder (FA and heme) and comparatively weaker
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binding ligands [33, 38]. Absence of dominant binding ligands such as FA and heme
in our system might allow detection and characterization of more subtle allosteric
channels.
Alternatively, perhaps when NAP is the first ligand added to HSA it binds primarily (most strongly) to site II. But to a lesser extent, NAP also binds site III. We
are not aware of any reports of BCG binding to site III on HSA. Site III or site IB
(located in subdomain IB) has been shown to be allosterically coupled to sites I and
II [10, 33, 35]. Binding to sites I and II is quite specific while site III binding seems
more promiscuous and relatively weaker. Site III is located very close to site I. Thus,
BCG bound at site I could affect NAP binding at site III. Although NAP binds site
II with KDII ≈ 0.83 µM, it has a much weaker binding constant for site III, that
has not been as well characterized [5]. Reported estimates on KDIII are two to three
orders of magnitude lower than KDII . Although conjectured involvement of site III
is attractive, since no evidence of multi-site binding by NAP to HSA was obtained,
binding of NAP to site III as the primary source of allosteric coupling with site I is
viewed as unlikely.
Alternatively, when BCG is first bound to HSA at site I, it must allosterically
perturb the structural environment of site II (and potentially III) which significantly
affects subsequent binding of NAP there. The result is a less stable state with a
relatively smaller standard state chemical potential of binding.
Ligand binding affects both the structural and chemical environments surrounding
sites I and II; and allosteric connectivity between the sites. This is consistent with
what has been observed for allosteric binding of other ligands (other than FA and
heme) that bind site I (eg. warfarin) that also effect binding of ligands at other
sites. While binding of ligands at site II have little allosteric effect on binding to
site I [11, 35–37, 39, 40]. This work confirmed the direct linkage for NAP and BCG
binding.
Binding linkage was assumed to be directly proportional to ln KD . Therefore, relative differences between specific standard state chemical potentials for ligand bind-

168

◦

◦

◦

ing, i.e. µL = µN AP or µBCG provided for meaningful comparisons; even though
experimentally derived values of µL were considerably smaller than binding energies
estimated from the binding constant. As demonstrated here explicit evaluation of
0

relationships between binding constants and measured µL ’s for ligands of different
types can provide significant quantitative insight regarding binding-stability linkage
in HSA.

6.4

Conclusion
Quantitative success achieved in evaluation of ligand binding parameters for NAP

and BCG supports the claim that DSC analysis can be used for screening ligand
interactions with HSA. As shown here DSC analysis is both a relatively fast and
simple means to assess ligand binding and quantitatively evaluate how ligand binding
affects HSA stability.
Interplay of allosteric ligand-ligand interactions as seen here for NAP and BCG
(and reported for FA, heme, etc.) and how these allosteric interactions are related and
modulate ligand binding activity, represents essential aspects of the ligand binding
characteristics of HSA. In particular, how these characteristics might be effectively
manipulated to specifically enhance or discourage site-specific ligand binding is of
primary interest.
Binding of ligands to plasma proteins, in particular HSA, is a critical determinant of effective drug delivery [25, 26, 41]. HSA binding impacts drug bioavailability,
potency, delivery and drug metabolism. Binding to plasma proteins also affects the
available concentration of drug to bind its target. A critical step in pre-clinical drug
discovery involves assaying how the drug interacts with HSA and other plasma proteins. As shown in Chapters 4 and 5 the binding-stability linkage provides a direct
means of evaluating ligand binding through DSC measurements of mixtures of “unknown” test ligands with HSA. High throughput capabilities of DSC combined with
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simplicity and speed of the measurement make real the possibility of DSC-based
high-throughput drug screening.
Although results convincingly demonstrated utility of the binding-stability relationship in characterizing interactions of NAP and BCG with HSA, general applicability of this approach to study multiple ligand interactions has also been found. To
this end a larger body of data for a wide variety of different ligands (29) in Chapter 5 that provides additional supporting evidence for the binding-stability linkage
and supports its utility for characterizing HSA/ligand binding. Results from these
endeavors were shown in Chapter 5 [18]. In Chapters 3 and 4, the binding-stability
linkage relationship was employed to characterize ligand binding with HSA and whole
plasma [17].
Finally, the ability to manipulate ligand binding characteristics requires a fundamental understanding of inter-relationships between molecular structure and thermodynamic stability of HSA bound by ligands. In general, there are a number of
important applications for capabilities of manipulating, enhancing and increasing,
ligand binding to HSA. These could play major roles in advancing pre-clinical drug
discovery of pharmaceuticals, ADMET analysis and pharmacokinetics. Applications
include engineering of modified HSA derivatives as specially designed affinity capture reagents for the directed purpose of binding and isolating ligands from plasma,
as described in Chapter 3 [17, 27]. In addition, modern design strategies for effective, HSA-based, therapeutic delivery systems in blood could benefit greatly from
detailed knowledge of HSA ligand binding thermodynamics and the binding-stability
linkage [25–28].
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CHAPTER 7: SUMMARY AND FUTURE WORK

7.1

Overview
The analysis of ligand interactions with proteins is an extremely broad field of

study. Specifically, our goal was to ascertain the effects of ligand binding on the
global structural stability of human serum albumin (HSA). HSA is a model protein
for studying ligand interactions due to the extensive body of work in characterizing
its structure and function over the last 70 years [1].
From previous work we know that HSA is the primary ligand transport protein in
blood plasma for both endogenous and exogenous ligands. Endogenous ligands are
natural circulating compounds whose abundance corresponds to normal hemostasis
or elevated levels that could be disease-specific molecular biomarkers. While exogenous ligands encompass the range of external drugs, biopharmaceuticals, and
ingested/inhaled compounds that may be found circulating in plasma. The thermodynamic stability of proteins change when they bind ligands. When measured by
differential scanning calorimetry (DSC) it is possible to generate a unique thermogram for the liganded protein. Thermograms measured for plasma can be sensitive
indicators of the presence of abnormal levels of exogenous and endogenous ligand
components based on the extent of perturbation from ”normal”.
In Chapter 3, a capture strategy was described and demonstrated for retrieving
ligand entities in plasma that bind HSA. The capture and retrieval strategy was
demonstrated for four ligands, of different types, in plasma. Thermogram features
were sensitive to the presence of ligands as thermograms of mixtures of plasma or HSA
with these ligands were significantly different than thermograms of plasma or HSA
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alone. These results demonstrated directly that significant perturbations of plasma
thermograms corresponded to ligand interactions with HSA in plasma.
While DSC has shown that it can accurately and reliably measure protein stability
it was stated to be unable to quantitatively assess ligand binding to proteins [2–6].
In Chapter 4 we showed that DSC can be a reliable quantitative method for straightforward and rapid evaluation of ligand binding constants for HSA. The ability to
assess thermodynamic stability and quantitative ligand binding constants using DSC
allowed for the evaluation of effects of structural or surface modification on ligand
binding.
Structural modifications were induced by pH, where HSA has been shown to
adopt different conformational shapes as a function of pH. Surface modifications were
achieved by variable biotinylation of surface lysine residues. Results revealed, for both
ligands, extent of biotinylation of HSAB and pH changes affected binding, reducing
binding constants from three to 100-fold. DSC analysis was able to delineate interrelationships between molecular structure and thermodynamic stability of HSA and
HSAB bound by ligands; and their variations with pH.
The ability to quantitatively assess ligand binding by DSC has great potential for
fast and accurate preclinical drug screening. In Chapter 5 we demonstrated rapid
assessment of drug binding it also provides useful insight into the physio-chemical
basis of drug interactions, and provides the means for defining significant relationships
between general chemical and structural features of drug/protein binding interactions.
Quantitative drug binding to HSA and stoichiometric analysis was performed for 29
drug compounds. In all cases excellent agreement was obtained with literature values.
Included in that list of compounds was aqueous insoluble or sparingly soluble compounds. While solutions of marginally soluble components can usually be prepared
using a diluted organic solvent mixture, there are at least two inherent potential complications associated with that procedure. The first is sample quantity. In order to
make an appropriate stock solution requires at least three orders of magnitude higher
concentration then the presumed binding constant. This results in tenths of a gram
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needed for nanomolar strength binders; and up to gram amounts for weaker binding
drugs [7–11]. The second complication involves associated solvent effects on protein
structure. Surface binding of solvent molecules plays a critical influential role in establishment and modulation of protein structure [4, 5, 12–14]. Thus, the presence of
organic solvent, even in minuscule amounts can have a significant effect on protein
structure. In Chapter 4 we reported that subtle difference in protein structure can
have quite large effects on ligand binding.
Our process to solubize insoluble compounds without organic solvents was exploited to quantitatively evaluate dissociation binding constants for seven insoluble
or poorly soluble compounds. Again, excellent agreement with established literature
values was reported for all compounds.
The binding of one ligand to a protein subsequently effecting the binding of a
second ligand is described as an allosteric interaction [15–18]. In Chapter 6 pure and
modified HSA was complexed with either or both of two site-specific binding ligands
and investigated by DSC. Experiments revealed that an unidirectional allosteric effect
exists between bromocresol green in Sudlow Site I and naproxen in Sudlow Site II.
Where binding of bromocresol green to HSA subsequently reduced the ability of
naproxen to bind. However, initial binding of naproxen showed minimal effect on
bromocresol green binding. The consistency and systematic fidelity of using DSC to
measure the binding-stability in HSA was exploited to quantitatively evaluate ligand
dependent allosteric interactions. This approach can be expanded to look at other
known or potential allosteric drug interactions [11, 19].
Results show the unique power that DSC provides to analyze protein structural
stability and assess quantitative ligand binding. Attaining quantitative ligand binding constants by DSC has historically yielded inaccurate results and was thought
to be impossible [2, 3]. Results presented here demonstrated that DSC is a viable
but underused technology for assessing ligand binding. Future work should expand
on these capabilities for analyzing more types of ligand interactions or working in
complex solutions.
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7.2

Future Work

7.2.1

Drug Analysis - Psilocin

Psilocybe mushrooms have long been known for the psychoactive effects brought
on from ingestion. With their inclusion in the Controlled Substances Act, there has
been very little academic research into these mushrooms until recently. However, this
is changing with the establishment of psychedelic research institutes and promising
research into Psilocybe mushroom’s ability to effectively treat a variety of mental
illnesses, including anxiety, depression, addiction, and post-traumatic stress disorder
(PTSD) [20–24]. Following on these results is the legalization of so called, “magic
mushrooms”. Denver, Oakland, and the state of Oregon have legalized their use in
medical treatments. The soon to be widespread availability and use of Psilocybe
mushrooms has exposed the dearth of fundamental research into the chemical nature
and in in vitro behavior of derived psychoactive compounds.
The two primary psychoactive compounds found in these mushrooms are psilocybin and psilocin. Psilocybin is a prodrug that is rapidly hydrolyzed in the digestive
system to yield psilocin [25–28]. From observational studies it is clear that psilocin
impacts brain chemistry. However, it is still not understood how, or if, psilocin interacts with the body’s plasma proteins [25].
For drugs that cross the blood-brain barrier it is traditionally assumed that the
drug must be free to be transported to the brain, i.e. not protein bound. Consequently, most drugs that act on the brain are assumed to have a low binding strength
to HSA. However, it has been reported that there is a likely carrier mediated transport system on the surface of the blood brain capillary endothelium that allows HSA
to aid in distribution of drugs to the brain [29]. From in vivo studies of rats, 30
minutes after ingestion of psilocybin there were large concentrations of psilocin found
in the liver and kidneys. This strengthens the case that psilocin is transported by
HSA [25,26,28]. Thus, determination of psilocin’s binding constant for HSA seems es-
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sential to elucidate transport mechanisms to the brain, implying subsequent allosteric
ligand effects could effect dosing.
The above hypothesis should have been easy to test using the methodologies
employed in Chapters 4, 5, and 6. However, in experiments, psilocin produced a
pronounced endothermic peak that was not present in any other ligand samples tested.
It has been reported that in aqueous solutions, over time, psilocin forms a black
product as we observed in the sample solutions [25, 28, 30]. This black solutions
has been conjectured to be the result of degradation [25, 30]. However, this view is
disputed and viewed as unlikely due to the structural similarity of psilocin to serotonin
and the subsequent lack of a degradation pathway in serotonin [28].
Preliminary results of studying psilocin by DSC can be found in Appendix E. The
ability to use DSC to study the inherent properties of a drug in addition to protein
binding provides a novel research direction.

7.2.2

Complex Fluid & Viral Analysis

Production of biopharmaceuticals (biologics) and low abundance proteins is accomplished using prokaryotic or eukaryotic expression systems. The ability to easily
produce low abundance proteins id critical for screening drug interactions and investigations into biological pathways [31]. An attractive feature of using protein expression
systems is the ability to produce biological compounds (proteins, peptides, antibodies) on large scales, in a cheap and rapid manner, insulin is a classic example of a
biologic that is mass-produced.
A major drawback to this approach is that while expression of the targeted biological compounds is cheap and fast, purification and isolation of targeted compounds is
expensive and time consuming. A conventional purification strategy for a moderately
abundant and soluble protein, requires roughly 27 individual steps and four days to
complete [32]. Also, purification steps might need to be repeated to achieve an ade-
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quate level of purity. Because of the expense associated with the purification steps,
purified low abundance proteins can retail for over $2,000 per milligram.
Likewise, in the biologics market it is necessary to generate multiple expression
vectors to produce a range of target compounds. This is similar to how small molecule
drug discovery works. Unlike in small molecule drug discovery, for biologics each lead
must be expressed, purified, and then tested for ADMET properties. Due to the
added costs, treatment with biologics may cost hundreds to thousands of dollars per
treatment [33]. Despite the costs biologics have shown great promise in treating
diseases, such as autoimmune disorders, that would otherwise remain untreatable
[34]. Currently there are 50,000 drugs in the clinical trial pipeline, 40% of these are
biologics [33].
Biologics also present unique challenges in the preclinical drug discovery pipeline.
Due to the nature of how biologics work in the body, testing of compounds in animal models is ineffective at best. Since these compounds tend to target very specific
receptors or epitopes, toxicological information does not translate between species
and only a few primate species have provento be viable [35]. Therefore, early pharmacokinetic/ pharmacodistribution (PK/PD) information is incredibly important for
guiding toxicological studies and human risk assessment [33]. This becomes an issue
when each lead compound must be expressed and purified before determining if it
binds to a targeted receptor and at what affinity.
Unpurified lysates are produced early in the expression process. First, a plasmid
that codes for the biological compounds of interest is added to the expression system.
Targeted compounds are produced until cells are unable to reproduce or survive. Cells
are then lysed and genetic material (DNA/RNA) is removed through centrifugation.
At this stage, depending on the properties of the targeted compound, the unpurified
protein can be found in either the lysed cellular media or in the culture supernatant.
Conventionally, this is where the purification process would begin. The expensive
purification steps would need to be completed before testing of compounds would be
possible. However, our ability to take the unpurified protein to assess ligand binding
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ability can potentially remove the necessity of expensive sample purification at early
stages of development.
Results detailed in Appendix F demonstrate the feasibility of using our approach
to analyze ligand-protein interactions in complex fluids. Ligand binding to expressed
proteins was analyzed in both prokaryotic (E. Coli) and eukaryotic (Human Embyonic Kidney cells) systems. These results present an interesting potential application
of the technology, i.e. detection and analysis of viral outbreaks. Our ability to determine binding in complex fluids lends perfectly to the capture and analysis of viruses.
Published DSC studies have shown that viruses display distinctly characteristic thermograms. Unique thermograms for viruses are thought to arise because of the unique
array of proteins that typically decorate viral surfaces [36].
Ostensibly the presence of viral infections can be detected from abnormal plasma
thermograms or thermograms of individual viral coat proteins. This presents an issue common to previous DSC studies of plasma thermograms and raises the following
question. From only the diseased plasma thermogram alone, can observed perturbations be attributed to the presence of the target virus (SARS-CoV-2), a different
virus, or a combination of disease states and medications? To minimize both false
positives and (more harmful) false negatives, identification and verification of the
disease specific analyte (virus) is paramount for accurate diagnosis [37].
It was recently reported that viruses display unique and diagnostic thermograms,
indicating their possible characterization by DSC [36,38–40]. Additional studies have
shown that patients infected with SARS-coronavirus have detectable, albeit in many
cases very low, levels of active virus or viral RNA in their blood plasma. A priori,
presence of viral RNA in plasma, as detected by standard PCR analysis, does not
necessarily signal the presence of active infection. Incorrectly assuming that it does
could lead to a false positive call. This is primarily because plasma is not the preferred
tissue compartment of COVID 19 [41,42]. However, preliminary results show that we
are able to work with complex fluids outside of blood plasma.
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Currently, other than culture and amplification (both costly and time intensive)
there are no methods available for accurate and rapid screening of biofluids for the
presence of active virus. Here is where our platform and approach can make significant contributions. From our perspective, with the presence of virus particles in
diseased biofluids or convalescent plasma comes the expectation that thermograms of
infected samples will be significantly different compared to the normal thermogram.
Thermograms could potentially be very sensitive indicators of viral infection. Further, the presence of virus particles in plasma can be unequivocally confirmed using
the capture component [43]. The actual physical isolation of virus particles directly
from plasma is a far more accurate indicator of active infection than detection of
remnants of viral RNA using PCR.
Although the above example is specifically targeted toward SARS-CoV-2, our
diagnostic platform is broadly applicable and not solely limited to this virus. Being founded on a physical measurement our platform provides a firm, but flexible
alternative. This enables rapid design and support of diagnostics for virtually any
disease, virus based, or otherwise. From a pure novelty perspective, a most unique
feature of our approach is complete non-reliance on viral genome sequences, or antibodies against the virus (or other infectious agents) for accurate diagnoses of infected
samples.
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APPENDIX A:
SUPPLEMENTAL MATERIAL FOR CHAPTER 4

A.1

Ligand-Binding-Isomerization (LBI) Model

The well-known linkage between ligand binding and thermodynamic stability of
the bound protein was utilized in this study to examine effects of ligand binding on
HSA and HSAB . The nature of this linkage is two-fold and should be elaborated
upon. Ligand binding to a native protein as a function of ligand concentration results
in an observed increase in thermodynamic stability of the protein. This is clearly evidenced by increased stability against denaturation as revealed by increases in melting
transition temperatures, Tm , of ligand-bound protein, with increased ligand concentration. Not unexpected, this observation is simply a well-known manifestation of Le
Chatelier’s principle as applied to protein-ligand binding [1]. That is, if a ligand binds
preferentially to the native rather than denatured conformation then inevitably the
thermal stability will be enhanced and the measured Tm increases with increased ligand concentration. Provided the measured calorimetric enthalpy of the heat-induced
denaturation transition of the ligand-bound protein remains unchanged as a function
of increased ligand concentration, the observed shift in Tm with ligand binding forms
the foundation of any standard temperature shift (T-shift) assay. An implicit assumption in the T-shift approach is that ligand binding does not change the melting
stability of HSA. That is, it is implicitly assumed that the thermodynamic stability
of HSA, whether free or ligand-bound is the same.
In addition, if the measured calorimetric enthalpy of the ligand-bound protein
does change with increased ligand concentrations (as we observed) this indicates that
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the equilibrium thermodynamic stability of the native protein structure changed due
to ligand binding. In this case observed changes in thermal stability directly reflect on
thermodynamic consequences of structural (perhaps subtle or not so subtle) perturbations of the protein structure associated with ligand binding. Reported measurable
effects of ligand binding on HSA thermodynamic stability were attributed to perturbations of the structure and dynamics of HSA induced by ligand binding [2–7].
Notably, effects of these perturbations with increased ligand concentration also contributes to increases in Tm of DSC thermograms. Herein lies a unique feature of
DSC analysis. It provides quantitative measurements of melting transition parameters of ligand-bound protein; and evaluations therefrom of the energetics of structural
perturbations of the protein associated with ligand binding.
In consideration of both mass action and protein structural perturbations linked
with ligand binding, the LBI model was employed. As described below this model
considers single site ligand binding coupled with the equilibrium of a structural change
or “isomerization” of bound protein and denaturation. With this model both the
ligand binding constant and isomerization constant were evaluated from analysis of
binding curves constructed from DSC thermogram data. Our approach is similar in
part to textbook treatments of protein/ligand binding and protein denaturation with
the added possibility for isomerization of HSA upon ligand binding [1, 8, 9].
Consider the model reaction schema in Fig A.1. This model captures both the
familiar mass action or LeChatlier’s principle contribution, plus the potential for
overall structural changes induced by ligand binding, also manifested as changes in
protein thermodynamic stability. All components of the reaction are assumed to be in
their standard states. First, consider the equilibrium thermal denaturation reaction
of normal HSAN (or HSAB ) alone to the denatured species, HSAN D , is given by,
0

KN D

HSAN ⇄ HSAN D

(A.1)
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Figure A.1.: Reaction schema for the Ligand Binding Isomerization (LBI) Model. As
described in the text the model considers transitions from the native form of HSA
(N) to the denatured form (D); formation of the ligand bound complex (N·L) and
denaturation of the complex; isomerization of the bound complex to the isomerized
complex (N·L)’ and denaturation.

Equation (A.1) is the control reaction. The thermodynamics of this reaction for
HSA and HSAB , form the basis for comparisons. The standard state equilibrium
0

constant for denaturation is HSAN D .
Ligand binding to a single site on native HSA (or HSAB ), with negligible binding
to the denatured form, is assumed. Now, in the presence of ligand (L), the following
series of reactions are assumed to occur,
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0

KA

HSAN + L ⇄ HSAN ⋅L

(A.2)

Which is the equilibrium association binding reaction for forming the ligand bound
0

protein, HSAN ⋅L , with the standard state ligand binding constant KA . Analogous
reactions occur for HSAB .
Now, to consider the possibility that ligand binding can also induce changes in
HSA structure and stability, sufficient enough to contribute to the measured thermodynamic parameters, consider the isomerization reaction for ligand bound protein.
0

KI

′

HSAN ⋅L ⇄ HSAN ⋅L

(A.3)

′

Where HSAN ⋅L is the perturbed (isomerized) ligand-bound protein. Thus, the
total non-denatured HSA concentration (free, ligand bound, or isomerized ligand
′

bound), HSANT , is given by HSANT HSAN + HSAN ⋅L + HSAN ⋅L .
With these considerations the observed overall reaction is then written as,
0

Kobs

HSANT ⇄ HSAN D

(A.4)
0

The observed standard state equilibrium constant Kobs is given by,
0

Kobs =

[HSAN D ]
[HSAN D ]
=
′
[HSANT ]
[HSAN ⋅L ] + [HSAN ⋅L ] + [HSAN ]

(A.5)
′

Since: [HSAN D ] = KN D ⋅[HSAN ]; [HSAN ⋅L ] = KA ⋅ [HSAN ] ⋅ L; [HSAN ⋅L ] =
0

0

KI ⋅ [HSAN ⋅L ]
0

0
Kobs

KN D
=
1 + [L]KA0 (1 + KI )

(A.6)

What is measured,

T otal

∆Gobs

0

0

0

= −RT lnKobs = RT (ln(1 + [L]KA (1 + KI ))) − lnKN D

(A.7)
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T otal

In the analysis that was performed, values of ∆∆Gobs = ∆Gobs

HSA

- ∆Gobs

de-

termined as a function of ligand concentration were used to construct binding curves
shown in Chapter 4, Fig 4.4. The expression in Eq (A.7) was used to fit the data while
fixing either KI or KA and varying KA or KI , respectively. (The observed equilibrium constant involves three native states. This could be a source of the oft-reported
non-two state melting behavior of HSA bound by ligands) [9–11].

191

A.2

Thermograms of HSA and HSAB at pH 6.0, 7.4, and 8.0.

Figure A.2.: Binding data for HSA at pH 6.0 in mixtures with naproxen (NAP) and
bromocresol green (BCG). (a) Titration thermograms for HSA at pH 6.0 with NAP
as a function of concentration. (n) Standard HSA at 28 µM, (l) HSA at pH 6.0 plus
NAP at: 25 µM (s), 75 µM (t), 150 µM (u). (b) Titration thermograms for HSA
at pH 6.0 with BCG as a function of concentration. (n) Standard HSA at 28 µM,
(l) HSA at pH 6.0 plus BCG at: 50 µM (s), 75 µM (t), 150 µM (u).

192

Table A.1.: Thermodynamic parameters evaluated for HSA thermal denaturation in
mixtures with increasing amounts of the ligands naproxen (NAP) and bromocresol
green (BCG) at pH = 6.0.
Naproxen
[NAP] (µM) ∆Hcal (kcal/mol)

Bromocresol green
0
∆G37

◦

Tm ( C) [BCG] (µM)

0

∆Hcal (kcal/mol) ∆G37

◦

Tm ( C)

HSA

0

154.9

12.0

62.5

0

154.9

12.0

62.5

HSA pH 6.0

0

172.6

15.8

68.3

0

172.6

15.8

68.3

25

206.4

20.2

70.6

50

193.3

18.7

70.1

75

219.2

22.1

71.7

75

203.7

20.1

71.0

150

218.4

22.7

73.0

150

182.5

19.7

74.5

Error

5%

± 0.2

± 0.2

Error

5%

± 0.2

± 0.2
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Figure A.3.: Binding data for HSAB1∶1 at pH 6.0 in mixtures with naproxen (NAP)
and bromocresol green (BCG). (a) Titration thermograms for HSAB1∶1 at pH 6.0
with NAP as a function of concentration. (n) Standard HSAB1∶1 at 28 µM, (l)
HSAB1∶1 at pH 6.0 plus NAP at: 25 µM (s), 75 µM (t), 150 µM (u). (b) Titration
thermograms for HSAB1∶1 at pH 6.0 with BCG as a function of concentration. (n)
Standard HSAB1∶1 at 28 µM, (l) HSAB1∶1 at pH 6.0 plus BCG at: 50 µM (s), 75
µM (t), 150 µM (u).

194

Table A.2.: Thermodynamic parameters evaluated for HSAB1∶1 thermal denaturation
in mixtures with increasing amounts of the ligands naproxen (NAP) and bromocresol
green (BCG) at pH = 6.0.
Naproxen
[NAP] (µM)
HSA
HSAB1∶1 pH 6.0

Bromocresol green
0

∆Hcal (kcal/mol) ∆G37

◦

Tm ( C) [BCG] (µM)

0

154.9

12.0

62.5

0

∆Hcal (kcal/mol) ∆G37

◦

Tm ( C)

0

154.9

12.0

62.5

0

211.2

19.9

69.3

0

211.2

19.9

69.3

25

217.4

21.9

71.8

50

216.7

21.6

71.4

75

222.3

22.9

72.7

75

213.8

22.3

73.1

150

223.3

23.9

74.1

150

218.4

24.0

75.2

Error

5%

± 0.2

± 0.2

Error

5%

± 0.2

± 0.2
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Figure A.4.: Binding data for HSAB1∶5 at pH 6.0 in mixtures with naproxen (NAP)
and bromocresol green (BCG). (a) Titration thermograms for HSAB1∶5 at pH 6.0
with NAP as a function of concentration. (n) Standard HSAB1∶5 at 28 µM, (l)
HSAB1∶5 at pH 6.0 plus NAP at: 25 µM (s), 75 µM (t), 150 µM (u). (b) Titration
thermograms for HSAB1∶5 at pH 6.0 with BCG as a function of concentration. (n)
Standard HSAB1∶5 at 28 µM, (l) HSAB1∶5 at pH 6.0 plus BCG at: 50 µM (s), 75
µM (t), 150 µM (u).
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Table A.3.: Thermodynamic parameters evaluated for HSAB1∶5 thermal denaturation
in mixtures with increasing amounts of the ligands naproxen (NAP) and bromocresol
green (BCG) at pH = 6.0.
Naproxen
[NAP] (µM)
HSA
HSAB1∶5 pH 6.0

Bromocresol green
0

∆Hcal (kcal/mol) ∆G37

◦

Tm ( C) [BCG] (µM)

0

154.9

12.0

62.5

0

∆Hcal (kcal/mol) ∆G37

◦

Tm ( C)

0

154.9

12.0

62.5

0

233.9

25.8

75.4

0

233.9

25.8

75.4

25

225.9

26.0

77.4

50

224.2

26.2

78.1

75

226.0

26.5

78.2

75

230.8

27.2

78.4

150

232.4

27.7

79.0

150

230.0

27.5

79.2

Error

5%

± 0.2

± 0.2

Error

5%

± 0.2

± 0.2
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Figure A.5.: Binding data for HSAB1∶10 at pH 6.0 in mixtures with naproxen (NAP)
and bromocresol green (BCG). (a) Titration thermograms for HSAB1∶10 at pH 6.0
with NAP as a function of concentration. (n) Standard HSAB1∶10 at 28 µM, (l)
HSAB1∶10 at pH 6.0 plus NAP at: 25 µM (s), 75 µM (t), 150 µM (u). (b) Titration
thermograms for HSAB1∶10 at pH 6.0 with BCG as a function of concentration. (n)
Standard HSAB1∶10 at 28 µM, (l) HSAB1∶10 at pH 6.0 plus BCG at: 50 µM (s), 75
µM (t), 150 µM (u).
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Table A.4.: Thermodynamic parameters evaluated for HSAB1∶10 thermal denaturation
in mixtures with increasing amounts of the ligands naproxen (NAP) and bromocresol
green (BCG) at pH = 6.0.
Naproxen
[NAP] (µM)
HSA
HSAB1∶10 pH 6.0

Bromocresol green
0

∆Hcal (kcal/mol) ∆G37

◦

Tm ( C) [BCG] (µM)

0

154.9

12.0

62.5

0

∆Hcal (kcal/mol) ∆G37

◦

Tm ( C)

0

154.9

12.0

62.5

0

234.0

26.2

76.1

0

234.0

26.2

76.1

25

233.7

27.3

78.0

50

236.8

27.7

78.1

75

235.6

27.8

78.4

75

233.0

27.7

78.9

150

234.7

28.2

79.3

150

234.6

28.1

79.2

Error

5%

± 0.2

± 0.2

Error

5%

± 0.2

± 0.2
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Figure A.6.: Binding data for HSAB1∶1 at pH 7.4 in mixtures with naproxen (NAP)
and bromocresol green (BCG). (a) Titration thermograms for HSAB1∶1 at pH 7.4
with NAP as a function of concentration. (n) Standard HSAB1∶1 at 28 µM, (l)
HSAB1∶1 at pH 7.4 plus NAP at: 25 µM (s), 75 µM (t), 150 µM (u). (b) Titration
thermograms for HSAB1∶1 at pH 7.4 with BCG as a function of concentration. (n)
Standard HSAB1∶1 at 28 µM, (l) HSAB1∶1 at pH 7.4 plus BCG at: 50 µM (s), 75
µM (t), 150 µM (u).
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Table A.5.: Thermodynamic parameters evaluated for HSAB1∶1 thermal denaturation
in mixtures with increasing amounts of the ligands naproxen (NAP) and bromocresol
green (BCG) at pH = 7.4.
Naproxen
[NAP] (µM)

Bromocresol green
0

∆Hcal (kcal/mol) ∆G37

◦

Tm ( C) [BCG] (µM)

0

∆Hcal (kcal/mol) ∆G37

◦

Tm ( C)

HSA

0

154.9

12.0

62.5

0

154.9

12.0

62.5

HSAB1∶1 pH 7.4

0

192.7

17.2

67.3

0

192.7

17.2

67.3

25

218.7

20.6

69.3

50

195.5

18.5

69.4

75

214.6

21.0

70.7

75

205.9

20.0

70.3

150

225.6

22.8

71.8

150

210.8

20.9

71.2

Error

5%

± 0.2

± 0.2

Error

5%

± 0.2

± 0.2
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Figure A.7.: Binding data for HSAB1∶5 at pH 7.4 in mixtures with naproxen (NAP)
and bromocresol green (BCG). (a) Titration thermograms for HSAB1∶5 at pH 7.4
with NAP as a function of concentration. (n) Standard HSAB1∶5 at 28 µM, (l)
HSAB1∶5 at pH 7.4 plus NAP at: 25 µM (s), 75 µM (t), 150 µM (u). (b) Titration
thermograms for HSAB1∶5 at pH 7.4 with BCG as a function of concentration. (n)
Standard HSAB1∶5 at 28 µM, (l) HSAB1∶5 at pH 7.4 plus BCG at: 50 µM (s), 75
µM (t), 150 µM (u).
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Table A.6.: Thermodynamic parameters evaluated for HSAB1∶5 thermal denaturation
in mixtures with increasing amounts of the ligands naproxen (NAP) and bromocresol
green (BCG) at pH = 7.4.
Naproxen

HSA
HSAB1∶5 pH 7.4

Bromocresol green

[NAP] (µM)

∆Hcal (kcal/mol)

0
∆G37

0

154.9

12.0

62.5

◦

Tm ( C) [BCG] (µM)

0

∆Hcal (kcal/mol) ∆G37

◦

Tm ( C)

0

154.9

12.0

62.5

0

200.6

20.6

72.5

0

200.6

20.6

72.5

25

213.0

22.8

71.8

50

202.9

21.3

73.3

75

229.2

25.1

75.2

75

210.7

22.5

74.0

150

232.0

25.9

76.0

150

210.6

23.1

75.1
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Figure A.8.: Binding data for HSAB1∶10 at pH 7.4 in mixtures with naproxen (NAP)
and bromocresol green (BCG). (a) Titration thermograms for HSAB1∶10 at pH 7.4
with NAP as a function of concentration. (n) Standard HSAB1∶10 at 28 µM, (l)
HSAB1∶10 at pH 7.4 plus NAP at: 25 µM (s), 75 µM (t), 150 µM (u). (b) Titration
thermograms for HSAB1∶10 at pH 7.4 with BCG as a function of concentration. (n)
Standard HSAB1∶10 at 28 µM, (l) HSAB1∶10 at pH 7.4 plus BCG at: 50 µM (s), 75
µM (t), 150 µM (u).
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Table A.7.: Thermodynamic parameters evaluated for HSAB1∶10 thermal denaturation
in mixtures with increasing amounts of the ligands naproxen (NAP) and bromocresol
green (BCG) at pH = 7.4.
Naproxen

HSA
HSAB1∶10 pH 7.4

Bromocresol green

[NAP] (µM)

∆Hcal (kcal/mol)

0
∆G37

0

154.9

12.0

62.5

◦

Tm ( C) [BCG] (µM)

0

∆Hcal (kcal/mol) ∆G37

◦

Tm ( C)

0

154.9

12.0

62.5

0

206.6

21.2

72.5

0

206.6

21.2

72.5

25

211.1

22.7

74.3

50

213.4

22.4

73.3

75

216.6

23.7

75.0

75

215.2

22.9

74.0

150

223.2

25.5

77.0

150

214.7

23.5

75.1
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Figure A.9.: Binding data for HSA at pH 8.0 in mixtures with naproxen (NAP) and
bromocresol green (BCG). (a) Titration thermograms for HSA at pH 8.0 with NAP
as a function of concentration. (n) Standard HSA at 28 µM, (l) HSA at pH 8.0 plus
NAP at: 25 µM (s), 75 µM (t), 150 µM (u). (b) Titration thermograms for HSA
at pH 8.0 with BCG as a function of concentration. (n) Standard HSA at 28 µM,
(l) HSA at pH 8.0 plus BCG at: 50 µM (s), 75 µM (t), 150 µM (u).
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Table A.8.: Thermodynamic parameters evaluated for HSA thermal denaturation in
mixtures with increasing amounts of the ligands naproxen (NAP) and bromocresol
green (BCG) at pH = 8.0.
Naproxen
[NAP] (µM) ∆Hcal (kcal/mol)

Bromocresol green
0
∆G37

◦

Tm ( C) [BCG] (µM)

0

∆Hcal (kcal/mol) ∆G37

◦

Tm ( C)

HSA

0

154.9

12.0

62.5

0

154.9

12.0

62.5

HSA pH 8.0

0

136.4

10.0

61.4

0

136.4

10.0

61.4

25

177.2

13.9

63.3

50

138.2

10.5

62.6

75

176.0

14.9

65.7

75

134.1

12.4

68.6

150

176.7

15.7

67.3

150

159.9

15.8

71.1

Error

5%

± 0.2

± 0.2

Error

5%

± 0.2

± 0.2
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Figure A.10.: Binding data for HSAB1∶1 at pH 8.0 in mixtures with naproxen (NAP)
and bromocresol green (BCG). (a) Titration thermograms for HSAB1∶1 at pH 8.0
with NAP as a function of concentration. (n) Standard HSAB1∶1 at 28 µM, (l)
HSAB1∶1 at pH 8.0 plus NAP at: 25 µM (s), 75 µM (t), 150 µM (u). (b) Titration
thermograms for HSAB1∶1 at pH 8.0 with BCG as a function of concentration. (n)
Standard HSAB1∶1 at 28 µM, (l) HSAB1∶1 at pH 8.0 plus BCG at: 50 µM (s), 75
µM (t), 150 µM (u).
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Table A.9.: Thermodynamic parameters evaluated for HSAB1∶1 thermal denaturation
in mixtures with increasing amounts of the ligands naproxen (NAP) and bromocresol
green (BCG) at pH = 8.0.
Naproxen
[NAP] (µM)
HSA
HSAB1∶1 pH 8.0

Bromocresol green
0

∆Hcal (kcal/mol) ∆G37

◦

Tm ( C) [BCG] (µM)

0

154.9

12.0

62.5

0

∆Hcal (kcal/mol) ∆G37

◦

Tm ( C)

0

154.9

12.0

62.5

0

154.2

12.8

65.2

0

154.2

12.8

65.2

25

154.2

14.3

68.7

50

146.0

13.4

68.4

75

181.5

17.8

70.7

75

148.0

13.9

69.1

150

189.4

18.6

70.8

150

180.7

17.9

71.0

Error

5%

± 0.2

± 0.2

Error

5%

± 0.2

± 0.2
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Figure A.11.: Binding data for HSAB1∶5 at pH 8.0 in mixtures with naproxen (NAP)
and bromocresol green (BCG). (a) Titration thermograms for HSAB1∶5 at pH 8.0
with NAP as a function of concentration. (n) Standard HSAB1∶5 at 28 µM, (l)
HSAB1∶5 at pH 8.0 plus NAP at: 25 µM (s), 75 µM (t), 150 µM (u). (b) Titration
thermograms for HSAB1∶5 at pH 8.0 with BCG as a function of concentration. (n)
Standard HSAB1∶5 at 28 µM, (l) HSAB1∶5 at pH 8.0 plus BCG at: 50 µM (s), 75
µM (t), 150 µM (u).
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Table A.10.: Thermodynamic parameters evaluated for HSAB1∶5 thermal denaturation in mixtures with increasing amounts of the ligands naproxen (NAP) and
bromocresol green (BCG) at pH = 8.0.
Naproxen
[NAP] (µM)
HSA
HSAB1∶5 pH 8.0

Bromocresol green
0

∆Hcal (kcal/mol) ∆G37

◦

Tm ( C) [BCG] (µM)

0

154.9

12.0

62.5

0

∆Hcal (kcal/mol) ∆G37

◦

Tm ( C)

0

154.9

12.0

62.5

0

173.6

17.2

71.1

0

173.6

17.2

71.1

25

184.0

19.3

73.3

50

165.4

17.1

72.7

75

226.6

24.2

74.0

75

168.0

17.5

73.0

150

228.1

24.8

74.8

150

180.2

19.2

74.0

Error

5%

± 0.2

± 0.2

Error

5%

± 0.2

± 0.2
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Figure A.12.: Binding data for HSAB1∶10 at pH 8.0 in mixtures with naproxen (NAP)
and bromocresol green (BCG). (a) Titration thermograms for HSAB1∶10 at pH 8.0
with NAP as a function of concentration. (n) Standard HSAB1∶10 at 28 µM, (l)
HSAB1∶10 at pH 8.0 plus NAP at: 25 µM (s), 75 µM (t), 150 µM (u). (b) Titration
thermograms for HSAB1∶10 at pH 8.0 with BCG as a function of concentration. (n)
Standard HSAB1∶10 at 28 µM, (l) HSAB1∶10 at pH 8.0 plus BCG at: 50 µM (s), 75
µM (t), 150 µM (u).
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Table A.11.: Thermodynamic parameters evaluated for HSAB1∶10 thermal denaturation in mixtures with increasing amounts of the ligands naproxen (NAP) and
bromocresol green (BCG) at pH = 8.0.
Naproxen
[NAP] (µM)
HSA
HSAB1∶10 pH 8.0

Bromocresol green
0

∆Hcal (kcal/mol) ∆G37

◦

Tm ( C) [BCG] (µM)

0

154.9

12.0

62.5

0

∆Hcal (kcal/mol) ∆G37

◦

Tm ( C)

0

154.9

12.0

62.5

0

181.2

18.2

71.7

0

181.2

18.2

71.7

25

188.1

20.0

73.8

50

175.9

18.3

72.9

75

215.8

22.9

73.8

75

176.4

18.4

73.2

150

211.0

23.0

75.0

150

182.5

19.4

73.9

Error

5%

± 0.2

± 0.2

Error

5%

± 0.2

± 0.2
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Figure A.13.: Binding data for HSA at pH 4.5 and 5.5 in mixtures with naproxen
(NAP) and bromocresol green (BCG). (a) Titration thermograms for HSA at pH 4.5.
(n) Standard HSA at 28 µM, (l) pH 4.5 HSA at 28 µM with: 25 µM NAP (s), 75
µM BCG (t). (b) Titration thermograms for HSA at pH 5.5. (n) Standard HSA at
28 µM, (l) pH 4.5 HSA at 28 µM with: 75 µM BCG (s).
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Table A.12.: Thermodynamic parameters evaluated for HSA thermal denaturation in
mixtures with naproxen (NAP) and bromocresol green (BCG) at pH = 4.5 and 5.5.

[L] (µM)

0

∆Hcal (kcal/mol) ∆G37

◦

◦

Tm1 ( C) Tm2 ( C)

HSA

0

154.9

12.0

62.5

HSA pH 4.5

0

148.7

12.4

65.2

HSA pH 4.5

25 NAP

177.4

14.2

64.0

HSA pH 4.5

75 BCG

159.8

14.0

66.8

55.3

HSA pH 5.5

0

171.0

16.7

70.5

63.2

HSA pH 5.5

75 BCG

190.8

20.3

73.9

Error

5%

± 0.2

± 0.2

54.7

± 0.2

215

A.3

Thermograms of HSA in the Presence Organic Solvents

Figure A.14.: Thermograms for HSA in the presence of organic solvents, methanol
(MeOH) and ethanol (EtOH). (n) Standard HSA at 27 µM with, (l) 1% MeOH,
(s) 2% MeOH, (t) 1% EtOH.
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Figure A.15.: Thermograms for HSA in the presence of organic solvents, dimethyl
sulfoxide (DMSO) and acetonitrile (ACN). (n) Standard HSA at 27 µM with, (l)
1% DMSO, (s) 2% DMSO, (t) 1% ACN.
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APPENDIX B:
SUPPLEMENTAL DRUG BINDING FIGURES
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28.62 ± 7.07

5.44 ± 0.31
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from Tm
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Naproxen

M)

Dotarem

1.64 ± 0.86

from

0
∆G37

Measured KD (10
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Drug

M)

2.7

0.8

2.3

1.1

1.3

10.8

3.0

1.72

1.62

3.18
380 ± 28.1

1

1
72.99 ± 8.95

46.60

No Binding

No Binding

No Binding

No Binding

1

147

1

12.5 ± 3.24

1

1

5000

21.7

1 ± 0.58

667

”Set to 1”

1

129.9
179

1

55.2

N/A

Displacement Binding [17]

Fluorescence Quenching [16]

Fluorescence Quenching (BSA) [15]

Fluorescence Quenching (BSA) [14]

NMR Relaxometry [10]

NMR Relaxometry [10]

NMR Relaxometry [10]

NMR Relaxometry [10]

NMR Relaxometry [13]

Mass Spectrometry [10, 11]

NMR Relaxometry [12]

Ultrafiltration [10]

NMR Relaxometry [10, 11]

Mass Spectrometry [10]

Capillary Electrophoresis [9]

Fluorescence Quenching [8]

Equilibrium Dialysis [7]

Crystallography [6]

10
2.1

Fluorescence Quenching [5]

Assumed 1

2.56 ± 0.04

Circular Dichoism [4]

Equilibrium Dialysis [3]

Assumed 1

6

0.83

Fluorometry [2]

Spectrophotometry [1]

Literature Method

1.82

1, 4.1

0.12

Stoichiometry

Literature

3

M)

1.43

−6

Literature KD (10

Test Compounds

Stoichiometry

Measured
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−6

0.92 ± 0.16

0.90 ± 0.51
7.89 ± 0.86
12.37 ± 0.93
72.04 ± 11.35
11.62 ± 3.75

DM1157

BP-DOTA (side)

BP-DOTA (corner)

NBAM-DO3A

BPAM-DO3A
10.23 ± 1.82

28.78 ± 3.91

2) 10.24 ± 2.82

DOTFA

0.28 ± 0.15

1) 0.21 ± 0.04

Buproprion

28.52 ± 13.65

21.54 ± 11.68

68.38 ± 10.22

10.45 ± 1.25

9.21 ± 0.50

3.04 ± 4.55

19.24 ± 2.08

Metoprolol

2.8

1.9

1.0

0.9

1.2

1.0

−6

338

N/A

1

8 low affinity

2.5
6.37 ± 0.23

2 high affinity

1
0.91

218.81

1

1

N/A

307 ± 17%
23.15 ± 0.107

4

1

329

0.104 ± 0.012

1

Assumed 1

1075
339 ± 2.28

1

1

624.6

N/A

Stoichiometry

Literature

389

M)

83.33

Literature KD (10

Unknown Compounds

2) 2.8

1) 1.3

0.2

30.30 ± 1.06

0.6

1) 1.58 ± 1.25

2.44 ± 0.36
2) 24.52 ± 2.37

Metformin

2) 0.7

1) 0.8

N.D.

Stoichiometry

Measured

1.4

M)

79.82 ± 12.82

56.16 ± 23.63

2) 254 ± 52

2) 381 ± 28

Fluorescein

1) 2.70 ± 0.30

1) 3.56 ± 0.27

N.D.

from Tm

−6

Measured KD (10

Thimerosal

M)

247 ± 33.34

from

0
∆G37

Measured KD (10

Caffeine

Drug

Table B.1 continued

[22]

HDM-PAMPA Predictive [30]

Fluorescence Quenching [29]

Equilibrium Dialysis (BSA) [28]

Equilibrium Dialysis (BSA) [28]

Fluorescence Quenching [27]

Fluorescence Quenching (BSA) [26]

Fluorescence Quenching [25]

Fluorescence Quenching [24]

Equilibrium Dialysis [24]

Fluorescence Quenching [23]

Fluoresence Quenching (BSA)

Fluorescence Quenching [21]

Fluorescence Quenching [20]

Fluorescence Quenching [19]

Fluorescence Quenching [18]

Literature Method
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−6

15.15 ± 1.65

13.61 ± 2.84

8.96 ± 0.36

0.048 ± 0.015

9.02 ± 1.34

0.25 ± 0.04

Ibuprofen

Decanoic Acid

∆9-tetrahydrocannabinol

β-Estradiol

Bilirubin

from

0
∆G37

Measured KD (10

Digitoxin

Drug

0.41 ± 0.30

26.86 ± 7.04

0.025 ± 0.005

7.88 ± 0.33

0.98 ± 0.08

14.56 ± 3.10

from Tm

−6

M) Measured KD (10
Stoichiometry

Measured

−6

Literature KD (10

1.6

3.2

2.0

0.9

3.7

1.0

Literature

5 low affinity

1

0.015

0.007

N/A

N/A

28.6

0.2

N/A
Evidence for multiple sites

11.2

Fluorescence Quenching [40]
Assumed 1

Fluorescence Quenching [46]

Fluorescence Quenching [45]

Enzymatic Oxidation [44]

Equilibrium Dialysis [43]

Solid Phase Microextraction [42]

Isothermal Titration Calorimetry [41]

Assumed 1

0.047
0.055 ± 0.001

Spectrophotometrically [38]
Spectrophotometrically [39]

1

Equilibrium Dialysis [37]

Equilibrium Dialysis [36]

Surface Plasmon Resonance [33]

Affinity Chromatography [35]

1 high 1 low

0.1
≤ 0.1

1

1

10
10

N/A

4.7 low affinity

1.4 high affinity

2.9

2.4

Equilibrium Dialysis [34]

Surface Plasmon Resonance [33]

N/A
3 high affinity

38

Equilibrium Dialysis [31]

Literature Method

0.37

1

Stoichiometry

Affinity Chromatography [32]

M)

N/A

19.2 ± 0.7

6.6 ± 0.4

Insoluble or Poorly Soluble Compounds

M)

Table B.1 continued

B.1

Test Compounds

Figure B.1.: Binding data for HSA in mixtures with bromocresol green (BCG). (a)
Titration thermograms for HSA with BCG as a function of concentration. (n) Standard HSA at 28 µM plus BCG at: 10 µM ( ), 50 µM (▶), 75 µM (◀), 150 µM (u),
200 µM ((t), 225 µM (s), 250 µM (l). (b) Dose response curves constructed from
0

experimentally derived ∆G37 . (c) Dose response curves constructed from experimentally derived TM .
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Table B.2.: Thermodynamic parameters evaluated for HSA thermal denaturation in
mixtures with bromocresol green (BCG) at pH = 7.4.

[L] (µM)

0

◦

∆Hcal (kcal/mol) ∆G37 (kcal/mol) Tm ( C)

0

154.9

12.0

62.5

1

170.1

13.1

62.9

10

177.0

13.8

63.3

25

182.1

14.4

63.6

50

189.8

15.2

64.0

75

187.8

15.3

64.6

125

182.3

16.2

67.2

150

178.8

16.7

69.0

175

169.8

15.9

69.1

200

167.4

16.2

70.3

225

167.2

16.4

70.8

Error

5%

± 0.15

± 0.15

224

Figure B.2.: Binding data for HSA in mixtures with naproxen (NAP). (a) Titration
thermograms for HSA with NAP as a function of concentration. (n) Standard HSA
at 28 µM plus NAP at: 1 µM ( ), 10 µM (▶), 50 µM (◀) , 100 µM (u), 175 µM (t),
200 µM (s), 225 µM (l). (b) Dose response curves constructed from experimentally
0

derived ∆G37 . (c) Dose response curves constructed from experimentally derived TM .

225

Table B.3.: Thermodynamic parameters evaluated for HSA thermal denaturation in
mixtures with naproxen (NAP) at pH = 7.4.

[L] (µM)

0

◦

∆Hcal (kcal/mol) ∆G37 (kcal/mol) Tm ( C)

0

154.9

12.0

62.5

1

184.4

14.4

63.2

10

208.7

16.4

63.5

25

211.1

17.0

64.2

50

208.6

17.9

66.1

75

204.5

17.9

66.8

100

192.5

17.6

68.2

150

193.6

18.0

68.7

175

192.5

17.9

68.8

200

192.0

17.9

68.9

225

193.0

18.4

69.7

Error

5%

± 0.15

± 0.15

226

Figure B.3.: Binding data for HSA in mixtures with chloroquine (CQ). (a) Titration
thermograms for HSA with CQ as a function of concentration. (n) Standard HSA
at 28 µM plus CQ at: 5 µM (l), 10 µM (s), 25 µM (t), 50 µM (u), 100 µM (◀),
200 µM (▶), 400 µM ( ), 1,000 µM (H), 2,500 µM ( ), 4,000 µM (⊚). (b) Dose
0

response curves constructed from experimentally derived ∆G37 . (c) Dose response
curves constructed from experimentally derived TM .
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Table B.4.: Thermodynamic parameters evaluated for HSA thermal denaturation in
mixtures with chloroquine (CQ) at pH = 7.4.

[L] (µM)

0

◦

∆Hcal (kcal/mol) ∆G37 (kcal/mol) Tm ( C)

0

156.8

11.9

62.5

5

157.1

12.0

62.6

10

165.7

12.6

62.5

25

182.9

13.9

62.6

50

183.3

14.0

62.6

100

184.0

14.0

62.5

200

184.6

14.0

62.5

400

185.7

14.1

62.5

1000

226.6

17.8

63.4

2500

249.2

20.0

64.0

5000

250.5

20.3

64.4

Error

5%

± 0.15

± 0.15

228

Figure B.4.: Binding data for HSA in mixtures with Multihance (MH). (a) Titration
thermograms for HSA with MH as a function of concentration. (n) Standard HSA
at 28 µM plus CQ at: 25 µM (l), 100 µM (s), 200 µM (t), 300 µM (u), 1,000
µM (◀), 15,000 µM (▶), 30,000 µM ( ), 60,000 µM (H), 90,000 µM ( ). (b) Dose
0

response curves constructed from experimentally derived ∆G37 . (c) Dose response
curves constructed from experimentally derived TM .
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Table B.5.: Thermodynamic parameters evaluated for HSA thermal denaturation in
mixtures with Multihance (MH) at pH = 7.4.

[L] (µM)

0

◦

∆Hcal (kcal/mol) ∆G37 (kcal/mol) Tm ( C)

0

156.8

11.9

62.5

25

162.0

12.3

62.6

100

176.7

13.4

62.5

200

178.9

13.6

62.5

300

181.4

13.7

62.3

1000

180.9

12.9

60.8

15000

186.1

14.4

63.0

30000

188.7

15.0

63.7

60000

223.2

18.1

64.3

90000

219.2

18.0

64.7

Error

5%

± 0.15

± 0.15

230

Figure B.5.: Binding data for HSA in mixtures with Ablavar (AB). (a) Titration
thermograms for HSA with AB as a function of concentration. (n) Standard HSA at
28 µM plus AB at: 50 µM (l), 100 µM (s), 250 µM (t), 500 µM (u), 1,000 µM
(◀), 5,000 µM (▶), 15,000 µM ( ). (b) Dose response curves constructed from exper0

imentally derived ∆G37 . (c) Dose response curves constructed from experimentally
derived TM .
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Table B.6.: Thermodynamic parameters evaluated for HSA thermal denaturation in
mixtures with Ablavar (AB) at pH = 7.4.

[L] (µM)

0

◦

∆Hcal (kcal/mol) ∆G37 (kcal/mol) Tm ( C)

0

156.8

11.9

62.5

50

165.3

12.8

63.1

100

169.8

13.2

63.2

250

181.0

14.6

64.1

500

189.4

15.6

64.8

1000

203.2

17.0

65.3

5000

208.8

19.3

68.5

15000

208.3

19.7

69.4

30000

206.3

19.4

69.2

Error

5%

± 0.15

± 0.15

232

Figure B.6.: Binding data for HSA in mixtures with tetracaine (TET). (a) Titration
thermograms for HSA with TET as a function of concentration. (n) Standard HSA
at 28 µM plus TET at: 0.1 µM (l), 0.5 µM (s), 1 µM (t), 5 µM (u), 10 µM (◀),
25 µM (▶), 150 µM ( ), 200 µM (H), 400 µM ( ), 500 µM (⊚), 1,000 µM (:), 2,000
µM (7), 5,000 µM ([). (b) Dose response curves constructed from experimentally
0

derived ∆G37 . (c) Dose response curves constructed from experimentally derived TM .
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Table B.7.: Thermodynamic parameters evaluated for HSA thermal denaturation in
mixtures with tetracaine (TET) at pH = 7.4.

[L] (µM)

0

◦

∆Hcal (kcal/mol) ∆G37 (kcal/mol) Tm ( C)

0

156.8

11.9

62.5

0.1

171.7

13.0

62.5

0.5

176.1

13.4

62.6

1

178.1

13.6

62.6

5

180.0

13.7

62.6

10

180.1

13.7

62.6

25

181.7

14.0

62.9

150

181.2

14.1

63.1

200

181.4

14.1

63.1

400

183.5

14.3

63.2

500

184.0

14.5

63.5

2000

205.9

18.3

67.3

5000

213.2

18.3

66.2

Error

5%

± 0.15

± 0.15

234

Figure B.7.: Binding data for HSA in mixtures with captopril (CAP). (a) Titration
thermograms for HSA with CAP as a function of concentration. (n) Standard HSA
at 28 µM plus Cap at: 10 µM (l), 25 µM (s), 50 µM (t), 75 µM (u), 100 µM
(◀), 125 µM (▶), 150 µM ( ), 200 µM (H), 300 µM ( ). (b) Dose response curves
0

constructed from experimentally derived ∆G37 . (c) Dose response curves constructed
from experimentally derived TM .
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Table B.8.: Thermodynamic parameters evaluated for HSA thermal denaturation in
mixtures with captopril (CAP) at pH = 7.4.

[L] (µM)

0

◦

∆Hcal (kcal/mol) ∆G37 (kcal/mol) Tm ( C)

0

163.0

12.9

63.6

10

169.01

13.2

63.4

25

170.9

13.4

63.5

50

192.5

15.1

63.4

75

195.8

15.4

63.5

100

206.1

16.1

63.4

125

208.2

16.3

63.4

150

214.1

16.7

63.2

200

216.9

16.8

63.1

300

216.6

16.8

63.0

Error

5%

± 0.15

± 0.15

236

Figure B.8.: Binding data for HSA in mixtures with caffeine (CAF). (a) Titration
thermograms for HSA with CAF as a function of concentration. (n) Standard HSA
at 28 µM plus CAF at: 1,000 µM (l), 2,500 µM (s), 5,000 µM (t), 10,000 µM
(u), 15,000 µM (◀), 20,000 µM (▶), 30,000 µM ( ), 50,000 µM (H), 75,000 µM ( ),
100,000 µM (⊚. (b) Dose response curves constructed from experimentally derived
0

∆G37 . (c) Dose response curves constructed from experimentally derived TM .
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Table B.9.: Thermodynamic parameters evaluated for HSA thermal denaturation in
mixtures with caffeine (CAF) at pH = 7.4.

[L] (µM)

0

◦

∆Hcal (kcal/mol) ∆G37 (kcal/mol) Tm ( C)

0

163.0

12.9

63.6

1000

176.7

14.0

63.7

2500

191.6

15.1

63.5

5000

198.8

16.1

64.3

10000

215.9

17.6

64.6

15000

233.3

19.0

64.6

20000

240.7

19.6

64.5

30000

243.3

19.7

64.4

50000

248.8

20.1

64.3

75000

259.4

20.6

63.7

100000

269.0

20.9

63.1

Error

5%

± 0.15

± 0.15
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Figure B.9.: Binding data for HSA in mixtures with thimerosal (TMS). (a) Titration
thermograms for HSA with TMS as a function of concentration. (n) Standard HSA
at 28 µM plus TMS at: 10 µM (l), 25 µM (s), 50 µM (t), 100 µM (u), 250
µM (◀), 500 µM (▶), 1,000 µM ( ), 2,500 µM (H), 5,000 µM ( ), 10,000 µM
(⊚), 20,000 µM (:), 30,000 µM (7), 40,000 µM ([). (b) Dose response curves
0

constructed from experimentally derived ∆G37 . (c) Dose response curves constructed
from experimentally derived TM .
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Table B.10.: Thermodynamic parameters evaluated for HSA thermal denaturation in
mixtures with thimerosal (TMS) at pH = 7.4.

[L] (µM)

0

◦

∆Hcal (kcal/mol) ∆G37 (kcal/mol) Tm ( C)

0

163.0

12.9

63.6

10

185.4

15.2

64.7

25

193.2

15.9

64.8

50

192.0

16.1

65.4

100

211.1

19.9

69.2

250

227.4

22.4

70.9

500

236.7

23.1

70.6

1000

230.8

23.5

72.2

2500

216.7

23.7

75.1

5000

212.5

24.4

77.2

10000

223.0

27.0

79.8

20000

240.6

30.5

82.1

30000

238.2

31.0

83.4

40000

234.1

30.9

84.2

Error

5%

± 0.15

± 0.15
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Figure B.10.: Binding data for HSA in mixtures with fluorescein (FSC). (a) Titration
thermograms for HSA with FSC as a function of concentration. (n) Standard HSA
at 28 µM plus FSC at: 10 µM (l), 25 µM (s), 50 µM (t), 100 µM (u), 200 µM
(◀), 500 µM (▶), 1,000 µM ( ), 2,000 µM (H), 5,000 µM ( ), 10,000 µM (⊚), 15,000
0

µM (:). (b) Dose response curves constructed from experimentally derived ∆G37 .
(c) Dose response curves constructed from experimentally derived TM .
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Table B.11.: Thermodynamic parameters evaluated for HSA thermal denaturation in
mixtures with fluorescein (FSC) at pH = 7.4.

[L] (µM)

0

◦

∆Hcal (kcal/mol) ∆G37 (kcal/mol) Tm ( C)

0

163.0

12.9

63.6

10

191.5

15.6

64.5

25

208.3

17.0

64.5

50

206.0

16.7

64.4

100

207.8

16.9

64.4

200

215.3

17.8

64.9

500

213.3

18.3

66.2

1000

209.0

19.0

68.0

2000

226.0

21.7

69.9

5000

220.2

22.2

71.8

10000

222.0

23.5

73.7

15000

219.5

33.6

74.4

Error

5%

± 0.15

± 0.15
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Figure B.11.: Binding data for HSA in mixtures with metformin (MET). (a) Titration
thermograms for HSA with MET as a function of concentration. (n) Standard HSA
at 28 µM plus MET at: 5 µM (l), 10 µM (s), 25 µM (t), 50 µM (u), 100 µM
(◀), 200 µM (▶), 400 µM ( ), 600 µM (H), 800 µM ( ), 1,000 µM (⊚), 1,200 µM
(:), 2,000 µM (7). (b) Dose response curves constructed from experimentally derived
0

∆G37 . (c) Dose response curves constructed from experimentally derived TM .
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Table B.12.: Thermodynamic parameters evaluated for HSA thermal denaturation in
mixtures with metformin (MET) at pH = 7.4.

[L] (µM)

0

◦

∆Hcal (kcal/mol) ∆G37 (kcal/mol) Tm ( C)

0

163.0

12.9

63.6

5

179.5

14.2

63.6

10

182.8

14.4

63.6

25

182.8

14.4

63.6

50

184.4

14.5

63.5

100

205.8

16.2

63.5

200

205.8

16.2

63.5

400

204.9

16.1

63.5

600

208.5

16.4

63.4

800

209.7

16.4

63.4

1000

207.0

16.2

63.3

1200

209.6

16.4

63.3

2000

206.3

16.1

63.3

Error

5%

± 0.15

± 0.15
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Figure B.12.: Binding data for HSA in mixtures with metoprolol (MEP). (a) Titration
thermograms for HSA with MEP as a function of concentration. (n) Standard HSA
at 28 µM plus MEP at: 25 µM (l), 100 µM (s), 250 µM (t), 500 µM (u), 1,000
µM (◀), 2,000 µM (▶), 4,000 µM ( ), 6,000 µM (H), 8,000 µM ( ), 10,000 µM (⊚),
15,000 µM (:). (b) Dose response curves constructed from experimentally derived
0

∆G37 . (c) Dose response curves constructed from experimentally derived TM .

245

Table B.13.: Thermodynamic parameters evaluated for HSA thermal denaturation in
mixtures with metoprolol (MEP) at pH = 7.4.

[L] (µM)

0

◦

∆Hcal (kcal/mol) ∆G37 (kcal/mol) Tm ( C)

0

163.0

12.9

63.6

25

166.0

13.3

64.0

100

174.2

13.8

63.7

250

179.7

14.2

63.6

500

188.1

14.8

63.5

1000

203.3

15.9

63.4

2000

203.6

15.9

63.3

4000

204.4

15.9

63.3

6000

209.2

16.3

63.3

8000

206.9

16.1

63.2

10000

205.9

16.0

63.2

15000

207.3

16.0

63.0

Error

5%

± 0.15

± 0.15
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Figure B.13.: Binding data for HSA in mixtures with bupropion (BPR). (a) Titration
thermograms for HSA with BPR as a function of concentration. (n) Standard HSA
at 28 µM plus BPR at: 5 µM (l), 10 µM (s), 25 µM (t), 50 µM (u), 100 µM
(◀), 150 µM (▶), 200 µM ( ), 300 µM (H), 500 µM ( ), 1,000 µM (⊚). (b) Dose
0

response curves constructed from experimentally derived ∆G37 . (c) Dose response
curves constructed from experimentally derived TM .
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Table B.14.: Thermodynamic parameters evaluated for HSA thermal denaturation in
mixtures with bupropion (BPR) at pH = 7.4.

[L] (µM)

0

◦

∆Hcal (kcal/mol) ∆G37 (kcal/mol) Tm ( C)

0

163.0

12.9

63.6

1

168.3

13.3

63.6

5

175.2

13.8

63.6

10

183.4

14.6

63.8

25

184.8

14.7

63.9

50

187.9

15.0

63.8

100

187.2

14.9

63.9

150

192.9

15.3

63.8

200

200.7

16.0

63.8

300

199.6

16.0

64.0

500

206.0

16.6

64.1

1000

208.8

17.1

64.6

Error

5%

± 0.15

± 0.15
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B.2

Unknown Compounds

Figure B.14.: Binding data for HSA in mixtures with DM1157 (DM1). (a) Titration
thermograms for HSA with DM1 as a function of concentration. (n) Standard HSA
at 28 µM plus DM1 at: 5 µM (l), 10 µM (s), 25 µM (t), 50 µM (u), 100 µM (◀),
200 µM (▶), 400 µM ( ). (b) Dose response curves constructed from experimentally
0

derived ∆G37 . (c) Dose response curves constructed from experimentally derived TM .
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Table B.15.: Thermodynamic parameters evaluated for HSA thermal denaturation in
mixtures with DM1157 (DM1) at pH = 7.4.

[L] (µM)

0

◦

∆Hcal (kcal/mol) ∆G37 (kcal/mol) Tm ( C)

0

156.8

11.9

62.5

10

171.8

13.1

62.6

25

192.0

14.7

62.8

50

201.1

15.6

63.0

100

219.0

17.0

63.1

200

220.2

17.1

63.1

400

220.4

17.1

63.1

Error

5%

± 0.15

± 0.15
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Figure B.15.: Binding data for HSA in mixtures with BP-DOTA (side) (BPs). (a)
Titration thermograms for HSA with BPs as a function of concentration. (n) Standard HSA at 28 µM plus BPs at: 50 µM (l), 100 µM (s), 200 µM (t), 400 µM
(u), 800 µM (◀), 1,000 µM (▶). (b) Dose response curves constructed from exper0

imentally derived ∆G37 . (c) Dose response curves constructed from experimentally
derived TM .
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Table B.16.: Thermodynamic parameters evaluated for HSA thermal denaturation in
mixtures with BP-DOTA (side) (BPs) at pH = 7.4.

[L] (µM)

0

◦

∆Hcal (kcal/mol) ∆G37 (kcal/mol) Tm ( C)

0

156.8

11.9

62.5

50

169.7

13.2

63.1

100

175.0

13.8

63.5

200

183.8

15.1

64.7

400

181.8

17.6

70.3

800

179.9

17.7

70.8

Error

5%

± 0.15

± 0.15
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Figure B.16.: Binding data for HSA in mixtures with BP-DOTA corner (BPc). (a)
Titration thermograms for HSA with BPc as a function of concentration. (n) Standard HSA at 28 µM plus BPc at: 50 µM (l), 100 µM (s), 200 µM (t), 400 µM
(u), 800 µM (◀), 1,000 µM (▶). (b) Dose response curves constructed from exper0

imentally derived ∆G37 . (c) Dose response curves constructed from experimentally
derived TM .
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Table B.17.: Thermodynamic parameters evaluated for HSA thermal denaturation in
mixtures with BP-DOTA (corner) (BPc) at pH = 7.4.

[L] (µM)

0

◦

∆Hcal (kcal/mol) ∆G37 (kcal/mol) Tm ( C)

0

156.8

11.9

62.5

50

188.7

14.6

63.0

100

193.0

15.4

64.0

200

190.2

15.7

64.9

400

204.1

20.1

70.9

800

221.6

22.5

72.0

1000

219.7

23.1

73.4

Error

5%

± 0.15

± 0.15
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Figure B.17.: Binding data for HSA in mixtures with NBAM-DO3A corner (NB3).
(a) Titration thermograms for HSA with NB3 as a function of concentration. (n)
Standard HSA at 28 µM plus NBD3 at: 200 µM (l), 500 µM (s), 1,000 µM (t),
2,500 µM (u), 5,000 µM (◀), 10,000 µM (▶). (b) Dose response curves constructed
0

from experimentally derived ∆G37 . (c) Dose response curves constructed from experimentally derived TM .
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Table B.18.: Thermodynamic parameters evaluated for HSA thermal denaturation in
mixtures with NBAM-DO3A (NB3) at pH = 7.4.

[L] (µM)

0

◦

∆Hcal (kcal/mol) ∆G37 (kcal/mol) Tm ( C)

0

156.8

11.9

62.5

200

182.3

14.1

62.6

500

189.4

14.5

62.7

1000

190.2

14.4

62.9

2500

189.3

16.4

66.4

5000

190.7

17.2

67.7

10000

192.7

17.0

67.1

Error

5%

± 0.15

± 0.15
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Figure B.18.: Binding data for HSA in mixtures with BPAM-DO3A (BP3). (a) Titration thermograms for HSA with BP3 as a function of concentration. (n) Standard
HSA at 28 µM plus BPD3 at: 50 µM (l), 100 µM (s), 200 µM (t), 400 µM (u),
800 µM (◀), 1,000 µM (▶), 2,500 µM ( ). (b) Dose response curves constructed
0

from experimentally derived ∆G37 . (c) Dose response curves constructed from experimentally derived TM .
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Table B.19.: Thermodynamic parameters evaluated for HSA thermal denaturation in
mixtures with BPAM-DO3A (BP3) at pH = 7.4.

[L] (µM)

0

◦

∆Hcal (kcal/mol) ∆G37 (kcal/mol) Tm ( C)

0

156.8

11.9

62.5

50

186.8

14.7

63.5

100

186.2

14.8

63.7

200

204.5

16.8

64.7

400

228.1

19.2

65.5

700

227.2

19.3

65.8

1000

236.9

21.5

68.0

2500

237.9

21.8

68.3

Error

5%

± 0.15

± 0.15
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Figure B.19.: Binding data for HSA in mixtures with DOTFA (DTF). (a) Titration
thermograms for HSA with DTF as a function of concentration. (n) Standard HSA
at 28 µM plus BPD3 at: 50 µM (l), 100 µM (s), 250 µM (t), 500 µM (u), 1,000
µM (◀), 2,500 µM (▶). (b) Dose response curves constructed from experimentally
0

derived ∆G37 . (c) Dose response curves constructed from experimentally derived TM .
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Table B.20.: Thermodynamic parameters evaluated for HSA thermal denaturation in
mixtures with DOTFA (DTF) at pH = 7.4.

[L] (µM)

0

◦

∆Hcal (kcal/mol) ∆G37 (kcal/mol) Tm ( C)

0

163.0

12.9

63.6

50

165.0

13.0

63.6

100

165.0

13.1

63.7

250

174.2

13.8

63.7

500

178.6

14.2

63.8

1000

184.8

14.8

64.0

2000

182.6

14.7

64.1

Error

5%

± 0.15

± 0.15
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B.3

Insoluble Compounds

Figure B.20.: Binding data for HSA in mixtures with digitoxin (DTX). (a) Titration thermograms for HSA with DTX as a function of concentration. (n) Standard
HSA at 28 µM plus DTX at: 50 µM (l), 100 µM (s), 250 µM (t), 350 µM (u),
500 µM (◀), 750 µM (▶), 1,000 µM ( ), 2,000 µM (H). (b) Dose response curves
0

constructed from experimentally derived ∆G37 . (c) Dose response curves constructed
from experimentally derived TM .
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Table B.21.: Thermodynamic parameters evaluated for HSA thermal denaturation in
mixtures with digitoxin (DTX) at pH = 7.4.

[L] (µM)

0

◦

∆Hcal (kcal/mol) ∆G37 (kcal/mol) Tm ( C)

0

163.0

12.9

63.6

50

178.5

14.9

65.3

100

177.4

15.0

65.6

250

179.5

15.2

65.7

350

181.7

15.9

66.7

500

185.9

16.3

66.8

750

190.7

17.4

68.1

1000

190.6

17.0

67.3

2000

188.9

17.2

68.0

Error

5%

± 0.15

± 0.15
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Figure B.21.: Binding data for HSA in mixtures with ibuprofen (IB). (a) Titration
thermograms for HSA with IB as a function of concentration. (n) Standard HSA at
28 µM plus IB at: 1 µM (l), 5 µM (s), 10 µM (t), 25 µM (u), 50 µM (◀), 100 µM
(▶), 150 µM ( ), 200 µM (H), 250 µM ( ), 300 µM (⊚). (b) Dose response curves
0

constructed from experimentally derived ∆G37 . (c) Dose response curves constructed
from experimentally derived TM .
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Table B.22.: Thermodynamic parameters evaluated for HSA thermal denaturation in
mixtures with ibuprofen (IB) at pH = 7.4.

[L] (µM)

0

◦

∆Hcal (kcal/mol) ∆G37 (kcal/mol) Tm ( C)

0

163.0

12.9

63.6

1

181.0

14.3

63.7

5

195.2

17.0

66.5

10

213.2

20.0

69.0

25

226.5

24.3

74.3

50

228.6

26.6

77.9

100

264.6

33.2

81.5

150

258.2

32.9

82.3

200

291.8

38.5

84.2

250

263.6

34.6

83.9

300

294.3

38.7

83.9

Error

5%

± 0.15

± 0.15
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Figure B.22.: Binding data for HSA in mixtures with decanoic acid (DCA). (a) Titration thermograms for HSA with DCA as a function of concentration. (n) Standard
HSA at 28 µM plus DEC at: 5 µM (l), 10 µM (s), 100 µM (t), 250 µM (u),
500 µM (◀), 1,000 µM (▶), 2,000 µM ( ), 5,000 µM (H). (b) Dose response curves
0

constructed from experimentally derived ∆G37 . (c) Dose response curves constructed
from experimentally derived TM .
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Table B.23.: Thermodynamic parameters evaluated for HSA thermal denaturation in
mixtures with decanoic acid (DCA) at pH = 7.4.

[L] (µM)

0

◦

∆Hcal (kcal/mol) ∆G37 (kcal/mol) Tm ( C)

0

163.0

12.9

63.6

5

188.2

14.9

63.6

10

191.7

15.1

63.6

50

200.0

16.6

65.0

100

223.6

19.3

66.3

250

246.7

29.4

78.9

500

296.7

39.7

84.9

1000

302.6

42.7

88.0

2000

303.9

43.1

88.2

5000

306.6

43.5

88.3

Error

5%

± 0.15

± 0.15

266

Figure B.23.: Binding data for HSA in mixtures with ∆-9-tetrahydrocannabinol
(THC). (a) Titration thermograms for HSA with THC as a function of concentration. (n) Standard HSA at 28 µM plus THC at: 0.1 µM (l), 0.5 µM (s), 1 µM
(t), 5 µM (u), 10 µM (◀), 25 µM (▶), 50 µM ( ), 100 µM (H), 150 µM ( ),
200 µM (⊚), 300 µM (:), 500 µM (7), 1,000 µM ([). (b) Dose response curves
0

constructed from experimentally derived ∆G37 . (c) Dose response curves constructed
from experimentally derived TM .
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Table B.24.: Thermodynamic parameters evaluated for HSA thermal denaturation in
mixtures with ∆-9-tetrahydrocannabinol (THC) at pH = 7.4.

[L] (µM)

0

◦

∆Hcal (kcal/mol) ∆G37 (kcal/mol) Tm ( C)

0

163.0

12.9

63.6

0.1

167.7

13.2

63.5

0.5

174.0

13.7

63.6

1

182.8

14.5

63.7

5

199.7

15.9

63.8

10

209.6

16.7

63.8

25

204.7

16.2

63.8

50

202.0

16.0

63.8

100

211.6

16.8

63.8

150

203.5

16.2

63.8

200

206.2

16.4

63.8

300

204.4

16.2

63.9

500

203.9

16.3

63.9

1000

208.6

16.8

63.9

Error

5%

± 0.15

± 0.15
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Figure B.24.: Binding data for HSA in mixtures with β-estradiol (BST). (a) Titration
thermograms for HSA with BST as a function of concentration. (n) Standard HSA
at 28 µM plus BST at: 100 µM (l), 200 µM (s), 400 µM (t), 600 µM (u), 800 µM
(◀), 1,000 µM (▶), 1,500 µM ( ). (b) Dose response curves constructed from exper0

imentally derived ∆G37 . (c) Dose response curves constructed from experimentally
derived TM .
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Table B.25.: Thermodynamic parameters evaluated for HSA thermal denaturation in
mixtures with β-estradiol (BST) at pH = 7.4.

[L] (µM)

0

◦

∆Hcal (kcal/mol) ∆G37 (kcal/mol) Tm ( C)

0

163.0

12.9

63.6

100

188.7

15.0

63.7

200

195.3

15.5

63.7

400

203.1

16.3

64.0

600

209.1

16.6

63.8

800

198.6

16.4

65.0

1000

201.2

16.5

64.7

1500

200.8

16.7

65.2

Error

5%

± 0.15

± 0.15

270

Figure B.25.: Binding data for HSA in mixtures with bilirubin (BIL). (a) Titration
thermograms for HSA with BIL as a function of concentration. (n) Standard HSA at
28 µM plus BIL at: 0.5 µM (l), 1 µM (s), 5 µM (t), 10 µM (u), 25 µM (◀), 50 µM
(▶), 100 µM ( ), 200 µM (H), 500 µM ( ), 1,000 µM (⊚). (b) Dose response curves
0

constructed from experimentally derived ∆G37 . (c) Dose response curves constructed
from experimentally derived TM .
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Table B.26.: Thermodynamic parameters evaluated for HSA thermal denaturation in
mixtures with bilirubin (BIL) at pH = 7.4.

[L] (µM)

0

◦

∆Hcal (kcal/mol) ∆G37 (kcal/mol) Tm ( C)

0

163.0

12.9

63.6

0.5

187.1

14.8

63.7

1

189.3

15.0

63.8

5

189.8

15.1

63.8

10

203.0

16.1

63.8

25

201.8

16.1

63.9

50

199.6

15.9

63.9

100

204.0

16.3

63.9

200

201.7

16.1

63.9

500

201.9

16.2

64.0

1000

203.4

16.3

64.0

Error

5%

± 0.15

± 0.15

272

Figure B.26.: Thermograms for drugs exhibiting no binding to HSA. Thermograms
shown for the compounds are (n) Standard HSA at 28 µM with 100,000 µM of (l)
Magnevist, (s) Prohance, (t) Gadovist, (u) Dotarem.
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Table B.27.: Thermodynamic parameters evaluated for HSA thermal denaturation in
mixtures with drugs that exhibit no binding to HSA, Magnevist (MAG), Prohance
(PRO), Gadovist (GAD), and Dotarem (DOT).
0

◦

Drug

[L] (µM)

∆Hcal (kcal/mol)

∆G37

Tm ( C)

HSA alone

0

156.8

11.9

62.5

Magnevist

100,000

157.7

12.0

62.5

Prohance

100,000

158.0

11.4

61.1

Gadovist

100,000

153.4

11.7

62.6

Dotarem

100,000

160.9

12.1

62.1

5%

± 0.15

± 0.15

Error
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[13] Robert N Muller, Bernd Radüchel, Sophie Laurent, Johannes Platzek, Corinne
Piérart, Peter Mareski, and Luce Vander Elst. Physicochemical characterization
of MS-325, a new gadolinium complex, by multinuclear relaxometry. European
Journal of Inorganic Chemistry, 1999(11):1949–1955, 1999.
[14] C Chilom and A Nistorescu. A spectroscopic study of the interaction of HSA
with tetracaine. Indian Journal of Biochemistry and Biophysics, 53:206–211,
2016.
[15] Amandeep Kaur, Parampaul Kaur Banipal, and Tarlok Singh Banipal. Local
anesthetic-bovine serum albumin interactional behaviour: Characterization by
volumetric, calorimetric, and spectroscopic methods. Journal of Molecular Liquids, 243:91–101, 2017.
[16] Xiaoyan Gao, Yingcai Tang, Wanqi Rong, Xiaoping Zhang, Wujie Zhao, Yanqin
Zi, et al. Analysis of binding interaction between captopril and human serum
albumin. American Journal of Analytical Chemistry, 2(02):250, 2011.
[17] Ting-Ting Liu, Li-Li Xiang, Jian-Ling Wang, and Dong-Ying Chen. Application of capillary electrophoresis-frontal analysis for comparative evaluation of
the binding interaction of captopril with human serum albumin in the absence
and presence of hydrochlorothiazide. Journal of Pharmaceutical and Biomedical
Analysis, 115:31–35, 2015.
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APPENDIX C:
SUPPLEMENTAL MATERIAL FOR CHAPTER 6

C.1

Allosteric Thermograms
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Figure C.1.: Binding data for HSA at pH 7.4 in mixtures with naproxen (NAP) and
bromocresol green (BCG) with 25 µM of pre-bound ligand. (a) Titration thermograms
for HSA at pH 7.4 with NAP as a function of concentration with 25 µM of pre-bound
BCG. (n) Standard HSA at 28 µM, (l) HSA at pH 7.4 plus BCG at 25 µM with
NAP at: 25 µM (s), 75 µM (t), 150 µM (u). (b) Titration thermograms for HSA
at pH 7.4 with BCG as a function of concentration with 25 µM of pre-bound NAP.
(n) Standard HSA at 28 µM, (l) HSA at pH 7.4 plus NAP at 25 µM with BCG at:
50 µM (s), 75 µM (t), 150 µM (u).
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Table C.1.: Thermodynamic parameters evaluated for HSA thermal denaturation in
mixtures with increasing amounts of the ligands naproxen (NAP) and bromocresol
green (BCG) with 25 µM of pre-bound ligand.
Naproxen

HSA

Bromocresol green

[NAP] (µM)

∆Hcal (kcal/mol)

0
∆G37

0

154.9

12.0

62.5

0

154.9

12.0

62.5

182.1

14.4

63.6

25 µM NAP

211.1

17.0

64.2

25

189.2

16.1

65.8

50

210.8

19.3

68.2

75

206.3

18.3

67.1

75

219.6

20.8

69.5

150

209.6

19.4

68.7

150

213.9

20.9

70.5

Error

5%

± 0.2

± 0.2

Error

5%

± 0.2

± 0.2

HSA 25 µM BCG

◦

Tm ( C) [BCG] (µM)

0

∆Hcal (kcal/mol) ∆G37

◦

Tm ( C)
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Figure C.2.: Binding data for HSA at pH 7.4 in mixtures with naproxen (NAP) and
bromocresol green (BCG) with 50 µM of pre-bound ligand. (a) Titration thermograms
for HSA at pH 7.4 with NAP as a function of concentration with 50 µM of pre-bound
BCG. (n) Standard HSA at 28 µM, (l) HSA at pH 7.4 plus BCG at 50 µM with
NAP at: 25 µM (s), 75 µM (t), 150 µM (u). (b) Titration thermograms for HSA
at pH 7.4 with BCG as a function of concentration with 25 µM of pre-bound NAP.
(n) Standard HSA at 28 µM, (l) HSA at pH 7.4 plus NAP at 50 µM with BCG at:
50 µM (s), 75 µM (t), 150 µM (u).
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Table C.2.: Thermodynamic parameters evaluated for HSA thermal denaturation in
mixtures with increasing amounts of the ligands naproxen (NAP) and bromocresol
green (BCG) with 50 µM of pre-bound ligand.
Naproxen

HSA

Bromocresol green

[NAP] (µM)

∆Hcal (kcal/mol)

0
∆G37

0

154.9

12.0

62.5

0

154.9

12.0

62.5

196.2

16.0

64.5

50 µM NAP

203.7

16.9

65.1

25

198.3

17.1

66.3

50

204.6

18.4

67.6

75

191.7

17.6

68.4

75

208.9

19.3

68.6

150

202.4

19.0

69.1

150

202.6

19.9

70.7

Error

5%

± 0.2

± 0.2

Error

5%

± 0.2

± 0.2

HSA 50 µM BCG

◦

Tm ( C) [BCG] (µM)

0

∆Hcal (kcal/mol) ∆G37

◦

Tm ( C)
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Figure C.3.: Binding data for HSAB1∶1 at pH 7.4 in mixtures with naproxen (NAP)
and bromocresol green (BCG) with 50 µM of pre-bound ligand. (a) Titration thermograms for HSAB1∶1 at pH 7.4 with NAP as a function of concentration with 50 µM of
pre-bound BCG. (n) Standard HSA at 28 µM, (l) HSAB1∶1 , (s) HSAB1∶1 at pH 7.4
plus BCG at 50 µM with NAP at: 25 µM (t), 75 µM (u), 150 µM (◀). (b) Titration
thermograms for HSAB1∶1 at pH 7.4 with BCG as a function of concentration with
50 µM of pre-bound NAP. (n) Standard HSA at 28 µM, (l) HSAB1∶1 , (s) HSAB1∶1
at pH 7.4 plus NAP at 50 µM with BCG at: 50 µM (t), 75 µM (u), 150 µM (◀).
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Table C.3.: Thermodynamic parameters evaluated for HSAB1∶1 thermal denaturation
in mixtures with increasing amounts of the ligands naproxen (NAP) and bromocresol
green (BCG) with 50 µM of pre-bound ligand.
Naproxen

Bromocresol green

[NAP] (µM)

∆Hcal (kcal/mol)

0
∆G37

HSA

0

154.9

12.0

62.5

0

154.9

12.0

62.5

HSAB1∶1

0

192.7

17.2

67.3

0

192.7

17.2

67.3

HSAB1∶1

50 µM BCG

195.5

18.5

69.4

50 µM NAP

216.7

20.8

70.0

25

215.1

21.4

71.2

50

213.0

21.7

72.2

75

217.2

21.9

71.8

75

223.0

22.6

71.9

150

226.0

23.3

72.7

150

222.4

23.0

72.7

Error

5%

± 0.2

± 0.2

Error

5%

± 0.2

± 0.2

◦

Tm ( C) [BCG] (µM)

0

∆Hcal (kcal/mol) ∆G37

◦

Tm ( C)
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Figure C.4.: Binding data for HSAB1∶5 at pH 7.4 in mixtures with naproxen (NAP)
and bromocresol green (BCG) with 50 µM of pre-bound ligand. (a) Titration thermograms for HSAB1∶5 at pH 7.4 with NAP as a function of concentration with 50 µM of
pre-bound BCG. (n) Standard HSA at 28 µM, (l) HSAB1∶5 , (s) HSAB1∶5 at pH 7.4
plus BCG at 50 µM with NAP at: 25 µM (t), 75 µM (u), 150 µM (◀). (b) Titration
thermograms for HSAB1∶5 at pH 7.4 with BCG as a function of concentration with
50 µM of pre-bound NAP. (n) Standard HSA at 28 µM, (l) HSAB1∶5 , (s) HSAB1∶5
at pH 7.4 plus NAP at 50 µM with BCG at: 50 µM (t), 75 µM (u), 150 µM (◀).
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Table C.4.: Thermodynamic parameters evaluated for HSAB1∶5 thermal denaturation
in mixtures with increasing amounts of the ligands naproxen (NAP) and bromocresol
green (BCG) with 50 µM of pre-bound ligand.
Naproxen

Bromocresol green

[NAP] (µM)

∆Hcal (kcal/mol)

0
∆G37

HSA

0

154.9

12.0

62.5

0

154.9

12.0

62.5

HSAB1∶5

0

200.6

20.6

72.5

0

200.6

20.6

72.5

HSAB1∶5

50 µM BCG

202.9

21.3

73.3

50 µM NAP

221.1

24.0

74.7

25

221.5

23.1

73.1

50

225.2

24.1

74.2

75

237.6

25.5

74.2

75

238.5

25.6

74.3

150

240.3

26.4

75.2

150

229.0

25.1

75.1

Error

5%

± 0.2

± 0.2

Error

5%

± 0.2

± 0.2

◦

Tm ( C) [BCG] (µM)

0

∆Hcal (kcal/mol) ∆G37

◦

Tm ( C)
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Figure C.5.: Binding data for HSAB1∶10 at pH 7.4 in mixtures with naproxen (NAP)
and bromocresol green (BCG) with 50 µM of pre-bound ligand. (a) Titration thermograms for HSAB1∶10 at pH 7.4 with NAP as a function of concentration with 50
µM of pre-bound BCG. (n) Standard HSA at 28 µM, (l) HSAB1∶10 , (s) HSAB1∶10
at pH 7.4 plus BCG at 50 µM with NAP at: 25 µM (t), 75 µM (u), 150 µM (◀).
(b) Titration thermograms for HSAB1∶10 at pH 7.4 with BCG as a function of concentration with 50 µM of pre-bound NAP. (n) Standard HSA at 28 µM, (l) HSAB1∶10 ,
(s) HSAB1∶10 at pH 7.4 plus NAP at 50 µM with BCG at: 50 µM (t), 75 µM (u),
150 µM (◀).
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Table C.5.: Thermodynamic parameters evaluated for HSAB1∶10 thermal denaturation
in mixtures with increasing amounts of the ligands naproxen (NAP) and bromocresol
green (BCG) with 50 µM of pre-bound ligand.
Naproxen

Bromocresol green

[NAP] (µM)

∆Hcal (kcal/mol)

0
∆G37

HSA

0

154.9

12.0

62.5

0

154.9

12.0

62.5

HSAB1∶10

0

206.6

21.2

72.5

0

206.6

21.2

72.5

HSAB1∶10

50 µM BCG

213.4

22.4

73.3

50 µM NAP

213.8

23.2

74.7

25

219.3

23.0

73.3

50

233.7

25.0

74.2

◦

Tm ( C) [BCG] (µM)

0

∆Hcal (kcal/mol) ∆G37

◦

Tm ( C)

75

224.3

24.0

74.2

75

236.2

25.3

74.2

150

233.6

25.9

75.7

150

232.8

25.0

74.3

Error

5%

± 0.2

± 0.2

Error

5%

± 0.2

± 0.2
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Figure C.6.: Binding data for HSA at pH 7.4 in mixtures with naproxen (NAP) and
bromocresol green (BCG) with 75 µM of pre-bound ligand. (a) Titration thermograms
for HSA at pH 7.4 with NAP as a function of concentration with 25 µM of pre-bound
BCG. (n) Standard HSA at 28 µM, (l) HSA at pH 7.4 plus BCG at 75 µM with
NAP at: 25 µM (s), 75 µM (t), 150 µM (u). (b) Titration thermograms for HSA
at pH 7.4 with BCG as a function of concentration with 75 µM of pre-bound NAP.
(n) Standard HSA at 28 µM, (l) HSA at pH 7.4 plus NAP at 75 µM with BCG at:
50 µM (s), 75 µM (t), 150 µM (u).
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Table C.6.: Thermodynamic parameters evaluated for HSA thermal denaturation in
mixtures with increasing amounts of the ligands naproxen (NAP) and bromocresol
green (BCG) with 75 µM of pre-bound ligand.
Naproxen

HSA

Bromocresol green

[NAP] (µM)

∆Hcal (kcal/mol)

0
∆G37

0

154.9

12.0

62.5

0

154.9

12.0

62.5

187.8

15.3

64.6

75 µM NAP

204.5

17.9

66.8

25

174.0

16.5

69.5

50

205.8

20.1

70.6

75

191.1

18.2

69.7

75

214.9

21.0

70.6

150

197.6

19.4

70.7

150

209.1

21.7

72.9

Error

5%

± 0.2

± 0.2

Error

5%

± 0.2

± 0.2

HSA 75 µM BCG

◦

Tm ( C) [BCG] (µM)

0

∆Hcal (kcal/mol) ∆G37

◦

Tm ( C)
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APPENDIX D:
PLASMA THERMOGRAMS

Figure D.1.: Thermograms of plasma with tetracaine. (n) Human plasma at 2mg/mL
plus Tet at 200 µM (l)
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Figure D.2.: Thermograms of plasma with chloroquine.

(n) Human plasma at

2mg/mL plus CQ at 200 µM (l)
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Figure D.3.: Thermograms of plasma with thiomersal.

(n) Human plasma at

2mg/mL plus TMS at 200 µM (l)
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Figure D.4.: Thermograms of plasma with fluorescein.

(n) Human plasma at

2mg/mL plus FSC at 200 µM (l)
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Figure D.5.: Thermograms of plasma with captopril. (n) Human plasma at 2mg/mL
plus CAP at 200 µM (l)
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Figure D.6.: Thermograms of plasma with caffeine. (n) Human plasma at 2mg/mL
plus CAF at 200 µM (l)
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Figure D.7.: Thermograms of plasma with DM1157. (n) Human plasma at 2mg/mL
plus DM1 at 200 µM (l)
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Figure D.8.: Thermograms of plasma with Multihance.

(n) Human plasma at

2mg/mL plus MH at 200 µM (l)
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Figure D.9.: Thermograms of plasma with Ablavar. (n) Human plasma at 2mg/mL
plus AB at 200 µM (l)
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Figure D.10.: Thermograms of plasma with Magnevist.

(n) Human plasma at

2mg/mL plus MAG at 200 µM (l)
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Figure D.11.: Thermograms of plasma with Dotarem. (n) Human plasma at 2mg/mL
plus DOT at 200 µM (l)
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Figure D.12.: Thermograms of plasma with Prohance.

(n) Human plasma at

2mg/mL plus PRO at 200 µM (l)
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Figure D.13.: Thermograms of plasma with Gadovist. (n) Human plasma at 2mg/mL
plus GAD at 200 µM (l)
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Figure D.14.: Thermograms of plasma with megulamine. (n) Human plasma at
2mg/mL plus MEG at 200 µM (l)
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Figure D.15.: Thermograms of plasma with BP-DOTA (corner). (n) Human plasma
at 2mg/mL plus BP-DOTAc at 200 µM (l)
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Figure D.16.: Thermograms of plasma with BP-DOTA (side). (n) Human plasma at
2mg/mL plus BP-DOTAs at 200 µM (l)
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Figure D.17.: Thermograms of plasma with D03A-BPAM. (n) Human plasma at
2mg/mL plus BPAM at 200 µM (l)
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Figure D.18.: Thermograms of plasma with D03A-NBAM. (n) Human plasma at
2mg/mL plus NBAM at 200 µM (l)
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Figure D.19.: Thermograms of plasma with D0TFA. (n) Human plasma at 2mg/mL
plus DOTFA at 200 µM (l)
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APPENDIX E:
PSILOCIN ANALYSIS

E.1

Results

Titrations of psilocin with HSA were performed as previously described [1, 2].
Thermograms are shown in Fig E.1.
In comparison with previous thermograms, there was a pronounced exotherm
present at psilocin (PSI) concentrations above 250 µM. In all previous experiments
∆CP = 0 for ligands alone and we did not observe measurable thermogram perturbations with increased ligand concentration [1, 2].
Thermograms of psilocin alone, in Fig E.2, were used to account for the exotherm
in the observed thermograms (Fig E.1). Thermograms in Fig E.2 were parameterized
using the mass and molecular weight for HSA as in previous curves. Thermograms
clearly show a pronounced exotherm at concentrations above 250 µM with decreasing
Tm at increased concentrations.
Since thermograms in Figs E.1 and E.2 used the same input parameters, it is
relatively straightforward to remove the contribution of psilocin from the original
curves. That is,
0

∆CP (HSA•P SI) = ∆CP (HSA•P SI) − ∆CP (P SI)

(E.1)

0

Where ∆CP (HSA•P SI) is the initial measured heat capacity from Fig E.1, ∆CP (P SI)
is the heat capacity for psilocin alone, and ∆CP (HSA•P SI) is the deconvoluted heat
capacity of the bound complex after accounting for psilocin. The deconvoluted thermograms are displayed in Fig E.3.
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Figure E.1.: Titration thermograms for HSA with psilocin (PSI) as a function of
concentration. (n) Standard HSA at 2mg/mL plus PSI at: 1 µM (l), 5 µM (s), 10
µM (t), 100 µM (u), 200 µM (◀), 250 µM (▶), 300 µM ( ), 400 µM (H), 500 µM
( ), 1,000 µM (⊚).

Thermodynamic parameters derived from thermograms in Fig E.3 are summarized
in Table E.1. Examinations of both the table and thermograms reveals that binding
increases with psilocin concentration up to ∼250 µM. Above 250 µM, coinciding with
appearance of the exotherm, a decrease in binding to HSA occurs as evidenced by
the decrease in Tm .
At this point, the cause of the exotherm is not determined. However, it can be
inferred that it lowered free psilocin available for binding to HSA.
It has been reported that psilocin forms a black ”degredation product” in aqueous
solutions [3, 4]. For samples prepared in both PBS buffer and H2 O, a black solution
formed within 24 hours when left at room temperature and within two weeks when
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Figure E.2.: Titration thermograms for psilocin (PSI) as a function of concentration
using HSA parameters. 250 µM (n), 300 µM (l), 400 µM (s), 500 µM (t), 1,000
µM (u).

◦

stored at 4 C. An image of these solutions is displayed in Fig E.4. The black solution
formed for all concentrations of psilocin in H2 O. However, heating psilocin solutions
past the Tm prevented the black solution from forming. Solutions remained clear for
at least 12 months.
UV-Visible spectra were measured for psilocin solutions before and after melting,
◦

Fig E.5. After 24 hours at 4 C, psilocin solutions were visibly clear but a peak
appeared at ∼280 nm. For solutions stored in H2 O for four months, the black solution
appeared and absorbs over the entire visible range out to 900 nm. Solutions that were
melted displayed a single peak at ∼230 nm and had minimal absorption over the 400-
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Figure E.3.: Deconvoluted titration thermograms for HSA with psilocin (PSI) as a
function of concentration. (n) Standard HSA at 2mg/mL plus PSI at: 1 µM (l), 5
µM (s), 10 µM (t), 100 µM (u), 200 µM (◀), 250 µM (▶), 300 µM ( ), 400 µM
(H), 500 µM ( ), 1,000 µM (⊚).

900 nm range. A single attempt was made to chemically break up the black solution
with the addition of 10 M HCl. No change in the spectrum was observed after seven
days.
A thermogram was measured for a 1 mM black psilocin solution that had been
◦

stored at 4 C for four months. The resulting thermogram in Fig E.6 is parameterized
for psilocin utilizing the molecular weight and solution density (204.27 g/mol and
0.20427 mg/mL). Similar to the thermograms in Fig E.2 a pronounced exotherm was
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Table E.1.: Thermodynamic parameters of deconvoluted psilocin (PSI) binding to
HSA.
[PSI] (µM)

0

◦

∆Hcal (kcal/mol) ∆Scal (kcal/mol K) ∆G37 (kcal/mol) Tm ( C)

0

163.0

484.0

12.9

63.6

1

170.3

505.6

13.4

63.6

5

186.9

555.2

14.7

63.6

10

195.3

579.8

15.4

63.6

100

211.4

626.9

16.9

64.0

200

210.8

624.0

17.3

64.7

250

214.6

629.2

19.4

67.9

300

208.1

618.7

16.2

63.2

400

228.4

679.3

17.7

63.1

500

230.7

685.6

18.0

63.3

1,000

244.0

726.2

18.8

62.9

Error

± 5%

± 5%

± 0.1

± 0.1

observed. After extraction from the instrument the black solution was clear; and
remained clear for at least 12 months.
Titration thermograms for psilocin were measured and solution density, input
parameter, was used for each concentration. Results in Fig E.7 show that increasing
psilocin concentrations reduced the overall thermodynamic stability, manifested as
0

decreases in Tm and ∆G37 . Table E.2 contains the thermodynamic parameters of
psilocin melting.
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◦

Figure E.4.: Images of 1 mM psilocin (PSI) solutions after 4 months at 4 C. (a) PSI
in acetonitrile, (b) PSI in H2 O, (c) melted PSI in H2 O.
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Figure E.5.: UV-Vis spectra of 250 µM psilocin (PSI) before and after melting. (n)
◦

◦

PSI in H2 O (24 hours at 4 C), (l) PSI in H2 O (24 hours at 4 C) after melting, (s)
◦

PSI in H2 O (24 hours at 25 C) after melting, (t) PSI in H2 O 4 months after melting
◦

◦

stored at 4 C, (u) PSI in H2 O 4 months at 4 C.
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Figure E.6.: Thermogram of black psilocin solution at 1 mM after storage in H2 O at
◦

4 C for 4 months.
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Figure E.7.: Thermograms for psilocin (PSI) as a function of concentration. 250 µM
(n) 500 µM (l), 1,000 µM (s),

Table E.2.: Thermodynamic parameters of psilocin (PSI) melting.
[PSI] (µM)

0

◦

∆Hcal (kcal/mol) ∆Scal (kcal/mol K) ∆G37 (kcal/mol) Tm ( C)

250

-75.3

-200.3

-13.2

102.8

500

-44.0

-122.3

-6.1

86.7

1,000

-28.5

-80.6

-3.5

80.8

Error

± 5%

± 5%

± 0.1

± 0.1
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E.1.1

Psilocin Analogs

In the literature the black solution has been reported to be a ”degredation product” [4, 5]. This view has been disputed due to the similarity in structure between
psilocin and serotonin, and the fact that serotonin does not display a degredation
pathway [3]. The nature of the black solution is in dispute. To date, there has been
no reported identification of this black solution through either mass spectrometry or
chromatography [4, 5].
An attempt was made to begin to further characterize the solution using nuclear magnetic resonance (NMR). Psilocin was purchased as a solution in acetonitrile
and solvent exchange was performed to prepare psilocin in chloroform-D for H-NMR
experiments. Measured NMR spectrum matched exactly with the manufacturer’s
certificate of analysis. However, solutions prepared in D2 O and allowed to turn black
displayed inconclusive NMR results with the absence of the expected aromatic peaks
corresponding to psilocin.

Figure E.8.: Structures of psilocin and analogs. (a) 5-hydroxyindole, (b) serotonin,
(c) psilocin.

Further DSC experiments were performed on psilocin and functional analogs to analyze the nature of the exotherm on the thermogram. Serotonin and 5-hydroxyindole
were chosen for analysis. Chemical structures are displayed in Fig E.8. The choice
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of analogs was to explore which functional group might be responsible for the observed exotherm of psilocin. All three structures contain a hydroxyindole component
with the hydroxy in the 5 position for 5-hydroxyindole and serotnin and 4 position for
psilocin. Both serotonin and psilocin have a 2-aminoethyl arm with the sole difference
being that the arm on psilocin is dimethylated.
Thermograms were measured for 5-hydroxyindole, serotonin, and psilocin at 1
mM and parameterized with molecular weight and solution density (133.15 g/mol
0.13315 mg/mL, 176.215 g/mol 0.176215 mg/mL, and 204.27 g/mol 0.20427 mg/mL,
respectively). Thermograms in Fig E.9 are distinctly different. Thermodynamic
parameters for melting are summarized in Table E.3.

Figure E.9.: Thermograms for psilocin analogs at 1 mM. Psilocin (n) Serotonin (l),
5-hydroxindole (s),
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◦

5-hydroxyindole displays a broad but minor exotherm with Tm = 109.8 C and a
0

small ∆G37 = -0.5 kcal/mol. In contrast, serotonin and psilocin have a significant
exotherm. The absence of a significant exotherm for 5-hydroxyindole indicates that
the hydroxyindole ring is unlikely to be the source of the exotherm and black solution
observed for psilocin. However, the presence of an exotherm for psilocin and serotonin
implicates the 2-aminoethyl arm as the possible cause.
Table E.3.: Thermodynamic parameters for psilocin analog melting.
[X] (1 mM)

∆Hcal (kcal/mol) ∆Scal (kcal/mol K)

0

◦

∆G37 (kcal/mol) Tm ( C)

Psilocin

-28.5

-80.6

-3.5

80.8

Serotonin

-21.2

-55.4

-4.0

109.8

5-hydroxyindole

-2.8

-7.4

-0.5

110.2

Error

± 5%

± 5%

± 0.1

± 0.1

Since the source of the exotherm seems to be the 2-aminoethyl arm; this provides a
clue to the origin of the observed behavior. Serotonin, despite displaying an exotherm,
has been extensively characterized and does not exhibit a black solution nor does it
have a documented degradation pathway [3].
For psilocin the 2-dimethylaminoethyl is expected to be more hydrophobic than
for the 2-aminoethyl of serotonin. Thus, it is plausible that in aqueous environments
psilocin forms a micelle. Formation of a micelle may originate from the hydrophilic
indole and the hydrophobic 2-dimethylaminoethyl arm. Possibility of psilocin forming
a micelle has not been reported. Formation of a micelle, in aqueous solutions, could
explain the difficulty in identifying the unknown product using MS, chromatography,
or NMR [3–5].
Further experiments are planned to identify if a micelle, is present using dynamic
light scattering and to determine whether the process of micellization is reversible by
drying and reconsitution in organic/aqueous solvents.
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The above results present an interesting situation where small drug molecules can
potentially form macromolecules in aqueous environments. Typically, in the drug
discovery and testing pathway, organic solvents are used as solubilizing agents or
as mobile phases for chromatography and MS. It is possible that the use of organic
solvents prevent small drug molecules from exhibiting this same behavior. In the
case of psilocin, the formation is obvious in the black colored solution. This may
not be the case for other compounds. If this explanation is correct, formation of
macromolecules from small drug compounds could have significant consequences for
drug dosing, bioavailability, and PK/PD.
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APPENDIX F:
COMPLEX FLUID ANALYSIS

F.1

E. Coli Lysate - Streptavidin-Biotin

To demonstrate feasibility of this process, standard E. Coli lysate samples were
purchased from Bio-Rad (Hercules, CA). The thermogram of this lysate is shown in
Fig F.1.
To mimic an expression system we used streptavidin from Alfa Aesar (Haverhill,
CA), a commonly expressed protein, and biotin from VWR (Radnor, PA) which binds
to streptavidin. Thermograms for 1 mg/mL streptavidin and streptavidin with two
molar equivalents of biotin is shown in Fig F.2. The binding interaction of streptavidin
to biotin is clearly detectable by DSC.
To simulate protein expression, in Figure F.3, 1 mg/mL of streptavidin was added
to 2 mg/mL of E Coli lysate and incubated for 24 hours. To one sample, biotin was
added at two molar equivalents. The streptavidin peak is clearly distinguished above
the E Coli lysate background. Similarly, there is a noticeable change in the sample
◦

containing biotin. The predominant streptavidin peak (∼80 C) decreases and the
◦

peak at ∼110 C increases.
Experiments at half concentration of lysate and protein produced comparable
results, as shown in Fig F.4. To test the limit of detection for our system, E Coli
lysate backgrounds were reproducible down to 0.5 mg/mL.
Previous examples demonstrated detection of ligand binding in a crude lysate
at an assumed protein expression of 33% (w/w%). While this value is not outside
the range of possibilities, 10% (w/w%) is assumed to be a moderate level of protein
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Figure F.1.: 2mg/mL purified E. Coli lysate standard.

expression [1]. To achieve this range 0.25 mg/mL of streptavidin was added to 2
mg/mL, simulating a ∼11% expression. Analogous to our 33% example the predom◦

◦

inant streptavidin peak (∼80 C) decreases and the peak at ∼110 C increases, shown
in Fig F.5.
Published experiments on analysis of streptavidin thermal denaturation using DSC
◦

showed similar behavior with a decrease of the streptavidin peak at ∼80 C and the
◦

rise of a biotin-streptavidin peak at ∼110 C [2]. Results clearly show that we are able
to detect binding of a ligand to an expressed protein in a crude lysate. However, this
was performed on a system of known parameters, e.g. expressed protein percentage,
total mass, etc. In a true expression system any or all of those parameters may not
be known at early stages of testing.
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Figure F.2.: Streptavidin with biotin control.

(n) 1 mg/mL streptavidin, (l)

1mg/mL streptavidin with 2 molar equivalents of biotin.

F.2

HEK293 - ACE2 & SARS-CoV-2 Receptor Binding Domain

Unpurified angiotensin converting enzyme 2 (ACE2) expressed in human embryonic kidney cells (HEK293) was purchased from RayBiotech (Peachtree Corners, GA).
ACE2 is found in the cell supernatant after expression and was provided with a standard cell supernatant background sample with no expressed proteins. Note that
samples were provided by volume and not mass. We have no information as to how
much protein is in the sample, by mass, or total mass of all proteins in the sample.
This lack of information would be similar to what would be faced in integrating this
technology into early stage screening of biologics.
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Figure F.3.: 2 mg/mL E Coli lysate spiked with streptavidin to mimic 33% protein
expression. (n) 2 mg/mL E Coli lysate standard, (l) 2 mg/mL E Coli lysate with 1
mg/mL streptavidin, (s) 2 mg/mL E Coli lysate and 1 mg/mL streptavidin with 2
molar equivalents of biotin.

Thermograms were maeasured for HEK293 cell supernatant background and containing ACE2. Fig F.6 shows that there is a noticeable difference between thermograms.
To isolate the contribution of ACE2, the cell supernatant background was subtracted from the ACE2 containing sample. The resulting ACE2 thermogram is shown
in Fig F.7.
Published DSC experiments on ACE2 show that there are two peaks in unmodified
◦

◦

ACE2 (55.3 C and 70.5 C) [3]. Similarly, after removing the background we show
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Figure F.4.: 1 mg/mL E Coli lysate spiked with streptavidin to mimic 33% protein
expression. (n) 1 mg/mL E Coli lysate standard, (l) 1 mg/mL E Coli lysate with
0.5 mg/mL streptavidin, (s) 1 mg/mL E Coli lysate and 0.5 mg/mL streptavidin
with 1 molar equivalents of biotin.

◦

◦

that there are two measured peaks in our thermogram at 55.6 C and 70.6 C. With no
knowledge of mass of components in the system, thermograms are left as raw energy
flux instead of being converted to molar heat capacity.
For comparison, samples of isolated and purified ACE2 were purchased from RayBiotech (Peachtree Corners, GA) and measured using DSC. The thermogram for
purified ACE2 is shown in Fig F.8.
It is interesting to note that the measured thermogram for the purified protein
does not match the measured thermogram for our measured unpurified ACE2 nor
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Figure F.5.: 2 mg/mL E Coli lysate spiked with streptavidin to mimic ≈11% protein
expression. (n) 2 mg/mL E Coli lysate standard, (l) 2 mg/mL E Coli lysate with
0.25 mg/mL streptavidin, (s) 2 mg/mL E Coli lysate and 0.25 mg/mL streptavidin
with 2 molar equivalents of biotin.

the published DSC thermograms for purified ACE2. This suggests that purification
◦

steps fundamentally changed the structure of the purified ACE2. The peak at ∼55 C
◦

corresponds to the C-domain of the protein with ∼70 C being N-domain [3]. This
demonstrates that purification may have drastic consequences on protein structure, in
this case, purified ACE2 had the structure of the N-domain destroyed by purification.
Conventional methods utilize gel chromatography to verify purified proteins, which
relies on protein mass rather than structure. Here, the mass of the protein can still
be correct while losing structural integrity as evidenced by the thermogram.
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Figure F.6.: Analysis of an unknown quantity of expressed ACE2 protein in HEK293
cell culture supernatant. (n) HEK293 cell culture supernatant standard, (l) ACE2
transfected HEK293 cell culture supernatant.

The consequences of this are large. Biologics work by targeting specific receptors
based on structure. If purification alters this structure, then the biologic will show a
lack of efficacy. For example, if the N-domain of ACE2 is altered by purification, any
drugs that would bind to that domain may generate a false negative and invalidate
an otherwise suitable drug compound. This serves to highlight the utility and broad
applicability of our technology in screening and analysis of purified and unpurified
proteins.
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Figure F.7.: Isolated ACE2 spectrum. (n) Resulting thermogram from subtracting
HEK293 cell culture supernatant signal from the ACE2 transfected HEK293 cell
culture supernatant.

Captopril, an ACE inhibitor, was used to analyze ligand binding to unpurified
ACE2. Captopril measurably impacted the thermogram of the unpurified ACE as
shown in Fig F.9.
By removing the cell supernatant background we are able to see the effect that
captopril had on ACE2, shown in Fig F.10.
After subtracting the ACE2 curve, we are able to see the effect of captopril on
structural stability of ACE2 in Fig F.11. These results show that captopril predominantly binds to the C-domain of ACE2.
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Figure F.8.: Isolated and purified ACE2 protein thermogram at 0.2 mg/mL. (n)
Note, compared to thermograms for ACE2 reported in the literature, our measured
thermogram only displays a single peak corresponding to the C-domain of ACE2 [1].

Lisinopril, another ACE inhibitor, was used to see if there were detectable differences to binding of drugs to unpurified ACE2. Thermograms of lisinopril binding to
unpurified ACE2 are compared with captopril in Fig F.12.
ACE2 containing lisinopril shows a greater degree of stability of ACE2 in comparison with captopril. Unlike captopril, lisinopril displays interactions with both
domains of ACE2 as shown in the background subtracted thermograms in Fig F.13.
By removing the ACE2 curves we are able to isolate effects of individual ligands on
the overall thermograms as shown in Fig F.14. This highlights the different binding
interactions between ligands within the same class of compounds.
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Previous examples dealt with small molecule drug binding to expressed proteins.
We also wanted to demonstrate the ability to measure protein-protein interactions in
unpurified systems. To that end, we utilized the receptor binding domain (RBD) of
the SARS-CoV-2 virus (COVID-19). Numerous studies have elucidated the primary
route of cellular infection by SARS-CoV-2 is binding the ACE2 protein [4–6]. Purified
SARS-CoV-2 RBD was purchased from RayBiotech and added to unpurified ACE2.
Thermograms of purified SARS-CoV-2 RBD and ACE2 with SARS-CoV-2 RBD are
shown in Fig F.15.

Figure F.9.: Detection of captopril binding to expressed ACE2 protein. (n) HEK293
cell culture supernatant standard, (l) ACE2 transfected HEK293 cell culture supernatant, (s) ACE2 transfected HEK293 cell culture supernatant with 250 µM of
captopril.
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Figure F.10.: Thermograms of ACE2 protein after subtraction of HEK293 cell culture
supernatant standard. (n) Isolated ACE2 transfected HEK293 cell culture thermogram, (l) Isolated thermogram of ACE2 transfected HEK293 cell culture with 250
µM of captopril.

To determine binding of SARS-CoV-2 RBD to ACE2 the individual backgrounds
of ACE2 and SARS-CoV-2 RBD were subtracted and the resulting difference thermogram, with comparisons to ACE inhibitor drugs is shown in Fig F.16. Qualitatively,
it demonstrates that the interaction of SARS-CoV-2 RBD to ACE2 is similar to that
of lisinopril binding ACE2.
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Figure F.11.: Isolation of binding interaction of captopril to ACE2. (n) ACE2 transfected HEK293 cell culture supernatant with 250 µM of captopril after subtraction
of ACE2 transfected HEK293 cell culture supernatant background.
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Figure F.12.: Detection of lisinopril binding to expressed ACE2 protein. (n) HEK293
cell culture supernatant standard, (l)ACE2 transfected HEK293 cell culture supernatant, (s) ACE2 transfected HEK293 cell culture supernatant with 250 µM of
captopril, (t) ACE2 transfected HEK293 cell culture supernatant with 250 µM of
lisinopril.
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Figure F.13.: Background subtracted thermograms of drug binding to ACE2. (n) Isolated ACE2 transfected HEK293 cell culture thermogram, (l) Isolated ACE2 transfected HEK293 cell culture with 250 µM of captopril, (s) Isolated ACE2 transfected
HEK293 cell culture with 250 µM of lisinopril, (t) Isolated, purified ACE2 protein
thermogram at 0.2 mg/mL.
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Figure F.14.: Isolation of binding interaction of captopril and lisinopril to ACE2
after subtraction of ACE2 transfected HEK293 cell culture supernatant background.
(n) Isolated ACE2 transfected HEK293 cell culture supernatant with 250 µM of
captopril, (l) Isolated ACE2 transfected HEK293 cell culture supernatant with 250
µM of lisinopril.
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Figure F.15.: Detection of SARS-CoV-2 receptor binding domain (RBD) binding to
expressed ACE2 protein. (n) ACE2 transfected HEK293 cell culture supernatant,
(l) 0.4 mg/mL purified SARS-CoV-2 RBD, (s) ACE2 transfected HEK293 cell
culture supernatant with 0.4 mg/mL purified SARS-CoV-2 RBD.
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Figure F.16.: Comparison of ligand binding to expressed ACE2 protein after subtraction of ACE2 transfected HEK293 cell culture supernatant and SARS-CoV-2 RBD
background. (n) Isolated ACE2 transfected HEK293 cell culture supernatant with
250 µM of captopril, (l) Isolated ACE2 transfected HEK293 cell culture supernatant
with 250 µM of lisinopril, (s) ACE2 transfected HEK293 cell culture supernatant
with 0.4 mg/mL purified SARS-CoV-2 RBD.
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